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Drug-protein binding can have a dramatic impact on the distribution and
metabolism of a drug. This manuscript describes the use of high-performance affinity
chromatography to examine the binding of various compounds to human serum albumin
(HSA) in normal and diabetic disease states.
The first study examined the use of four coumarin compounds as possible
alternatives to warfarin as a probe for Sudlow site I on HSA. High-performance affinity
chromatography and immobilized HSA columns were used to compare and evaluate the
binding properties of these probe candidates. It was found from this group that 4hydroxycoumarin was the best alternative to warfarin for drug-protein binding studies on
HSA.
The primary portion of this manuscript examined the binding of sulfonylurea
drugs to HSA as the glycation level of HSA was increased. This work was performed by
using high-performance affinity chromatography to determine the binding regions,
affinities, and the number of binding sites on HSA for sulfonylureas. The first part of this
study examined the binding of two sulfonylureas to non-glycated HSA. Frontal analysis
and competition studies indicated that the sulfonylureas had two major classes of binding

sites on HSA, with strong interactions occurring at both Sudlow sites I and II. The
second part of this study examined the binding of two probe compounds, warfarin and Ltryptophan, to HSA as glycation levels of this protein increased. This study found no
significant difference in the binding of warfarin to glycated HSA but observed some
increases in the binding constant of L-tryptophan. The third part of the study examined
the binding of the sulfonylureas to HSA with increasing levels of glycation. Minor
alterations in binding were observed as the level of glycation increased.

Lastly,

theoretical studies were also performed to elucidate the appropriate analyte
concentrations necessary for examining multi-site binding systems, such as those
observed for some drug-protein interactions.

iv
ACKNOWLEDGEMENTS

There have been so many people that have helped me on my journey through
graduate school. I would like to begin by expressing my sincere gratitude to Dr. Hage for
his patience and guidance over the last five years. Thank you for allowing me the
freedom to explore my creativity and widen my scientific knowledge and thank you for
always answering my stupid questions without laughing too hard! I would also like to
thank my supervisory committee Dr. James Carr, Dr. Jody Redepenning, Dr. Barry
Cheung and Dr. Julie Stone for all of their support and direction throughout my time at
UNL.
I am also grateful to the Hage lab members who shared in life’s ups and downs;
we laughed, we cried, we vented, and we learned. I learned things from each one of you
that I will carry with me for the rest of my life. A special thanks to Annette for her
guidance in learning the ropes when I was just a “newbie” and to John for inadvertently
continuing my training after Annette graduated. Jeanethe, I hope that I have imparted
some sort of wisdom to you; just remember, don’t do as I do, do as I say! Thank you,
Michelle for all the good conversation that kept me grounded and sane these last few
years and to the rest of the Hage lab that helped me learn along the way, especially
Corey, Rangan, Efthimia, Mandi, Omar, Tong, Abby, and Erika.
Most of all I want to thank my family that put up with me through classes,
teaching, research, RUI, OPO, and writing this manuscript.

Thank you, Albie and

Sammie, the two most wonderful dogs in the world, for always being the most happy and
uplifting friends a girl could ever hope for. Thank you, Ed, Theresa, and Tony for being

v
such supportive in-laws. Your support and enthusiasm are always so welcoming and
appreciated and your constant reminders to do what makes me happy will always be my
own little mantra. Mom and Joe, what can I say? You have always stood behind me,
lifting me up when I feel down, you have always stood beside me, whispering words of
love and encouragement in my ears, and you have always stood in front of me, pulling
me forward to do my best. I love you guys. Thanks for everything! To my wonderful
and adoring husband, I always said “thank God that I’m married to a psychiatrist so he
can either supply good drugs or have me committed when I finally crack under all the
pressure.” Luckily, all I needed was sleep… lots of sleep! Just think, Tom, if we can
make it through grad school and residency together, we survive anything! You are my
strength and my love. Thank you. I love you! Thank you, God, for getting me through.
You are my rock and my salvation. “I can do everything through him who gives me
strength” (Phil. 4:13). “This is the day the Lord has made; let us rejoice and be glad in
it!” (Psalm 118:24).

vi
TABLE OF CONTENTS

CHAPTER 1
GENERAL INTRODUCTION
Diabetes…………………………………………………………………… 1
Sulfonylureas……………………………………………………………… 3
Human Serum Albumin (HSA)…………………………………………… 6
High Performance Affinity Chromatography……………………………... 14
Frontal Analysis…………………………………………………………… 15
General Principles………………………………………………… 16
Binding Studies…………………………………………………….. 21
Competition Studies……………………………………………….. 24
Temperature and Solvent Studies…………………………………. 29
Practical Considerations………………………………………….. 29
Zonal Elution……………………………………………………………… 33
General Principles………………………………………………… 33
Binding and Competition Studies…………………………………. 38
Temperature and Solvent Studies…………………………………. 44
Characterization of Binding Sites…………………………………. 48
Practical Considerations………………………………………….. 48
Overall Goals and Summary of Dissertation……………………………… 54
References…………………………………………………………………. 57

vii
CHAPTER 2
THE EVALUATION OF WARFARIN PROBE ALTERNATIVES FOR HUMAN
SERUM ALBUMIN
Introduction………………………………………………………………... 64
Theory……………………………………………………………………… 69
Frontal Analysis……………………………………………………. 69
Zonal Elution………………………………………………………. 73
Experimental………………………………………………………………. 74
Reagents…………………………………………………………… 74
Apparatus………………………………………………………….. 75
Methods……………………………………………………………. 76
Results and Discussion……………………………………………………. 79
NMR Stability Studies……………………………………………… 79
Frontal Analysis Studies…………………………………………… 82
Competition Studies………………………………………………... 91
Effects of Coumarin Structure on Binding to Sudlow Site I……….. 96
Conclusion………………………………………………………………..... 97
References………………………………………………………………….. 100

CHAPTER 3
THE BINDING OF SULFONYLUREAS TO NORMAL HSA
Introduction………………………………………………………………… 104
Experimental……………………………………………………………….. 108

viii
Reagents……………………………………………………………. 108
Apparatus…………………………………………………………... 108
Methods…………………………………………………………….. 109
Results and Discussion…………………………………………………….. 112
Frontal Analysis Studies Using Acetohexamide…………………… 112
Frontal Analysis Studies Using Tolbutamide……………………… 123
Zonal Elution Studies Using Acetohexamide………………………. 126
Zonal Elution Studies Using Tolbutamide…………………………. 133
Conclusion…………………………………………………………………. 142
References………………………………………………………………….. 144

CHAPTER 4
THE BINDING OF WARFARIN AND L-TRYPTOPHAN TO GLYCATED HSA
Introduction………………………………………………………………… 147
Experimental……………………………………………………………….. 152
Reagents……………………………………………………………. 152
Apparatus…………………………………………………………... 153
Methods…………………………………………………………….. 153
Results and Discussion…………………………………………………….. 158
Preparation and Initial Studies of Glycated HSA………………….. 158
Binding of Warfarin to Glycated HSA……………………………... 163
Binding of L-Tryptophan to Glycated HSA………………………… 173
Conclusion…………………………………………………………………. 177

ix
References………………………………………………………………….. 179

CHAPTER 5
THE BINDING OF SULFONYLUREAS TO GLYCATED HSA
Introduction………………………………………………………………… 182
Theory……………………………………………………………………… 184
Frontal Analysis……………………………………………………. 184
Zonal Elution………………………………………………………. 186
Experimental……………………………………………………………….. 187
Reagents……………………………………………………………. 187
Apparatus…………………………………………………………... 188
Methods…………………………………………………………….. 189
Results and Discussion…………………………………………………….. 193
Preparation of Glycated HSA……………………………………… 193
Acetohexamide Binding to gHSA1…………………………………. 193
Acetohexamide Binding to gHSA2…………………………………. 208
Acetohexamide Binding to gHSA3…………………………………. 212
Tolbutamide Binding to gHSA1……………………………………. 216
Tolbutamide Binding to gHSA2……………………………………. 223
Tolbutamide Binding to gHSA3……………………………………. 225
Conclusion.………………………………………………………………… 226
References………………………………………………………………….. 228

x
CHAPTER 6
THEORETICAL CONSIDERATIONS IN DRUG-PROTEIN BINDING
Introduction………………………………………………………………… 231
Theory……………………………………………………………………… 233
Frontal Analysis Theory…………………………………………… 233
Concentration Effects……………………………………………… 234
Concentration Determinations Using Confidence Intervals………. 238
Experimental……………………………………………………………….. 239
Results and Discussion…………………………………………………….. 239
Conclusion…………………………………………………………………. 253
References…………………………………………………………………. 254

CHAPTER 7
SUMMARY AND FUTURE WORK
Summary of Work…………………………………………………………. 255
Future Work………………………………………………………………... 258
References………………………………………………………………….. 259

1
CHAPTER 1
GENERAL INTRODUCTION

Diabetes
Diabetes is a growing problem in the United States and around the world. In
2000, when the International Diabetes Federation released its first volume of the Diabetes
Atlas, the global population suffering from the disease was 151 million. The estimate for
2010 has almost doubled to 285 million people and the estimate for 2030 has continued
increasing to a staggering 438 million people around the world.1 Today, more than 6% of
the world’s population suffers from diabetes. In the United States, 23.6 million children
and adults have diabetes, with 1.6 million new cases being diagnosed each year.2 In
2006, UN Resolution 61/225 recognized the epidemic by stating that “diabetes is a
chronic, debilitating and costly disease associated with severe complications, which poses
severe risks for families, Member States and the entire world…”3 It is estimated that
over 376 billion dollars will be spent on healthcare costs in 2010, over 11.6% of total
healthcare expenditures.1 The United States alone is projected to spend over 50% of the
global expenditure.
Diabetes is classified as a group of heterogeneous disorders that pertain to insulin
deficiency, insulin ineffectiveness, or a combination of the two, which result in glucose
intolerance or hypoglycemia.1 Diabetes can be classified into four main types: type 1,
type 2, gestational, and other. The two most prevalent forms are type 1 and type 2.
Type 1 diabetes, formerly called juvenile diabetes, is typically diagnosed in
children and young adults. This type of diabetes is actually an autoimmune disease

2
where the body has turned against itself to attack the insulin-producing beta cells in the
pancreas.1, 4 In type 1 diabetes, little to no insulin is produced and insulin injections are
required for the patient to survive. Type 1 diabetes accounts for 5-10% of diagnosed
diabetes cases.
The most common form of diabetes is type 2, or non-insulin dependent, diabetes.
This type of diabetes accounts for 90-95% of the diagnosed cases of diabetes and it is
typically associated with obesity, age, or a family history of the disease.1,
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In type 2

diabetes, a two-fold deficit occurs: insulin resistance and insulin deficiency. Type 2
diabetes was originally discovered by Yalow and Berson in 1960 when they observed
that patients with type 2 diabetes often generate more insulin than a normal individual.5
Although this is true for early stages of the disease, subsequent research found that the
insulin levels of these patients eventually fell below normal levels. This led to the
hypothesis that a degree of insulin resistance initially leads to an increase in insulin
production in the body, where the pancreas produces excess insulin. Unfortunately, the
pancreas cannot keep up with this demand and over time many of the beta cells decrease
insulin production.
Symptoms of diabetes include increased thirst, frequent urination, constant
hunger, weight loss, extreme fatigue, and blurred vision. While the appearance of type 1
diabetes is sudden and the associated symptoms appear quickly, type 2 diabetes can be
asymptomatic for many years. Both types of diabetes can lead to severe complications
including cardiovascular disease (heart disease/stroke), neuropathy (nerve damage),
nephropathy (renal failure), and retinopathy (blindness).

However, with proper

treatment, many of these complications can be delayed or even prevented entirely.

3
Sulfonylureas
During the years of World War II, another threat was underway: typhoid fever. A
French pharmacologist by the name of Marcel Janbon asked the French government to
send him a drug that might act against the illness.5, 6 He was sent a sulfonylurea. In
1942, during his animal testing, the animals displayed strange behavior that would
sometimes end in death. It soon became evident that the behavior matched the symptoms
of hypoglycemia. Janbon contacted a colleague, August Loubatiéres, and asked that he
test the drug. Loubatiéres’ studies also ended with the same result: the production of
hypoglycemia in normal fasting dogs. However, he also observed that this drug did not
affect dogs which had their pancreas previously removed. Further testing by the two led
to the hypothesis that there was a type of diabetes, characterized by “sluggish insulin
secretion” (type 2 diabetes), that could be treated with sulfonylureas.6
Since the work of Janbon and Loubatiéres, an entire line of sulfonylureas have
been developed to aid in the treatment of type 2 diabetes. Sulfonylureas were the first
class of oral medications used to treat diabetes and they have been used for over 50 years
(i.e., since tolbutamide was first introduced in 1956).6,
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Tolbutamide, tolazamide,

acetohexamide, and chlorpropamide are the first-generation sulfonylureas. Since then,
second and third generation sulfonylureas have been developed that have an increase in
potency and a decrease in drug interactions. Sulfonylureas are widely used due to their
reliability, limited side effects, and low cost. They are often recommended alone or in
combination with other therapies.7
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Figure 1-1.

Mechanism of insulin release during a diabetic disease state. Glucose
regulates insulin secretion in the beta cell of the pancreas. Sulfonylureas
can also stimulate the release of insulin by entering through the (SUR)-1
receptor, altering the ion channel activity and leading to insulin secretion.
(Adapted from: Powers Alvin C, "Chapter 338. Diabetes Mellitus"
(Chapter). Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL,
Jameson JL, Loscalzo J: Harrison's Principles of Internal Medicine, 17e:
http://www.accessmedicine.com.)
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Sulfonylureas work by stimulating insulin release from the beta cells in the
pancreas (see Figure 1-1).8-11 This occurs when a sulfonylurea binds to the sulfonylurea
receptor unit (SUR)-1 of the adenosine-triphosphate (ATP)-sensitive potassium channels
on the beta cell membrane. This closes the channels and reduces potassium efflux,
leading to membrane depolarization. The voltage-dependent calcium channels then open,
resulting in the influx of calcium ions which in turn stimulate the release of insulin from
available storage granules in the cell.
Like many other drugs, sulfonylureas are mainly bound to serum proteins as they
are distributed throughout the body. In fact, they bind primarily to human serum albumin
(HSA). Sulfonylureas can bind to HSA at one or multiple binding sites, depending on the
specific sulfonylurea. The binding affinity as well as the rate of displacement can also
differ dramatically between different sulfonlyureas.12-14

Human Serum Albumin (HSA)
HSA is the most abundant protein in human plasma.

It has a typical

concentration of ~40-45 g/L and accounts for about 60% of the total protein in blood
serum.15-17 HSA is synthesized in the liver and exported as a single, non-glycosylated
chain of 585 amino acids.15, 18 It is a globular protein consisting of three domains (I, II,
and III) that each contain two subdomains (A and B) connected by a random coil (Figure
1-2). These domains create a heart-shaped protein with a molecular weight of ~66,500
Da and an approximate size of 80 x 80 x 30 Å, with three lobes that correspond to each of
the three homologous domains. The secondary structure is made up of 67% α-helices,

7

Figure 1-2.

Structure of human serum albumin (HSA). The locations of Sudlow sites
I and II are indicated. This structure was obtained from the Protein Data
Bank (ID: 1AO6).
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Sudlow Site II
Sudlow Site I

9
23% extended chain, and 10% β-turn, with the first six of ten total α-helices in each
domain belonging to subdomain A and the last four to subdomain B.16, 19, 20
In 1975, Gillian Sudlow proposed that there are two high affinity binding sites on
HSA for small heterocyclic or aromatic compounds.21,

22

These sites are located on

subdomains IIA and IIIA which are now often referred to as Sudlow sites I and II.
Sudlow site I, or the warfarin-azapropazone site, is the binding site for bulky heterocyclic
anions such as warfarin and salicylate, while Sudlow site II is the primary binding site for
aromatic carboxylates like ibuprofen and indoles. At least two minor binding sites have
also been proposed for compounds such as digitoxen and tamoxifen.23, 24
HSA is the most important nonspecific transporter protein in the circulatory
system.

It has an excellent binding capacity for many endogenous and exogenous

compounds. The main role of HSA is to bind and transport unesterified fatty acids,
making these compounds more soluble and evenly distributed throughout the body. HSA
also binds other endogenous compounds such as bilirubin, bile salts, steroid hormones,
hematin, tryptophan, thyroxine, and some vitamins and metal ions.16 Yet one of the more
remarkable attributes of HSA is its ability to transport a large number of drugs throughout
the body. This ability gives HSA a primary role in pharmacokinetics (i.e. absorption,
distribution, metabolism, and excretion). The distribution of the drugs to their receptor
site ultimately occurs by first binding to HSA in order to be transported to their targets.
A pharmaceutical compound could even be cut short in production if testing shows
unfavorable binding with this protein.
The activity of a drug at the receptor site is often related to the amount of the
unbound (or free) drug in circulation and the affinity of many drugs for HSA strongly
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affects the free drug fraction in plasma. In most cases, it is the free drug fraction that has
the ability to transfer into tissues in order to carry out its therapeutic activity. However,
Herve, et. al. found that a small fraction of the bound drug can also be dissociated in
capillaries and become available for drug transfer.25 These two behaviors are referred to
as permissive and restrictive binding.
Permissive and restrictive drug-protein interactions were originally seen in the
liver when studies showed that although >90% of propanolol was bound to plasma
proteins, >90% is also able to be extracted by the liver. This led to the conclusion that a
significant amount of bound propanolol in the circulation was still available for drug
transfer, a binding that was said to be “permissive” in nature.25 In this type of binding,
drugs have a high volume of distribution, always more than 0.6 L/kg (the volume of free
body water), and drugs with higher values are not only distributed in body fluids but in
tissues as well. In constrast, >99% of warfarin is bound in plasma and the extraction ratio
of this drug was found to be extremely low (<0.3%) meaning that the bound portion of
the drug cannot be used but rather the free fraction is necessary for drug transfer. This
type of binding is said to be “restrictive” and the drug is almost completely contained
within the compartment of distribution of its binding protein. This type of behavior was
eventually extended to all tissues and found to be independent of drug-protein association
constants. Any modification of the binding protein in this case could alter the free
fraction of a drug, thereby altering the interaction the drug has at its target.
HSA has no sites for enzymatic glycosylation. However, it can undergo nonenzymatic glycosylation, also known as glycation. In fact, in average adults 6-13% of
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Figure 1-3.

The non-enzymatic glycation of a protein.
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HSA is glycated.16, 26-28 This number can increase dramatically to 20-30% in people with
diabetes.26-28 Glycation takes place between a reducing sugar and a free amine group
such as the α- or ε- amino groups on a protein.28-30 This mechanism (see Figure 1-3)
begins when the carbohydrate performs a neuclophilic attack on an amine group to form a
Schiff base. The Schiff base can either dissociate or rearrange to form an irreversible
ketoamine, also known as an Amadori product.28, 30, 31 The Amadori product can then
undergo a series of oxidative rearrangements and degradations to form a group of
compounds known collectively as advanced glycation end-products (AGEs).

The

primary sites of glycation on HSA are lys-525, lys-199, lys-281, and lys-43927-29, 32 but
other residues are susceptible to glycation as well.28, 32
Glycation is thought to alter the secondary and tertiary structure of HSA,
potentially leading to changes in the stability and biological properties of this protein.
Changes in this protein due to glycation are also thought to affect drug-protein
interactions, potentially resulting in a decreased or increased binding of drugs to HSA.27
Some of the glycation sites on HSA are known to be at or near Sudlow sites I and II. For
instance, lys-199 is known to be at the pocket entrance to Sudlow site I. Studies have
already been performed to explore the structural changes induced in HSA by glycation27,
28

as well as binding studies with various drugs including naproxen,33 salicylic acid,33

warfarin,26, 27, 33 sulfonylureas,34 L-tryptophan,35 Bromocresol Purple and Phenol Red.26
Drug binding studies have been performed by many methods, such as equilibrium
dialysis, ultrafiltration, circular dichroism and fluorescence spectroscopy, the HummelDreyer method, and fluorescence quenching. This dissertation will present data on drug-
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binding studies by high-performance affinity chromatography (HPAC) using the methods
of frontal analysis and zonal elution.

High-Performance Affinity Chromatography (HPAC)
Affinity chromatography (AC) is a type of liquid chromatography that uses a
biological ligand as the stationary phase.36 This technique has been used for decades for
the purification and analysis of biologically-related samples.

It uses reversible

interactions that are found in biological systems, including the binding of an antigen to an
antibody or a hormone to a protein.

In this method, one of a pair of interacting

compounds is immobilized onto a support for use as a stationary phase, while the other
compound is contained within the injected sample or mobile phase. A common support
for this application is a carbohydrate-based gel such as agarose or sepharose. These
support materials are often used when purifying samples under gravity flow or using a
peristaltic pump. These materials are easy and inexpensive to use, however, they are
structurally stable only at low back-pressures.
High-performance affinity chromatography (HPAC) is a modification on this
method in which the support material is made of small, rigid particles that are able to
withstand high back-pressures.36 Typical supports in HPAC include silica and polymeric
monolith materials. The stability of these supports allows them to be used with typical
HPLC equipment, including gradient pumps at high flow rates. Although this technique
is more difficult to perform and more costly than traditional affinity chromatography due
to the need for specialized equipment, the advantages of HPAC make this technique
preferable in analytical applications.
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One of the greatest advantages of HPAC is that the immobilized ligand can often
be used for numerous sample applications in binding studies. This increases the precision
of the experiments by reducing run-to-run variations. It also lowers costs by reducing the
amount of ligand needed for binding studies. This is especially important when the
ligand is an expensive monoclonal antibody or cell receptor.37

This method also

increases the speed of the experiments by allowing for a wider range of flow-rates to be
employed.
One common application for HPAC is in studying the binding equilibrium and
thermodynamics of biological systems. This is most often performed by the methods of
frontal analysis or zonal elution.

Frontal Analysis
Frontal analysis was originally used as a purification technique. However, it has
grown into a popular method for gathering equilibrium data on the affinities and binding
sites of various analyte-ligand systems. Kasai and Ishii were the first to explore the use
of frontal analysis and affinity columns for this purpose in 1975 when they used a lowperformance affinity column to study the affinity of trypsin for a mixture of oligopeptides
obtained from a tryptic digest of protamine.38

The use of silica columns for

biointeraction studies began about a decade later,39 with other HPLC media such as
monoliths and capillary systems also now being employed for such work.40-42
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General Principles
Frontal analysis is performed when an analyte is continuously applied to a column
containing an immobilized ligand (see Figure 1-4). As the analyte interacts with the
ligand, the binding sites slowly become saturated. Upon saturation, excess analyte leaves
the column and forms a characteristic breakthrough curve (see Figure 1-5).

If fast

association and dissociation kinetics are present for this system, the center of this
breakthrough curve can be related to the concentration of applied analyte, the number of
binding sites within the column, and the affinity to which the analyte binds to the ligand.
The advantages of using frontal analysis and affinity chromatography for
biointeraction studies are its speed, precision, and automation along with the small
amounts of sample required to run an experiment. Although frontal analysis requires a
larger volume of sample than zonal elution, a technique that will later be discussed in
greater detail, this method also provides more information per analysis.

The main

advantage of frontal analysis is that equilibrium constants and binding capacities can be
obtained separately, making it possible to characterize both binding affinities and column
properties. These experiments can also be carried out using a standard HPLC system
with the addition of a temperature controller. Applications of frontal analysis include
binding studies, competition studies, and temperature and solvent studies.

Frontal

analysis has also been used in recent years to screen the binding of a ligand against
mixtures of compounds. The following sections provide more details on each of these
applications.
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Figure 1-4.

A typical frontal analysis experimental system is composed of the
following components: (A) mobile phase reservoir, (B) isocratic pump,
(C) valve, (D) column oven, (E) column, (F) detector, (G) computer with
data collection software, and (H) lines going to excess.

B

A
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Figure 1-5.

Example of frontal analysis experiments examining the binding of 7hydroxycoumarin to immobilized HSA. The frontal analysis curves were
obtained for the application of solutions that contained (from left-to-right)
of 10, 7.5, 5.0, 2.5, or 1.0 µM 7-hydroxycoumarin.

Absorbance (327 nm)
10
12

Time (min)
14
16

20
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Binding Studies
One of the most common uses of frontal analysis is in the determination of the
affinity and binding capacity of an analyte with an immobilized ligand. This can be
accomplished by measuring the breakthrough time or breakthrough volume of the analyte
that has been continuously applied to a column containing an immobilized ligand. Once
obtained, the breakthrough time or volume can be related to the apparent number of
moles of analyte needed to saturate the column, mLapp. For instance, if an analyte binds
reversibly to the immobilized ligand at only one type of site, Equations 1-1 and 1-2 can
be used to relate the measured value of mLapp to the parameters that describe the affinity
of this interaction (as represented by Ka) and the amount of binding sites in the column
(as represented by mL).43
mLapp =

m L K a [A ]
1 + K a [A]

(1-1)

or

1
m Lapp

=

1
1
+
K a m L [A] mL

(1-2)

Equivalent expressions can be written in terms of the breakthrough volume, as will be
discussed later. For a system with 1:1 binding, Equation 1-2 can be used to find the
values of both Ka and mL if a plot is made of 1/mLapp versus 1/[A]. An example of such
a plot is shown in Figure 1-6. Alternatively, Equation 1-1 and a non-linear fit can also be
used to analysis such data.
If, however, more than one binding site is involved in the interaction of the
applied analyte with the immobilized ligand, a negative deviation will occur at high
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Figure 1-6.

(a) Single-site binding of coumarin and (b) multi-site binding of 4hydroxycoumarin to an immobilized HSA column, as examined by frontal
analysis and Equation 1-2.
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analyte concentration (or lower 1/[A] values), as shown in Figure 1-6b. These deviations
indicate that multi-site binding is present, which requires the use of expanded forms of
Equations 1-1 or 1-2. As an example, the following equations would be used to model a
system that has two-site binding,44

m Lapp =

m L1 K a1 [A]
m K [A]
+ L2 a2
(1 + K a1 [A]) (1 + K a 2 [A])

(1-3)

or
1
m Lapp

2

=

1 + K a1 [A] + β 2 K a1 [A] + β 2 K a1 [A]2
2

mL {(α 1 + β 2 − α1 β 2 ) K a1 [A] + β 2 K a1 [A]2 }

(1-4)

where β2 = Ka2/Ka1 and α1=mL1/mL2, and all other terms are as defined previously.
Because frontal analysis can provide information on both the number of binding
sites and association equilibrium constants for an interaction, this is a valuable method
for biointeraction studies. A number of studies have been done in this area, as has been
discussed in previous reviews.36, 45 More recent examples have included work examining
the binding of HSA with

carbamazepine,46 α1-acid glycoprotein (AGP) with

oxybutynin47 and R- and S-propranolol,48 quinidine carbamate with naproxen,49 and BSA
with berberine chloride. 50

Competition Studies
Competition studies can also be performed by frontal analysis through the use of a
competing agent that is added to the mobile phase. An example of this is the competition
of sulphamethizole with salicylic acid performed by Nakano, et. al.51 Typically, a shift to
shorter breakthrough times is seen in these studies as the amount of competing analyte is
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increased. The degree of competition, including positive or negative allosteric effects,
can also be observed using this method.
Over the last decade there has been a large amount of work in the use of frontal
analysis and affinity chromatography in screening mixtures of compounds for any targets
that might bind to a given immobilized ligand. The combination of these tools with mass
spectrometry, a method commonly known as frontal affinity chromatography-mass
spectrometry (FAC-MS), has been of particular interest.52 This approach has been shown
to be able to screen mixtures of compounds in a relatively short amount of time. As a
mixture of analytes flows through the column, the individual analytes bind to the ligand
based on their affinity for this agent. Using mass spectrometry as the detection method
allows for a multitude of analytes to be evaluated simultaneously, as shown by the
example in Figure 1-7 for a mixture of eight solutes that were injected onto a column
containing immobilized sorbitol dehydrogenase. Selective detection at the characteristic
mass-to-charge (m/z) value for each compound makes it possible to generate separate
breakthrough curves for each of these analytes. This information is then used to evaluate
and rank the relative affinity of each compound in the mixture for the ligand in the
affinity column.42
An expression that is often used with breakthrough volume measurements in these
competition studies to evaluate binding affinity is given in Equation 1-5,42 which is
equivalent to the mass relationship that was given earlier in Equation 1-1.
V A − VM =

Bt
[ A] + K D

(1-5)
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In this alternative expression, VA is the measured breakthrough volume, VM is the column
void volume, [A] again represents the concentration of applied analyte, Bt is the total
amount of immobilized active ligand, and KD is the dissociation equilibrium constant for
the interaction (where KD = 1/Ka).
One variation of this approach is to make sequential injections of the analytes
starting with the lowest concentrations and finishing at the highest concentrations. These
injections are performed without washing steps in between infusions. The breakthrough
volumes that are measured are then related to the applied concentrations of the analyte
by using the following equation,42



1
[A] j + y j = Bt 
 − KD
V Aj − VM 

(1-6)

j −1

∑ ([A]

i

where

yj =

− [A]i −1 )(V Aj − VM )

i −1

V Aj − VM

(1-7)

for the jth injection in a series. A plot of the analyte concentration versus the corrected
breakthrough volume is then used to give a graph where the slope is equal to the column
capacity and the negative of the intercept is equal to the dissociation equilibrium
constant.
Examples of systems that have recently been studied using this approach include
galactosaminoglycans as a ligand for galectins,53 jacalin as a ligand for various
glycopeptides,54 HSA with thyroxine,55 and high-throughput lectin-oligosaccharide
systems.56 A number of articles have been published using this method in the past few
years and more detailed information can be found in the literature.42, 53, 54, 56-63
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Figure 1-7.

Use of FAC/MS to examine the binding by eight compounds in a library
to an immobilized sorbitol dehydrogenase column (with permission from
D.C. Schriemer, Anal. Chem. 76 (2004) 440A).42
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Temperature and Solvent Studies
The ability to measure both the amount of binding sites and affinity is a useful
feature of frontal analysis in examining how changes in temperature or other conditions
alter biological interactions.

Temperature studies have been performed with this

technique with systems such as HSA with R- and S-warfarin,64 carbamazepine,46 D- and
L-tryptophan,65 aptamers with adenosine,66 and BSA with berberine chloride.50 In these
studies, it has been shown that the shifts in retention with temperature can correspond to a
change in the number of available binding sites46, 50, 64, 65 as well as the binding affinity of
the compound.50,

64-66

Figure 1-8 is an example of such a study, showing how the

retention, activity, and affinity constant for berberine chloride change under various
conditions when using an immobilized BSA column. Frontal analysis has also been used
to examine how changes in solvent composition affect solute-ligand binding, as has been
used for systems such as quinidine carbamate with naproxen,49 and HSA with D- and Ltryptophan65 and carbamazepine.46

Practical Considerations
Many of the practical factors that should be considered in the use of frontal
analysis are the same as those that will be further described for zonal elution. The key
differences in these methods are the approaches they use for sample application and data
analysis. In the case of binding studies that are performed by frontal analysis, it is
necessary to have an observable shift in the breakthrough curve as the concentration of
analyte is varied. It is possible to determine the optimum analyte concentrations to use
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Figure 1-8.

Observed changes as a function of temperature in (a) the retention factor,
(b) moles of active binding sites, and (c) and association equilibrium
constant for berberine chloride on an immobilized BSA column (with
permission from Lei, G., et. al. Chromatographia, 66, 847-852, 2007).50
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for this experiment by using an expression like Equation 1-8, which has been previously
derived for systems with 1:1 interactions between the analyte and ligand.67
m Lapp
mL

=

K a [A]
1 + K a [ A]

(1-8)

According to this expression, as the analyte concentration [A] ranges from zero to
infinity, the fraction of binding sites that are occupied by the analyte at equilibrium (as
given by the ratio mLapp/mL) will be between zero and one, respectively. It is at some
intermediate analyte concentration that this ratio will have its greatest change with
analyte concentration. For a 1:1 binding system, this occurs when [A] = 1/Ka, with
concentrations both above and below this optimum then being used for binding studies.
Somewhere within these values, the analyte will have a concentration range that will
show its greatest shift in retention. Analyte solubility and detectability must also be
considered in choosing the range of analyte concentrations to be used in these studies.
It is relatively easy to analyze and determine the breakthrough time of a simple,
symmetrical frontal analysis curve. In this situation, the point that is halfway between the
baseline and plateau would be the breakthrough time. Unfortunately, many breakthrough
curves are not perfectly symmetrical in shape and, therefore, the analysis approach has to
be slightly altered. One approach is to find the point at which the areas below the front
portion of the curve and above the latter half of the curve are equal.

An equivalent

approach for analyzing a breakthrough curve is to take the first derivative of the curve
and then determine the central moment of this derivative.36 This second approach can be
easily handled with the correct data analysis software.
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Zonal Elution
Zonal elution is currently the most common way in which binding studies are
conducted through the use of affinity chromatography.36 Zonal chromatography is
typically used in affinity chromatography and in HPLC to separate compounds by
injecting a small plug of sample onto a column. However, this method can also be used to
obtain information on the binding equilibria and thermodynamic properties of the analyte
as it interacts with the stationary phase (i.e., the immobilized ligand in the case of an
affinity column). This type of experiment is usually performed under linear elution
conditions to simplify the analysis,67 although some work under non-linear conditions has
also been reported.68, 69
The first reported use of zonal elution for thermodynamic studies in affinity
chromatography was in 1974 when a low-performance Sepharose column containing
thymidine-5’-phosphate-3’-aminophenylphosphate was used to characterize the binding
by the enzyme staphylococcal nuclease to soluble thymidine biphosphate.70 Over the last
few decades, this method has been used to examine interactions in numerous systems and
has been used in both low- and high-performance systems with affinity columns.
Examples of these applications can be found in Table 1-1 and in previous reviews that
have appeared on this topic.43, 45, 71-73

General Principles
In zonal elution, a small plug of analyte is injected onto a column in the presence
of a mobile phase with a known composition that is being applied at a constant flow-rate.
The mobile phase is often a buffer with a physiological pH but may also contain a known
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Table 1-1
Applications of Affinity Chromatography in Equilibrium and Thermodynamic Studies
Method

Ligand

Analyte

Zonal Applications

Serum Proteins

Warfarin;64 coumarins;74, 75 benzodiazepines,
triazole derivatives;75 carbamazepine;46
phenytoin, ibuprofen;76 for a more complete
list see36

Frontal Applications

Serum Proteins

Carbamazepine;46 oxybutinin;47
propanolol;48 berberine chloride;50 salicylic
acid;51 thyroxine;55 warfarin;64 tryptophan65

Enzymes/Receptors

Nicotine, β-estradiol;42 enzyme inhibitors;57,
for a more complete list see42

77

Lectins

Glycopeptides;54 oligosaccarides;56, 61
glycosaminoglycans53

Aptamers

Adenosine66

Quinidine Carbamate

Naproxen49
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concentration of a salt, organic modifier or a competing agent that is known to bind at a
specific site on the immobilized ligand. As the analyte interacts with the immobilized
ligand, it is retained by the column. The retention time or volume of the analyte can be
measured either on-line or off-line by using an appropriate detector. Information on
analyte retention can be obtained by examining the changes in mobile phase composition.
This technique can also be used to explore changes in the system due to alterations in
temperature, pH, or mobile phase conditions.
An example of a typical zonal elution study is shown in Figure 1-9. In this
example, racemic warfarin was used as a competing agent in the mobile phase while 7hydroxycoumarin was injected as the analyte of interest.74

The column contained

immobilized HSA as the ligand. These studies were performed to examine the binding of
7-hydroxycoumarin with respect to warfarin. The 7-hydroxycoumarin peaks shifted to the
left as the concentration of warfarin increased, indicating that some type of direct or
allosteric competition was occurring between these two compounds and HSA. The
advantages that have been noted for this type of experiment include its high precision,
small sample requirements, and the ability to perform this method on a standard HPLC
system with the addition of a device for temperature control.36
Zonal elution has been used in a large assortment of studies to gain information
on analyte-ligand systems.36, 45 A majority of these studies focus on binding in order to
determine the strength and location of the bound analyte to the ligand. Other studies look
at how those interactions change as conditions are altered. These studies often look at
temperature, pH, or mobile phase variations. Yet other studies look at altering the ligand
itself by mutations or structural changes. More details on these applications will follow.

36

Figure 1-9.

Example of zonal elution experiments examining the binding of 7hydroxycoumarin to immobilized HSA.

The results were obtained

through competition studies performed by injecting samples of 5.0 µM 7hydroxycoumarin in the presence of mobile phases that contained (from
top-to-bottom) 20, 15, 10, 5.0, 1.0, or 0 µM racemic warfarin as a
competing agent.

Absorbance (327 nm)
6
8
10

Time (min)

12
14
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All of these applications rely on the same foundation: the analyte will have some
reversible interaction with the immobilized ligand within the column. The extent of this
interaction can be examined by measuring the retention factor (k) of the analyte as it
passes through the column, as defined below.
k=

t R − t M VR − VM
=
tM
VM

(1-9)

In this equation, tR is the retention time of the analyte of interest while tM is the elution
time of a non-retained compound (i.e., the void time). VR is the corresponding retention
volume and VM is the void volume. The retention factor that is calculated according to
Equation 1-9 for an affinity column can also be related by Equation 1-10 to the number of
binding sites within the column as well as the binding affinity to each site.78
k=

( K a1n1 + ... + K an nn )mL
VM

(1-10)

The terms Ka1 through Kan in this equation represent the association equilibrium constants
at binding sites 1 through n within the column, and n1 through nn represent the fraction of
each type of individual site in the column. The term mL represents the total moles of
binding sites within the column. It can be seen from this equation that a change in the
binding strength, location of binding, or number of binding sites within the column could
significantly alter the retention factor for the analyte.

Binding and Competition Studies
One of the primary applications for zonal elution in biointeraction studies is to
examine the extent of binding between an analyte and the immobilized ligand. One way
this can be done is to relate the retention factor of an injected analyte to the ligand bound
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fraction of the analyte (b) and free fraction of analyte in solution (f) at the center of the
analyte’s peak. This can be done under linear elution conditions for a system with fast
association/dissociation kinetics by using Equation 1-11.
k=

b
f

(1-11)

The sum of bound and free analyte fractions must equal one (i.e., b + f = 1), which means
Equation 1-11 can be rearranged so that either the bound or free fraction of the analyte at
equilibrium can be calculated from the measured retention factor.75
b=

k
1+ k

(1-12)

Binding studies in this area have been used to explore a variety of analyte-ligand
systems. Examples of such work include the binding of groups of benzodiazepines,
coumarins, and triazole derivatives to HSA.75 The retention factors of two solutes can
also be compared if they bind to the same site on a ligand. If the binding site is identical
for the two solutes and they each interact at only a single specific region on the ligand,
the ratio of their two retention factors should also be equal to the ratio of the association
equilibrium constants. These values cannot be compared, however, if the analytes bind to
the ligand at multiple sites or if their binding sites are slightly different from one another.
This latter situation occurs because binding regions on an immobilized ligand may lose
activity to slightly different extents when covalent immobilization methods are
employed.43, 79
The most prevalent application for zonal elution is in competition studies. This
application can be used to see if the binding site for one solute is also a binding site for a
second solute. This type of experiment is performed by continuously passing through the
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affinity column a mobile phase with a known amount of competing agent I, which
represents one of the two solutes being compared, while injecting a small plug of the
second solute or analyte A onto the column. If A and I compete for the same sites on the
ligand and both have fast association/dissociation kinetics, the following equation can be
used to describe the observed change in the retention factor for A as it competes with I
for binding sites in the column.36, 51
VM
1 K aI VM [I]
=
+
k
K aA mL
K aA mL

(1-13)

The terms KaI and KaA in this equation represent the association equilibrium constants for
the ligand with the competing agent and analyte, respectively, at their site of competition
in the column. Similar equations can also be derived for more complex models, such as
those that involve more than one binding site, non-specific interactions or allosteric
effects.36
Relationships like the one in Equation 1-13 can be valuable tools in determining
the nature of the competition that occurs between the analyte and mobile phase
additive.46,

74, 76

For example, if a plot of 1/k versus [I] that is made according to

Equation 1-13 gives a linear relationship, then A and I are following a model in which
they have competition at a single class of binding sites on the immobilized ligand. If this
plot shows only random variations in the value of 1/k (or k) as [I] is increased, this
behavior indicates that the analyte and competing agent are not binding at a common site
nor do they have any allosteric interactions with one another. If the response of the plot
is non-linear with a positive slope, the analyte is either binding to multiple sites or there
are negative allosteric effects occurring between the analyte and the competing agent. If
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a non-linear plot is obtained with a negative slope, this is an indication that positive
allosteric effects are present between A and I as they interact with the ligand.36
Advantages of this method are the rapid speed of the experiments, the good runto-run precision, and the need for only a small amount of analyte per run. Once an
appropriate model has been found to describe the retention data (e.g., the use of Equation
1-13 for a system with single site binding), it is possible to also determine the association
equilibrium constants for the competing agent and/or analyte with the ligand from these
experiments. The precision of these measurements is typically in the range of 5-10%
using a standard HPLC system, with a long-term change in ligand activity resulting in
only a small variation in the association equilibrium constants that are determined by this
approach.43
Zonal elution has been used in many past studies in a quantitative fashion to
examine direct competition between solutes and to estimate the association equilibrium
constants for these interactions. It has also been shown more recently how quantitative
information can be obtained from zonal elution and competition studies to look at
allosteric effects between two compounds. Allosteric effects occur when the binding of
an analyte to a ligand at one binding site interferes with the binding of a second analyte to
the ligand at a different binding site. This interference can either hinder or promote the
binding of the analytes to the ligand. The effect of these interactions during a zonal
elution study can be described by the following equation,76 where k0 is the retention
factor for the ligand in the absence of any competing agent in the mobile phase.

 1

k0
1
=
× 
+ 1
k − k 0 β I → A − 1  K aI [I] 

(1-14)
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Figure 1-10. Allosteric effect of R- and S-ibuprofen on the binding of S-lorazepam
acetate to an immobilized HSA, as analyzed according to Equation 1-14
(with permission from Chen, J., and D.S. Hage, Nat. Biotechnol., 22,
1445-1448, 2004).76
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In this equation, the ligand is viewed as having at least two binding sites, one for the
injected analyte (A) and one for the competing agent in the mobile phase (I). The
binding of A with the ligand is altered as I also binds to the ligand, which causes the
association equilibrium constant for A with the ligand to change from KaL to KaL’. This
change is represented in the above equation by the coupling constant βIA, which is equal
to the ratio KaL’/KaL. Equation 1-14 predicts that a plot of k0/(k-k0) versus 1/[I] will give a
linear relationship for a simple allosteric interaction and that, through this relationship,
the values of βIA and KaI can be obtained.76 An example of such a plot is shown in
Figure 1-10. Studies on drug-protein systems have been performed to examine the
allosteric effects occurring between competing agent, such as the interactions between Ror S-ibuprofen with S-lorazepam or the enantiomers of oxazepam on HSA, as well as the
interactions between L-tryptophan and phenytoin on HSA.76

Temperature and Solvent Studies
Zonal elution can also be used to see how a biological interaction will change as
one varies the conditions under which this interaction takes place. For instance, altering
the temperature of a system has been shown to have an effect on the association
equilibrium constants for a variety of compounds with HSA.46, 64, 65 This relationship can
be described for a system with single site binding and over a reasonably narrow
temperature range by using the following equation,
ln K a =

− ∆H ∆S
+
RT
R

(1-15)
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in which ∆H is the change in enthalpy of the reaction, ∆S in the change in entropy, T is
the absolute reaction temperature, and R is the gas law constant. Preparing a plot of ln Ka
versus 1/T in this situation would be expected to result in a graph where the slope is equal
to –∆H/R and the intercept is equal to ∆S/R. Using this information, it is possible to
calculate the overall change in enthalpy and entropy of the reaction. The total change in
free energy (∆G) can also be calculated using Equation 1-16.
∆G = − RT ln K a

(1-16)

This information can be used to determine what force has the greatest contribution to the
free energy on the binding of an analyte to a ligand.64
Three other factors that can be altered during zonal elution experiments are the
pH, ionic strength, and content of organic modifier in the mobile phase. Figure 1-11
shows examples of experiments in which these parameters were varied during a zonal
elution study. Increasing the ionic strength of a buffer solution, for instance, tends to
decrease coulombic interactions in this particular example by a creating a shielding effect
that occurs due to the increase in ion concentration. However, increasing the ionic
strength also tends to increase the adsorption of non-polar solutes onto the column. A
change in pH can alter the conformation of the ligand and the overall net charge of the
ligand, which will also change coulombic interactions. Adding organic modifier can
disrupt the analyte-ligand binding. For example, if the ligand is a protein, the non-polar
bonds could be affected as well as the protein conformation by adding only a small
amount of organic solvent.
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Figure 1-11. Shift in the retention factor of carbamazepine on an immobilized HSA
column with changes in pH (a), ionic strength (b), or organic content of
the mobile phase additive (with permission from Kim, H.S., and D.S.
Hage, J. Chromatogr. B, 816, 57-66, 2005).46
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Characterization of Binding Sites
Zonal elution-based competition studies are often used as a way to characterize
and determine the location of an analyte’s binding site on a ligand. In these studies,
competing agents with known binding sites on the ligand are used to determine whether
they compete with an analyte for interactions with the ligand. This type of competition
experiment not only allows the binding site to be identified for the analyte, but also
provides the association equilibrium constant for the analyte at this specific binding site,
such as is obtained through the use of Equation 1-13 or related expressions.
Another way to map out the binding sites for a particular analyte is by chemically
altering these binding regions and then using zonal elution to determine if there are any
resulting changes in the retention of the analyte. This approach has been used along with
the modification of specific residues on HSA that are thought to lie within one of its
major binding sites. One such study examined the binding of drugs to the Sudlow site II
of HSA by altering Tyr-411 on this protein; the resulting affinity column was shown to
have altered binding for a number of compounds when compared to normal HSA in zonal
elution studies.80 Similar results were obtained for analytes that could bind to Sudlow
site I when Trp-214 on HSA was modified and the resulting ligand was compared to
normal HSA in zonal elution and frontal analysis studies.81

Practical Considerations
While zonal elution is an easy method with which to work, it does have a number
of factors that must be considered to ensure that this approach is properly performed. For
example, the choice of affinity column must be considered and reported. Items that
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should be noted include the column dimensions, the support within the column and the
immobilized ligand. The support within the column should be chosen based upon factors
such as the mobile phase pH that will be used, the desired flow rate range for the
experiments, the allowed column backpressure, and the degree of non-specific binding
that can be tolerated.82 If the experiments will be using high-flow rates, for example, the
backpressure that would be created with a porous silica column might be too high and a
more suitable approach might involve the use of a monolithic column.41,

82

Some

supports such as silica have a limited range of pH stability, which must also be
considered. For example, silica will start to dissolve above a pH of approximately 8.0 or
below 2.0. This pH range of stability can be increased by several means, such as
incorporating zirconium or aluminum on to the silica surface which might improve its
stability under these alkaline conditions.40
When a new column has been created with unknown binding properties, it should
be tested using an analyte with known binding properties to ensure that the column,
support, and immobilized ligand have all been chosen properly for upcoming studies.
Also, when measuring analyte retention, it is crucial that the true center of the peak be
determined. Due to peak tailing, this is typically not the tallest point of the peak but
rather the point at which the two areas of the peak would be equal if the peak were to be
split in half vertically. It is recommended that this be done with computer software to
obtain the most accurate results.
If the analyte has high retention, a low-capacity column might be desirable to
produce shorter retention times. The easiest way to solve this problem is to simply use a
smaller column. This could mean shortening the column length, decreasing the inner
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diameter of the column, or both. Whenever a column containing an immobilized ligand
is created, a control column that was made following the same procedure (minus the
addition of the ligand) should be used to account for any non-specific binding that might
occur. One precaution that must be followed when reducing column size during binding
studies is that it must be ensured that conditions are still present that allow a local
equilibrium to be established as the true center of the analyte’s peak. This is true if
consistent results are still being obtained in the retention factor as the column size is
altered.
Another point to consider when performing zonal elution studies is the
concentration range that should be used for the competing agent or additive in the mobile
phase. It is important to be able to observe a shift in analyte retention, and in order to do
so the appropriate concentration range must be chosen for the competing agent. This can
be done by looking at the shift in k as it moves between its maximum (kmax) and its
minimum (kmin), as shown in Figure 1-12.

The following equation can be used to

describe this relationship for an analyte and a competing agent that engage in direct
competition for a single binding site.36
k − k min
1
=
k max − k min 1 + K aI [I]

(1-17)

It is important to note in this particular case that the shift in retention is due only to the
concentration and association equilibrium constant of the competing agent ([I] and KaI,
respectively).

The ideal range for this experiment is when the mobile phase

concentration of the competing agent gives the greatest change in (k-kmin)/(kmax-kmin).
This occurs between values of 0.1 and 0.9 for this term in Figure 1-12. However, other
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Figure 1-12. Relative shift in analyte retention as a function of competing agent
concentration for a zonal elution experiment in which there is direct
competition between A and I at a single site on an immobilized ligand, as
predicted by Equation 1-13.
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concentrations above or below this optimum level should also be used to ensure that the
correct model is being used to describe the biological interaction.36
Although it is possible to work under non-linear elution conditions,68,

69

zonal

elution studies are usually performed under linear elution conditions. This is the region
where the concentration of analyte is small compared to the amount of immobilized
active ligand within the column. Columns containing larger ligands, such as proteins,
often have a smaller capacity than traditional small molecule columns, thus making it
more difficult to stay within this region. Fortunately, testing for linear elution conditions
simply involves injecting a range of analyte concentrations and observing whether there
is any shift in retention.

Samples concentrations are then selected over which no

significant change in retention occurs. The concentration conditions often vary from one
compound to the next, so it is important to test this feature with each new compound that
is to be examined by zonal elution methods.65
Other factors to consider are the solubility and response or detectability of the
analyte. Solubility will place an upper limit on the concentration range that can be used
for the analyte, while the detector response and analyte detectability will place a lower
limit on this range. Solubilizing agents such as cyclodextrins can often be used to
increase the solubility of an analyte. However they require the use of more complex
models to describe how the retention of an analyte will vary with the concentrations of
both the competing agent and solubilizing agent.83 Absorbance detectors are often used
for zonal elution studies, but if there are issues with the detectability of the analyte then a
more sensitive detection mode can be employed.
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Overall Goals and Summary of Dissertation
The overall goal of this dissertation is to use HPAC to examine the binding of
drugs (e.g., sulfonylurea compounds and others) with HSA and determine the influence
of protein glycation on these binding processes. Chapter 2 will examine the possible use
of four coumarin compounds (i.e., coumarin, 4-hydroxycoumarin, 7-hydroxycoumarin,
and 7-hydroxy-4-methylcoumarin) as alternatives to warfarin, as Sudlow site I probes in
drug-protein binding studies with HSA. HPAC will be used in this work to compare and
evaluate the binding properties of each probe candidate. Frontal analysis studies will be
performed in order to examine the binding constants for each of the compounds. The
data will be fitted to single- and multi-site models to determine the overall binding
relationship of each compound with HSA.

Competition experiments based on the

method of zonal elution will be used to observe the binding interactions between these
compounds and warfarin. The results from these studies will then be used to determine
which of these compounds might be useful as probes for Sudlow site I.
The work in chapter 3 will assess the binding of two sulfonylurea drugs (i.e.,
acetohexamide and tolbutamide) to normal HSA using HPAC. The method of frontal
analysis will be used to estimate the overall binding parameters for each drug with HSA,
while competition studies and zonal elution experiments will be used with R-warfarin and
L-tryptophan as site-selective probes to examine the locations of these interactions on
HSA. The data will be fitted to a number of different models, including single-site, twosite, three-site, and modified three-site models, to obtain a better understanding of these
drug-protein binding interactions. These studies will also be used to illustrate how frontal
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analysis and zonal elution studies can be used to compliment each other in obtaining
information about the interactions that can take place between a drug and a protein.
Chapter 4 will explore how the binding of site-specific probes for Sudlow site I
(warfarin) and Sudlow site II (L-tryptophan) are affected by an increase in HSA
glycation. This investigation will be performed using HPAC and the method of frontal
analysis. Association equilibrium constants and binding capacities for the given probe
compounds will be measured and compared as glycation levels on HSA increase. The
results will be used to clarify how such binding parameters might change within this
system as a result of HSA glycation.
The work in chapter 5 will investigate the drug-protein binding that occurs
between sulfonylureas drugs (i.e., acetohexamide and tolbutamide) and HSA as the
degree of glycation is increased on this protein. In these studies, glycated HSA that has
been prepared in vitro will be used to obtain a range of glycation levels for HPAC
columns. Frontal analysis will then be used to look at the binding for each drug on each
set of glycated HSA columns to determine how the binding parameters for these drugs
are altered as the level of glycation for HSA is increased. Competition experiments will
be performed to further explore how the binding interactions for these drugs are affected
at Sudlow sites I and II on HSA.
Chapter 6 will examine how ligand heterogeneity may affect the results that are
obtained in HPAC studies. These studies will examine the analyte concentrations and
conditions that are necessary to see shifts in analyte-protein binding due to multi-site
interactions in frontal analysis work.

Computer modeling and the use of

chromatographic theory will be used in this work to determine the conditions that are best
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suited for studying changes in analyte-ligand interactions when modifications such as
glycation are occurring in the immobilized ligand.
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CHAPTER 2
THE EVALUATION OF WARFARIN PROBE ALTERNATIVES FOR HUMAN
SERUM ALBUMIN

Introduction
The analysis of drug binding to plasma proteins is important in the pharmaceutical
industry for characterizing the pharmacokinetics and pharmacological effects of drugs.1-6
One plasma protein that has been extensively investigated during such work is human
serum albumin (HSA).7

HSA is the most abundant protein in plasma, with a

concentration that ranges from 35-50 g/L or 0.6-0.7 mM.1, 6-10 This protein is involved in
transporting and distributing many drugs within the body and also binds to a variety of
endogenous and exogenous compounds to aid in their transport and to improve their
solubility.8-12
Numerous techniques have been utilized to look at HSA and drug-protein
interactions, including ultrafiltration,13 ultracentrifugation,14 equilibrium dialysis,15-17
fluorescence,18,

19

UV/Vis

absorption,19

circular

electrophoresis,24-27 surface plasmon resonance,28,

29

dichroism,20-23

capillary

and nuclear magnetic resonance

(NMR) spectroscopy.30, 31 Another technique that has been popular for some time in this
type of application is high-performance affinity chromatography (HPAC).32-36 HPAC is a
specialized form of HPLC that makes use of an immobilized biological ligand (e.g.,
HSA) as the stationary phase.32,

33, 37-39

It has been previously shown that columns

containing immobilized HSA are effective models for soluble HSA in drug binding
studies, making it possible to rapidly obtain accurate and precise estimates of the
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association equilibrium constants and number of binding sites for drugs on HSA, while
also providing a means for studying drug-drug competition for this protein.32, 33, 39 These
properties make HPAC and HSA columns appealing for the high throughput screening of
drug binding to HSA.
Both the number of binding sites and affinity of a drug are important in
determining the interaction of such an agent with HSA.40 This protein is known to
contain two major binding sites for drugs (i.e., Sudlow site I and II),41,

42

as well as

several minor binding sites.43 One way the binding of a drug at a particular site on HSA
can be identified is by determining if this drug has direct competition with a specific
probe for that site. Warfarin (i.e., 3-(α-acetonylbenzyl)-4-hydroxycoumarin) is an anticoagulant drug that is frequently used as a probe for Sudlow site I (also often called the
warfarin-azapropazone site of HSA).44 Warfarin has a relatively high affinity for HSA
and well-characterized interactions with this protein.42

There are, however, several

disadvantages to using warfarin in binding studies. For instance, the strong binding of
warfarin to HSA can lead to long retention times for this drug on HPAC columns that
contain immobilized HSA.45 In addition, although the two enantiomers of warfarin have
the same binding region but slightly different affinities for HSA,44, 45 it can be expensive
to use these separate enantiomers in binding studies (see Table 2-1); this has lead to the
frequent use of racemic warfarin as a probe in many past investigations of solute
interactions with HSA.32,

33, 37, 45

In addition, recent studies have shown that warfarin

undergoes a slow conversion in aqueous solution that can lead to measurable shifts in its
binding to HSA over time.44
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Table 2-1.

Relative cost of warfarin and selected probe candidates for Sudlow site I

of HSA.

Analyte

Relative Cost (U.S. dollars per gram)a

R-Warfarin

$72,800

S-Warfarin

$74,800

Racemic Warfarin

$8.38

Coumarin

$0.31

7-Hydroxycoumarin

$1.32

7-Hydroxy-4-methylcoumarin

$0.35

4-Hydroxycoumarin

$0.35

a

These numbers are based on 2007/2008 list prices from Sigma-Aldrich.
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Figure 2-1.

Structures of warfarin and compounds that were examined as possible
alternative probes for Sudlow site I on HSA.
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The purpose of this study is to examine several compounds that are closelyrelated to warfarin in structure with the goal of determining if these might be used as
alternative probes for Sudlow site I in drug-protein binding studies. Ideally, a suitable
warfarin replacement for high throughput studies should be specific for Sudlow site I and
have few non-specific interactions with HSA or the analysis system. This probe should
also have a good long-term stability in aqueous solution and be present in only a single
form in solution.

Figure 2-1 shows the various coumarin compounds that will be

examined in this study as possible probes for Sudlow site I. These compounds are all
achiral, which avoids the possibility of having any differences in binding by separate
chiral forms; this property also makes these compounds more cost-effective to use (as
illustrated in Table 2-1) and easier to obtain than the separate enantiomers of warfarin. In
this study, the stability for each of these compounds will be examined by NMR
spectroscopy. This will be followed by an evaluation of their binding properties for HSA
by using HPAC. From the results it will be possible to compare these compounds and
determine which might be suitable replacements for warfarin for use in high throughput
screening of drug interactions with HSA. The data obtained in this study should also
provide clues as to how the various structural features of warfarin and related coumarin
compounds contribute to their binding to Sudlow site I.

Theory
Frontal Analysis
The method of frontal analysis (or frontal affinity chromatography) will be used
to determine the number of binding sites and association equilibrium constants for each
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probe candidate examined in this study. This technique is carried out by continuously
applying a solution with a known concentration of the analyte (e.g., a probe candidate) to
a column that contains an immobilized ligand (e.g., HSA). As the analyte binds to the
ligand, the binding sites in the column become saturated, forming a breakthrough curve
like the one shown in Figure 2-2(a). If fast association and dissociation kinetics are
present, the mean position of this breakthrough curve can be directly related to the
concentration of the applied analyte [A], the total moles of active binding sites in the
column for the analyte (mL), and the association equilibrium constant (Ka) for analyteligand binding. The following two equivalent equations can be used to relate these terms
for a system where the analyte binds to a single type of site on a ligand.32, 37

m Lapp =
1
m Lapp

=

m L K a [A]
(1 + K a [A])

(2-1)

1
1
+
( K a m L [A]) m L

(2-2)

In these equations mLapp is the apparent moles of analyte that are required to reach the
mean position of the breakthrough curve at any given concentration of applied analyte,
[A]. According to Equation 2-2, a plot of 1/mLapp versus 1/[A] for a system with 1:1
binding will make it possible to determine both the binding capacity of the column and
the association equilibrium constant by finding the inverse of the intercept and the ratio
of the intercept divided by the slope, respectively.
If multi-site binding occurs between the analyte and ligand, a plot prepared
according to Equation 2-2 will result in a non-linear relationship and produce negative
deviations from a linear response at high analyte concentrations (i.e., low values for
1/[A]).46 To deal with this situation, Equations 2-1 and 2-2 can be expanded into the

71

Figure 2-2.

(a) Frontal analysis curves for 7-hydroxycoumarin at concentrations (from
left-to-right) of 10, 7.5, 5.0, 2.5 or 1.0 µM. (b) Zonal elution competition
studies performed with warfarin in the mobile phase while samples of 5.0
µM 7-hydroxycoumarin were injected; the concentration for warfarin in
the mobile phase (from top-to-bottom) was 20, 15, 10, 5.0, 1.0 or 0 µM.

72

Absorbance (327 nm)

(a)

10

12

14

16

Time (min)

Absorbance (327 nm)

(b)

6

8

10

Time (min)

12

14

73
following forms for the case in which an analyte has two different groups of binding sites
within a column.32, 46

m Lapp =
1
m Lapp

=

m L1 K a1 [A]
m K [A]
+ L2 a2
(1 + K a1 [A]) (1 + K a 2 [A])

1 + K a1 [A] + β 2 K a1 [A] + β 2 K a21 [A] 2
m Ltot {(α 1 + β 2 − α 1 β 2 ) K a1 [A] + β 2 K a21 [A] 2 }

(2-3)

(2-4)

In these expanded equations, Ka1 is the association equilibrium constant for the binding
site with the highest affinity for the analyte, and Ka2 is the association equilibrium
constant for the site with weaker binding, where 0 < Ka2 < Ka1. The term α1 is the
fraction of all binding sites for the analyte that belong to the first group of sites (where α1
=mL1,tot/mLtot), and β2 is the ratio of the association equilibrium constants for the low
affinity binding sites versus the high affinity sites (where β2=Ka2/Ka1).

Similar

expressions can be written for systems with more than two classes of binding sites for an
analyte.46

Zonal elution
The method of zonal elution was utilized in this study to examine the competition
of warfarin with each probe candidate on HSA columns. This type of experiment is
performed by continuously passing a competing agent (I) with a known concentration of
[I] through a column that contains the immobilized ligand of interest (e.g., HSA). A
small plug of the analyte (A) is then injected onto the column, as demonstrated in Figure
2-2(b). If A and I compete for a single class of binding sites on the ligand and have fast
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association/dissociation kinetics for their binding, the following relationship can be used
to describe how the retention of A will be affected by the presence of I.32, 37

VM
1 K aI VM [ I ]
=
+
k
K aA m L
K aA m L

(2-5)

In this equation, k is the observed retention factor for the analyte, as given by k = (tR tM)/tM where tR is the measured retention time for the injected analyte and tM is the
column void time (i.e., the retention time for a non-retained compound). Also included in
Equation 2-5 are the association equilibrium constants for the competing agent and the
analyte with the ligand (KaI and KaA, respectively) and the column void volume (VM).
Equation 2-5 is useful in studying drug-drug competition because it indicates that a plot
of 1/k versus [I] should result in a linear relationship if there is direct competition
between the competing agent and analyte at a single common binding site on the
immobilized ligand, provided the analyte has no other separate binding sites in the
column. Non-linear behavior in this plot will be seen for allosteric competition and
negative deviations at low values of [I] will be noted for multi-site interactions.32

Experimental
Reagents
The coumarin, 4-hydroxycoumarin, 7-hydroxycoumarin and 7-hydroxy-4methylcoumarin were purchased from Aldrich (Milwaukee, WI, USA); all of these
compounds were of analytical grade (>97% pure). The racemic warfarin (98%) was
purchased from Sigma (St. Louis, MO, USA). The HSA (>96%, essentially fatty acid
free) was also from Sigma. The Nucleosil Si-300 silica (7 µm particle diameter, 300 Å
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pore size) was from Macherey-Nagel (Düren, Germany).

Reagents used in the

bicinchoninic acid (BCA) protein assay were from Pierce (Rockford, IL, USA). All
aqueous solutions were prepared using water obtained from a NANOpure system
(Barnstead, Dubuque, IA, USA) and were filtered using 0.20 µm GNWP nylon
membranes from Millipore (Billerica, MA, USA).

Apparatus
NMR studies were carried out on a DRX 500 MHz NMR (Bruker, Billerica, MA,
USA) equipped with a cryoprobe. All 1H NMR spectra were acquired in D2O using 128
scans per sample.

The chromatographic system consisted of a Waters 590 pump

(Milford, MA, USA) and a Beckman 118 Solvent Module (Fullerton, CA, USA). While
both of these components were used in the frontal analysis experiments, only the Waters
590 pump was required for the zonal elution experiments. The chromatographic system
also contained a Jasco UV-975 UV/Vis absorbance detector (Tokyo, Japan) and a sixport Rheodyne Advantage PF valve (Cotati, CA, USA) equipped with a 20 µL sample
loop during the zonal elution experiments.

An Isotemp water bath from Fisher

(Pittsburgh, PA, USA) was used in conjunction with a column water jacket (Alltech, IL,
USA) to maintain a temperature of 37 (± 0.1) ºC during all binding studies.

The

chromatographic data were collected and processed using LabView 5.1 or LabView 8.0
software (National Instruments, Austin, TX, USA). The BCA protein assay was carried
out using a UV 160U spectrophotometer (Shimadzu, Kyoto, Japan) and the diol assay
was performed on a P/ACE MDQ capillary electrophoresis system (Beckman, Fullerton,
CA, USA).
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Methods
1

H NMR spectroscopy was used to monitor the stability of each probe candidate

in a pH 7.4, 0.067 M potassium phosphate buffer. These studies were conducted using an
approach identical to that described previously to examine the stability of warfarin in this
same buffer.44 The photosensitivity of each candidate probe was examined by using split
samples in which one set was stored in the dark and the other set was continuously
exposed to ordinary laboratory light.

Both sets of samples were stored at 25°C

throughout the duration of the stability studies.
The Nucleosil Si-300 silica was converted into a diol form according to the
literature.47 The diol content of the resulting material was 250 (± 20) µmol per gram
silica (1 S.D.), as determined in triplicate by an iodometric capillary electrophoresis assay
48

. This diol silica was used along with the Schiff base method for the immobilization of

HSA.49 This immobilization was carried out by placing two 0.55 g portions of the diol
silica into two separate 20 mL test tubes and combining each of these portions with 0.55
g sodium periodate. A 10 mL portion of a 90:10 acetic acid/water solution was then
added to each test tube and mixed for 2 h at room temperature. The silica in each test
tube was washed six times by centrifugation and resuspension in water. After the final
washing step, 10 mL of pH 6.0, 0.10 M potassium phosphate buffer was added to each
silica sample and the resulting slurries were degassed for approximately 5 min under
vacuum. A 0.055 g portion of HSA was added to one of the silica slurries while the
slurry in the other test tube was used as control with no HSA being added.
Approximately 0.03 g of sodium cyanoborohydride was added to the slurry in each test
tube, with these test tubes then being tightly covered and placed in a rocking shaker at
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4ºC for 6 days. The silica in each test tube was later washed three times by centrifugation
and resuspended in pH 8.0, 0.10 M potassium phosphate buffer. A total of 0.1375 g
sodium borohydride was slowly added in three portions to each of these test tubes over
90 min while the silica slurry was being shaken. The silica was then washed as described
earlier, including three washes with pH 8.0, 0.10 M potassium phosphate buffer that
contained 0.5 M sodium chloride, followed by four more washings with pH 7.4, 0.067 M
potassium phosphate buffer. The final HSA silica and control support with no HSA
added were then stored in pH 7.4, 0.067 M potassium phosphate buffer at 4ºC until use.
The HSA silica and control silica were packed into separate 5.0 cm x 4.6 mm I.D.
stainless steel columns. These columns were downward slurry packed at 3000 psi (0.21
Mbar) using pH 7.4, 0.067 M potassium phosphate buffer as the packing solution. A
small amount of the remaining HSA silica was dried overnight in a vacuum oven and
analyzed by using a BCA assay to determine its protein content.

This assay was

performed in triplicate using soluble HSA as the standard and the control support as the
blank, giving a protein content of 40 (± 2) mg HSA per g silica, or 600 (± 30) nmol per g
silica.
All samples and competing agent solutions for the chromatographic studies were
prepared in pH 7.4, 0.067 M phosphate buffer. This same buffer was used as the
application buffer and isocratic elution buffer during the chromatographic studies. The
mobile phases were stored at 4ºC and were degassed for at least 20 min prior to use. All
chromatographic studies were carried out at 37ºC using a flow rate of 0.5 ml/min. A sixport valve was used to change between the buffer and analyte solutions during the frontal
analysis studies.
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Frontal analysis studies were performed by applying to the HSA column and
control column buffered solutions that consisted of the mobile phase or a known
concentration of the desired probe candidate dissolved in the mobile phase. UV/Vis
absorbance detection was used to monitor the eluting analyte, with the detection
wavelength being adjusted during the study to ensure that the signal was always within
the linear response range of the detector. The concentrations of the probe candidates
ranged from 1-500 µM and the detection wavelengths were as follows: 1-10 µM
coumarin, 275 nm; 50-500 µM coumarin, 241 nm; 1-100 µM 7-hydroxycoumarin, 327
nm; 250-500 µM 7-hydroxycoumarin, 260 nm; 1-10 µM 7-hydroxy-4-methylcoumarin,
327

nm;

50-500

µM

7-hydroxy-4-methylcoumarin,

258

nm;

1-50

µM

4-

hydroxycoumarin, 286 nm; and 65-500 µM 4-hydroxycoumarin, 325 nm. The retained
analyte was eluted and the column was regenerated by changing the mobile phase to a pH
7.4, 0.067 M potassium phosphate buffer. Breakthrough times for each probe compound
on the HSA column and control column were determined by using the equal area
method.32 The breakthrough times for the control column were subtracted from those for
the HSA column to correct for non-specific binding by each probe candidate to the
support. The association equilibrium constants and binding capacities for each probe
candidate on the HSA column were then determined by analyzing the data according to
Equations 2-1 through 2-4.
Competition studies were performed through the use of zonal elution experiments
by injecting 20 µL samples of the probe compounds onto the HSA or control column in
the presence of a known concentration of warfarin in the mobile phase.

Racemic

warfarin was acceptable for use as a probe for Sudlow site I in this particular case
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because both R- and S-warfarin bind to Sudlow site I with only slightly different affinities
for these interactions,44, 45 and the primary goal of this competition study was to identify
if each achiral probe candidate could compete with warfarin for binding at this specific
site. Racemic warfarin is also of general interest for such studies because it is the form of
warfarin that is commonly used in therapeutic preparations. The detection wavelengths
used in the competition studies were as follows: coumarin, 277 nm; 7-hydroxycoumarin,
325 nm; 7-hydroxy-4-methylcoumarin, 325 nm; and 4-hydroxycoumarin, 286 nm. A 5
µM sample of each probe candidate was injected; no significant change in the retention
factors were noted by using lower concentration samples, indicating that these conditions
allowed work to be performed under linear elution conditions. The concentration of
warfarin that was added to the mobile phase ranged from 1-20 µM. This concentration
range was determined in advance to be within the optimum range needed to observe a
shift in analyte retention based on the known association equilibrium constant of warfarin
with HSA.32 The retention factors for the analyte peaks were found by using their central
moments32 using PeakFit 4.12 (Jandel Scientific Software, San Rafael, CA, USA). After
correcting the data for the retention observed on the control column, the resulting
retention factors were plotted according to Equation 2-5 to determine the type of
competition that was present for each probe candidate with warfarin.

Results and Discussion
NMR stability studies
A previous study examined the stability of warfarin in pH 7.4, 0.067 M phosphate
buffer by using 1H NMR spectroscopy.44 It was found in this earlier report that warfarin

80

Figure 2-3.

1

H NMR spectra for 7-hydroxycoumarin when stored in pH 7.4, 0.067 M

phosphate buffer for various lengths of time at 25º C. The same results
were obtained for samples that were stored in the dark or in the presence
of normal laboratory lighting.
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has a slow conversion in structure from one form to another over time. It is believed that
this conversion involves a change in warfarin between one cyclic epimer and another due
to the presence of two chiral centers in the cyclic form of warfarin (Note: although
warfarin is generally drawn in an open chain form, it is known to exist as a cyclic
hemiketal in solution).50 This slow change in structure is temperature-dependent and
follows a first-order decay process that has a rate constant of 0.0086 h-1 (2.39 x 10-6 s-1) at
25°C.44
Similar experiments were conducted in this current report to examine the stability
of each candidate probe.

Some typical results are shown in Figure 2-3 for 7-

hydroxycoumarin, which gave no observable change in its 1H NMR spectrum over the
course of four weeks in pH 7.4, 0.067 M phosphate buffer. Similar results were obtained
for all of the other candidate probes in both the presence and absence of normal
laboratory lighting. These results indicated that each of these probe candidates had better
long-term stability than warfarin in a pH 7.4, 0.067 M phosphate buffer. This greater
stability was not surprising because none of these probe candidates are capable of
forming a cyclic hemiketal in solution, the feature believed to create a change in the
dominant structure of warfarin over time when present in an aqueous solution.44 These
results indicated that all of these probe candidates were stable for at least one month
when stored in a pH 7.4, 0.067 M phosphate buffer. This feature is useful because this is
the same buffer that is commonly used in drug binding studies with HSA.

Frontal analysis studies
Frontal analysis was performed using HPAC and an immobilized HSA column to
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determine the number of binding sites and association equilibrium constants for each
probe candidate with HSA.

Figure 2-2(a) shows some typical frontal analysis

breakthrough curves that were obtained for the binding of 7-hydroxycoumarin to the
HSA column. The breakthrough curves in this type of experiment shifted to the left, and
to smaller breakthrough times, as the concentration of the analyte was increased. Similar
results were obtained for the other probe candidates and in work performed with the
control column.
Each of the probe compounds showed some non-specific binding to the support in
the control column. This binding ranged from a corrected breakthrough time at 0.5
ml/min of 0.3-1.2 min (when using a void time of 1.5 min). The non-specific binding
was low for most of the probe candidates and made up only 6-15% of the total binding
noted on the HSA column when applying a 1.0 µM solution of the given probe candidate.
The only exception was coumarin, for which non-specific binding to the support made up
48% of the capacity measured on the HSA column under the given experimental
conditions.

This higher level of non-specific binding may limit the usefulness of

coumarin as an alternative probe to warfarin when working with columns that are based
on silica supports; however, it is possible that coumarin might still be usable with HPAC
columns that are prepared using other support materials.
Equation 2-2 was initially used to examine the frontal analysis data. Double
reciprocal plots of 1/mLapp versus 1/[A] that were obtained are shown in Figure 2-4 for 7hydroxycoumarin, coumarin, and 7-hydroxy-4-methylcoumarin at applied concentrations
that ranged from 1-500 µM. These plots had correlation coefficients that ranged from
0.9983-0.9998 (n = 10), but they did show some negative deviations at high analyte
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Figure 2-4.

Double reciprocal plot of frontal analysis data obtained for (a) 7hydroxycoumarin, (b) coumarin, and (c) 7-hydroxy-4-methylcoumarin on
an HSA column. The error bars represent a range of ± 1 S.D. The best-fit
lines were obtained by using Equation 2-2. The inset shows an expanded
view of the negative deviations that occur at high analyte concentrations
(i.e., low values for 1/[analyte]).

85
180

10

1/mLapp (x 106 mol-1)

5

120
0
0

10

20

30

40

50

60

(a)
0
0

250

500

750
3

1000

-1

1/[7-Hydroxycoumarin] (x 10 M )

800

50

1/mLapp (x 106 mol-1)

25

600

0
0

10

20

30

40

50

400

200

(b)
0
0

250

500

750
3

1000

-1

1/[Coumarin] (x 10 M )

160

10

1/mLapp (x 106 mol-1)

5

120

0
0

10

20

30

40

50

80

40

(c)
0
0

250

500

750
3

-1

1/[7-Hydroxy-4-methylcoumarin] (x 10 M )

1000

86
concentrations (i.e., above 30-50 µM, as demonstrated by the inset in Figure 2-4). These
results suggested that these three compounds each had a single major class of binding
sites on HSA (creating the good linearity seen at low-to-moderate concentrations of these
analytes), as well as a group of weaker binding sites (producing the negative deviations
observed at high analyte concentrations).

The same conclusion was reached for 4-

hydroxycoumarin, which showed more apparent deviations from linearity at higher
concentrations.
Figure 2-5 shows the results that were obtained when plots of mLapp versus the
concentration of the applied analyte were prepared for 4-hydroxycoumarin and examined
according to a one-site or two-site model. These data were found to produce the best fit
to the two-site model described by Equation 2-3, giving a correlation coefficient of
0.9998 (n =10) and only random variations in the corresponding residual plot, with an
absolute residual sum of squares that was equal to 6.3 x 10-17 (see graph in lower part of
Figure 2-5). When the same plot was analyzed according to a one-site model described
by Equation 2-1, the correlation coefficient was 0.9890 and non-random deviations were
noted in the residual plot at both low and high analyte concentrations; this residual plot
also showed a much larger absolute residual sum of squares (5.3 x 10-15) than that
obtained with the two-site model. The other probe candidates also gave better fits to a
two-site model than a one-site model for such plots, with correlation coefficients of
0.9997-0.9999, smaller absolute residual sum of squares, and only random deviations in
the residual plots for the two-site model.
Table 2-2 summarizes the association equilibrium constants and binding
capacities that were estimated from these plots based on a two-site model. The term "Site
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Figure 2-5.

Fit of frontal analysis data for 4-hydroxycoumarin to a (a) one-site model
or a (b) two-site binding model and the corresponding residual plots for
these graphs (see inserted figures). The best-fit parameters for the two-site
model are given in Table 2-2. The values of the residuals in the inserted
graphs were calculated by taking the difference between the actual and
predicted values for mLapp at each given concentration of [4hydroxycoumarin].
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Table 2-2.

Association equilibrium constants (Ka) and binding capacties (mL)

measured for each of the tested probe candidates on an HSA column using a two-site
model.

Analyte

Ka (M-1)

mL (mol)

Site 1: 6.4 (± 5.1) x 103

Site 1: 1.2 (± 1.6) x 10-7

Site 2: 7.3 (± 8.1) x 102

Site 2: 7.8 (± 2.6) x 10-7

Site 1: 8.2 (± 0.9) x 103

Site 1: 5.3 (± 0.7) x 10-7

Site 2: 8.6 (± 1.4) x 102

Site 2: 1.5 (± 0.1) x 10-6

7-Hydroxy-4-methyl-

Site 1: 2.2 (± 0.8) x 104

Site 1: 2.8 (± 0.8) x 10-7

coumarin

Site 2: 3.8 (± 30) x 101

Site 2: 3.7 (± 0.3) x 10-5

4-Hydroxycoumarin

Site 1: 5.5 (± 0.5) x 104

Site 1: 2.4 (± 0.1) x 10-7

Site 2: 4.4 (± 2.5) x 102

Site 2: 1.5 (± 0.6) x 10-6

Coumarin

7-Hydroxycoumarin

The values in parenthesis represent a range of ± 1 SD. All of these measurements were
made at 37ºC in the presence of pH 7.4, 0.067 M potassium phosphate buffer.
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1" in this table refers to the higher affinity binding region for each probe candidate, while
"Site 2" refers to the weaker binding regions that were detected. The high affinity sites
had association equilibrium constants for these probe candidates that ranged from 6.4 x
103 M-1 (for coumarin) up to 5.5 x 104 M-1 (for 4-hydroxycoumarin) at 37° C and pH 7.4.
These values were approximately 4.5- to 40-fold lower than the average association
equilibrium constant of 2.5 x 105 M-1 that has been reported for warfarin enantiomers
with HSA under similar conditions.44, 45 It is interesting to note that the probe candidate
with the closest similarity to warfarin in its structure also gave the largest association
equilibrium constant for its high affinity site. This observation fits with a model in which
at least some of these probe candidates were binding to Sudlow site I of HSA.
The binding capacities obtained for the high affinity site of each probe compound
were compared to the amount of HSA in the HPAC column to give the specific activities
for these sites. The total number of moles of HSA in this column was calculated to be
224 (± 11) nmol based on the known protein content of the HSA support, the packing
density of this material and the total column void volume.

The resulting specific

activities of the high affinity site for coumarin, 7-hydroxy-4-methylcoumarin and 4hydroxycoumarin were in the range of 0.5-1.2 mol probe/mol HSA, as would be expected
for interactions at a single binding region on HSA.44, 45 The specific activity obtained for
7-hydroxycoumarin was 2.3 mol/mol HSA, suggesting that this probe candidate might
have interacted with two sites on HSA that had similar association equilibrium constants;
such a feature would limit the usefulness of this particular compound if the goal is to use
it as a specific probe for only Sudlow site I.
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The weak affinity regions for these probe candidates had apparent association
equilibrium constants in the range of only 38-860 M-1 at 37°C and pH 7.4.

These

interactions probably represent non-specific binding of these compounds to the structure
of HSA. This conclusion is supported by the binding capacities that were estimated for
these regions, which gave specific activities that ranged from 3.4-16 mol/mol HSA.
These large specific activities agree with what would be expected for a group of nonselective interactions between a solute and a protein rather than binding at a specific
binding site. A similar set of low affinity interactions at secondary sites has been noted
between warfarin and HSA, with a reported association equilibrium constant of 1.4 x 104
M-1 at 25°C.51

Competition studies
Zonal elution studies were carried out to determine if the probe candidates could
compete directly with warfarin for Sudlow site I on HSA. These studies were performed
by adding various known concentrations of racemic warfarin to the mobile phase while a
small and fixed amount of each candidate was injected onto the column. Figure 2-2(b)
shows how the retention of 7-hydroxycoumarin changed with increasing concentrations
of warfarin in the mobile phase. Figure 2-6 shows the results that were obtained when
the data of such studies were analyzed according to Equation 2-5.

Coumarin, 7-

hydroxycoumarin, and 7-hydroxy-4-methylcoumarin (see Figure 2-6(a)-(c)) gave a linear
response at warfarin concentrations of at least 5 µM or higher, along with a small
negative deviation from this linear behavior at lower warfarin concentrations or when no
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Figure 2-6.

Zonal elution competition studies for injections of (a) coumarin, (b) 7hydroxycoumarin,

(c)

7-hydroxy-4-methylcoumarin,

and

(d)

4-

hydroxycoumarin in the presence of racemic warfarin on an HSA column.
The best-fit lines in (a)-(d) were found by using Equation 2-5 along with
data obtained at warfarin concentrations of 1-20 µM for plot (a), and 5-20

µM for plots (b)-(d).
follows:

The equations for these best-fit lines were as

(a) y = 3.08 (± 0.10) x 104 x + 0.906 (± 0.013);
(b) y = 3.21 (± 0.06) x 103 x + 0.144 (± 0.001);
(c) y = 4.48 (± 0.24) x 103 x + 0.135 (± 0.003);
(d) y = 6.05 (± 0.07) x 103 x + 0.0236 (± 0.0010).

The correlation coefficients for all of these plots were in the range of
0.9971-0.9998 (n = 4-5). Values in parentheses represent ± 1 SD.
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warfarin was present. The relative difference in the retention factors calculated from the
best-fit intercept and actual intercept for each of these plots was in the range of 12.8 to
16.7%.

4-Hydroxycoumarin gave slightly different behavior, with a linear response

being seen in Figure 2-6(d) at warfarin concentrations above 5 µM and a slight positive
deviation being noted at lower warfarin concentrations.
For each probe candidate, the intercept of the best-fit line was consistent with the
value predicted for the high affinity site by using the data in Table 2-2 and Equation 2-5.
This result indicated that competition between warfarin and the probe candidates at their
high affinity sites was the dominant interaction being observed in the linear regions of
these plots. In addition, the difference in the actual intercept and the best-fit intercept
from the linear region for plots with negative deviations was consistent with the level of
retention predicted from Table 2-2 for the weak affinity regions of these probe
candidates. The relative size of the contributions of the weak sites to retention in the
absence of any warfarin (i.e., at the y-intercept in Figure 2-6) was estimated from the data
in Table 2-2 to be about 5% for 4-hydroxycoumarin, 23% for 7-hydroxycoumarin and
19% for 7-hydroxy-4-methylcoumarin. The relative contribution of the weak sites to
retention was 43% for coumarin, which again suggested that this candidate would have
limited usefulness as a site-specific probe for HSA.
The behavior observed for coumarin, 7-hydroxycoumarin and 7-hydroxy-4methylcourmin for plots like those in Figure 2-6 is consistent with a model in which
direct competition is occurring between warfarin and these probe candidates at both their
high and weak affinity sites. Competition at the high affinity sites was noted to dominate
at moderate-to-high concentrations of warfarin (creating the linear response seen in this
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region), while both the weak and high affinity sites had significant contributions to
retention at lower warfarin concentrations. Similar behavior has been noted previously
for other solute systems with competition at two groups of sites on HSA.32 The results for
4-hydroxycoumarin are consistent with a slightly different model.

For this probe

candidate, it appears that 4-hydroxycoumarin and warfarin were again competing for the
high affinity site of this probe at moderate-to-low concentrations of warfarin. However,
the positive deviations seen when only small concentrations of warfarin were present
suggest that at least some of the weak affinity sites for 4-hydroxycoumarin were showing
little or no binding for warfarin under these conditions.
The ratio of the slope and intercepts for the best-fit lines in these plots were used
along with Equation 2-5 to estimate the value of warfarin’s association equilibrium
constant at its site of competition with each probe candidate. It was found that warfarin
had an association equilibrium constant of 2.6 (± 0.1) x 105 M-1 as it underwent binding
at the high affinity site for 4-hydroxycoumarin. This value is statistically identical to the
average association equilibrium constant of 2.5 x 105 M-1 that has been reported for Rand S-warfarin at Sudlow site I of HSA, thus confirming that the high affinity site of 4hydroxycoumarin was the same as this binding region.44, 45 Thus, it appeared from this
result that 4-hydroxycoumarin could indeed be used as a replacement for warfarin as a
probe for examining the binding of other solutes at Sudlow site I.
The association equilibrium constants determined for racemic warfarin at its site
of competition with the other probe candidates were about an order of magnitude lower
than the full value for warfarin at Sudlow site 1. These calculated values were as
follows: competition with coumarin, 3.4 (± 0.1) x 104 M-1; competition with 7-
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hydroxycoumarin, 2.23 (± 0.05) x 104 M-1; and competition with 7-hydroxy-4methylcoumarin, 3.3 (± 0.2) x 104 M-1. Because warfarin has only one major binding site
on HSA, these results indicate that these probe candidates are binding to and competing
with warfarin at only part of this site. A similar effect has been noted in the competition
of octanoic acid with various drugs for binding to HSA.36 This scenario is consistent
with the fact that each of these three probe candidates contains only part of the structure
of warfarin (i.e., as is the case for coumarin) or contain additional groups that are not
present in warfarin (e.g., the 7-hydroxyl group in 7-hydroxycoumarin and 7-hydroxy-4methylcoumarin). This would also explain why the association equilibrium constant
calculated for warfarin during its competition with 4-hydroxycoumarin was essentially
the same as the full value reported for warfarin at Sudlow site I because this particular
probe candidate has the closest structure to that of warfarin and the best chance for fully
competing with warfarin at Sudlow site I.

Effects of Coumarin Structure on Binding to Sudlow Site I
Although the main goal of this study was to identify alternatives to warfarin as
probes for Sudlow site I, the results that were obtained in the frontal analysis and zonal
elution studies do provide some information on the nature of the binding of warfarin and
related compounds to HSA. It is known that many solutes like warfarin that bind at
Sudlow site I are bulky heterocyclic compounds that also contain anionic groups near a
central location of the molecule.51, 52 This general model was confirmed in this current
report by the fact that the probe with the greatest similarity to warfarin in its affinity for
Sudlow site I was 4-hydroxycoumarin, a compound which contains the same type of
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heterocyclic ring and anion-forming, acidic hydroxyl group that appears in warfarin.
Removal of the hydroxyl group from this structure (leaving only the coumarin backbone)
produced a decrease in Ka of 8.5-fold, as noted in Table 2-2 when comparing the results
at Site 1 for 4-hydroxycoumarin and coumarin.
It is also clear from the data in Table 2-2 that the structure shared by 4hydroxycoumarin and warfarin is only partly responsible for the high affinity of warfarin
at Sudlow site I. This result is demonstrated by the 4.5-fold difference in affinity at this
site that was measured for 4-hydroxycoumarin versus the average Ka value of 2.5 x 105
M-1 that has been reported for warfarin enantiomers under equivalent conditions.44,

45

This comparison indicates that the 3-(α-acetonylbenzyl) group on warfarin (see lower left
portion of the warfarin structure in Figure 2-1) plays a significant role in contributing to
the high affinity of this drug at Sudlow site I.
The positions of the hydroxyl group and other side chains about the coumarin ring
were also found to affect the affinity of the tested probe compounds for HSA. Table 2-2
indicates that moving the hydroxyl group from the 4- to 7-position created a 6.7-fold
lower affinity for 7-hydroxycoumarin versus 4-hydroxycoumarin as these compounds
were bound by Sudlow site I. Placing a methyl group in the 4-position regained some of
this affinity, as shown in Table 2-2 by the 2.7-fold increase in the association equilibrium
constant at Site 1 when going from 7-hydroxycoumarin to 7-hydroxy-4-methylcoumarin.

Conclusions
This study examined the binding of four coumarin compounds to HSA using
HPAC.

It was determined by frontal analysis that all of the probe candidates had
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interactions with HSA that followed a two-site model, including a high affinity site and a
second group of weak, non-specific binding regions. It was found in zonal elution
competition studies that all of these probe candidates gave direct competition with
warfarin at their high affinity sites, as well as either direct competition or no competition
at their weak affinity sites (the latter behavior been noted in the case of 4hydroxycoumarin). The results of this study not only allowed new probes for HSA to be
identified, but also provided information on how the coumarin ring, hydroxyl group and
3-(α-acetonylbenzyl) group that are part of warfarin each contribute to the binding of this
drug at Sudlow site I.
Of the various probe candidates that were examined, 4-hydroxycoumarin was
found to be the best alternative for warfarin in its binding to Sudlow site I of HSA. Some
advantages of using 4-hydroxycoumrin for this purpose include its good long term
stability in a pH 7.4 phosphate buffer and its ability to be obtained in an inexpensive and
single form for binding studies. 4-Hydroxycoumarin also has slightly weaker binding
than warfarin to HSA, which would avoid the need for long elution times when working
with such an agent in HPAC.
The other tested probes had several limitations. Coumarin had high non-specific
binding to silica supports and a relatively large contribution by its weak affinity sites on
HSA to its overall binding to this protein. In addition, coumarin, 7-hydroxycoumarin and
7-hydroxy-4-methylcoumarin all appeared to compete with warfarin for only part of
Sudlow site I. 7-Hydroxycoumarin and 7-hydroxy-4-methylcoumarin did have small
non-specific interactions with the support and with HSA, which may make them useful in
some situations as probes for drug binding studies.

However, binding capacity
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measurements did suggest that 7-hydroxycoumarin may have more than one high affinity
site on HSA. Thus, 4-hydroxycoumarin was found to be the best overall alternative to
warfarin as a probe for Sudlow site I of HSA.
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CHAPTER 3
THE BINDING OF SULFONYLUREAS TO NORMAL HSA

Introduction
Sulfonylureas are a group of drugs used to treat type II diabetes (i.e., adult onset
or non-insulin dependent diabetes). These drugs stimulate acute insulin release from the
beta cells of pancreatic islet tissue.1 Tolbutamide and acetohexamide are two common
“first-generation” sulfonylurea drugs (see Figure 3-1).1-3 These agents have been widely
used since the introduction of tolbutamide in 1956.2, 4 All sulfonylureas bind tightly to
serum proteins, with human serum albumin (HSA) being the main protein that is believed
to be involved in these interactions.2
HSA is the most prevalent plasma protein.5, 6 This protein is composed of a single
peptide chain and has a typical concentration in blood of 35-50 mg/ml (i.e., 0.6-0.7
mM).5-9 HSA is known to act as a transport protein that binds to a wide variety of
compounds, including many drugs, hormones, bilirubin, and fatty acids.5-8 In this role,
HSA and its interactions with drugs can have a strong influence on the free
concentrations of drugs in plasma6,
properties of a drug.5-8,

11

7, 10

and the pharmacologic and pharmacokinetic

For instance, this binding can affect drug adsorption,

distribution, metabolism and excretion.5, 12
Previous studies have been conducted to investigate the binding of both
acetohexamide4, 13-15 and tolbutamide3, 13-19 to HSA using equilibrium dialysis, dynamic
dialysis, equilibrium gel filtration, fluorescence quenching, ultrafiltration, isothermal
titration calorimetry, heteronuclear 2-D NMR, and reversed-phase liquid
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Figure 3-1.

Structures of acetohexamide and tolbutamide.

106

Acetohexamide

O
O

O
S
N
H

H3C

N
H

Tolbutamide

CH3

107
chromatography.

However, the binding constants that have been obtained in these

studies have ranged by almost ten-fold for both acetohexamide ([0.4 to 4.1] x 105 M-1)4, 15
and tolbutamide ([0.4 to 3.0] x 105 M-1).15-20 It is also not yet apparent as to whether one
or several major sites on HSA are involved in these interactions.4, 16-18
This current report will use the method of high-performance affinity
chromatography (HPAC) to obtain more detailed information on the strength and location
of the binding sites on HSA for acetohexamide and tolbutamide. This method has
previously been used to examine the binding of HSA to many other drugs and small
solutes, such as coumarins,20-22 indoles,23 carbamazepine,20,

24, 25

ibuprofen and

benzodiazepines.22, 26 The benefits of HPAC over traditional methods like ultrafiltration
and equilibrium dialysis include its use of smaller amounts of sample, its better
reproducibility and precision, and its ease of automation.27-29
The combined use of HPAC with frontal analysis (i.e., frontal affinity
chromatography) and immobilized HSA columns will first be used in this study to
estimate the total number of binding sites and association equilibrium constants of
acetohexamide and tolbutamide with HSA. Zonal elution and competition with siteselective probe compounds for HSA will then be used to examine the binding of these
two sulfonylurea drugs at the major binding regions for drugs on this protein (i.e.,
Sudlow site I and II).30, 31 The results will be compared to previous observations made in
the literature and should provide a more complete picture of how these drugs bind with
HSA and are transported by this protein in the circulation. This work will also be used to
illustrate how HPAC and several tools available in this method (e.g., equations for
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examining multi-site interactions or allosteric effects)26 can be utilized to examine
relatively complex drug-protein interactions.

Experimental
Reagents
The acetohexamide, tolbutamide (≥ 99.9 %), warfarin (≥ 97%), and L-tryptophan
(98%) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The buffer salts and
HSA (essentially fatty acid free, ≥ 96%) were also obtained from Sigma-Aldrich. The
Nucleosil Si-300 (7 micron particle diameter, 300 Å pore size) was from MachereyNagel (Düren, Germany). Reagents used in the bicinchoninic acid (BCA) protein assay
were from Pierce (Rockford, IL, USA). All solutions were made using water obtained
from a NANOpure system (Barnstead, Dubuque, IA, USA). Prior to use, all aqueous
solutions were filtered through a 0.20 µm GNWP nylon membrane from Millipore
(Billerica, MA, USA).

Apparatus
The chromatographic system consisted of a DG-2080-53 three-solvent degasser,
two PU-2080 isocratic HPLC pumps, a UV-2075 absorbance detector, and a AS-2055
autosampler (Jasco, Tokyo, Japan), along with a Rheodyne Advantage PF 6-port valve
(Cotati, CA, USA). A Jasco CO-2060 column oven was used to control the column
temperature. All of the chromatographic components were controlled through EZChrom
Elite software v3.2.1 (Scientific Software, Inc., Pleasanton, CA, USA) via Jasco LC Net
hardware. In-house programs written in Labview 5.1 (National Instruments, Austin, TX,
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USA) were used to determine the analyte breakthrough times in the frontal analysis
experiments. PeakFit 4.12 (Jandel Scientific Software, San Rafael, CA, USA) was used
to determine the peak central moments in the zonal elution studies.

Methods
Nucleosil Si-300 silica was modified to produce diol silica by using a previouslypublished procedure.32 This diol silica was then used to immobilize HSA by the Schiff
base method, also according to previous methods.21, 33 A control support was made in the
same manner without any added HSA. A small amount of the HSA immobilized support
and the control support was dried overnight in a vacuum oven, and a bicinchoninic acid
(BCA) assay was used to determine the final protein content of this material. This assay
was performed in triplicate using soluble HSA as the standard and the control support as
the blank. The amount of immobilized HSA was estimated to be 38 (± 3) mg/g silica, or
approximately 600 (± 30) nmol HSA/g silica. Separate 2.0 cm x 2.1 mm ID stainless
steel columns containing either the HSA silica or the control support were downward
slurry packed with the silica at 3000 psi (20.7 MPa) using pH 7.4, 0.067 M potassium
phosphate buffer as the packing solution. These columns were stored in pH 7.4, 0.067 M
potassium phosphate buffer at 4 ºC when not in use. Experiments were performed over a
period of eleven months and over the course of less than 500 sample applications or
injections; similar HSA columns have been shown to maintain good stability in drug
binding studies under these conditions.34
All aqueous solutions of samples and competing agents were prepared using pH
7.4, 0.067 M potassium phosphate buffer. This buffer was used as the application and
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regeneration buffer during the frontal analysis and zonal elution studies (note: no elution
buffer was needed in this work because the drugs and competing agents that were applied
to the HSA columns could later be eluted under isocratic conditions by this same buffer).
All solutions were filtered through a 0.2 µm nylon filter and degassed under vacuum for
at least 15 min prior to use. A flow rate of 0.5 ml/min was used throughout this work for
sample application and injection. This flow rate has been shown in previous work to
obtain reproducible binding capacities and retention factors for other drugs or small
solutes on similar HSA columns.35 During frontal analysis, the application of either the
pH 7.4, 0.067 M phosphate buffer or the desired drug solution was made by alternating
between these solutions through the use of a six-port valve. The application of samples
in the zonal elution experiments was controlled through the autosampler and was carried
out by using an injection volume of 20 µL.
Frontal analysis studies were performed by first equilibrating the HSA column in
the presence of pH 7.4, 0.067 M potassium phosphate buffer at 37 ºC. A switch was then
made from this buffer to the same buffer that also contained a known concentration of the
analyte of interest (i.e., fifteen concentrations of acetohexamide ranging from 1 to 1000
µM, and nine concentrations of tolbutamide ranging from 1 to 200 µM). Once the
analyte had saturated the column and created a breakthrough curve, the system was
switched back to applying only the pH 7.4 buffer to elute the retained analyte from the
column.

Elution of the analyte was monitored using a UV/Vis detector, with the

wavelength of detection being adjusted at high concentrations to ensure that a linear
change in signal with concentration was always present. Acetohexamide was monitored
at 248 nm for applied concentrations of 1-20 µM and at 315 nm for concentrations of 30-
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1000 µM. Tolbutamide was monitored at 250 nm for all of its applied concentrations.
These runs were performed in triplicate on both the HSA column and the control column.
Breakthrough times were determined using the equal area method27 and were corrected
for non-specific binding to the support by subtracting the values for the control column
for those measured on the HSA column at each given concentration of the analyte (e.g.,
interactions with the support made up 33% of the total binding noted for 1 µM
tolbutamide and 21% for 1 µM acetohexamide on the HSA columns, but a correction for
these non-specific interactions could be effectively made in this manner, as demonstrated
for other analytes in previous studies with HSA columns).20-22 The resulting data were
analyzed according to various binding models, as described in the Results and Discussion
section.

Linear regression was performed using Microsoft Excel 2003 (Microsoft

Corporation, Redmond, WA, USA). Non-linear regression was carried out using DataFit
8.1.69 (Oakdale Engineering, PA, USA).
The competitive binding, zonal elution studies were performed using R-warfarin
and L-tryptophan as the injected agents. These compounds have been shown in the past
to bind to Sudlow sites I and II, respectively, and are often used as probes in drug-binding
studies.30, 31 Additions of 20 µL samples containing 5 µM R-warfarin or L-tryptophan
were injected onto a column equilibrated with a mobile phase that contained a known
concentration of the drug of interest.

The injected agent was always kept at a

concentration of 5 µM, a value found in additional experiments to provide linear elution
conditions for the HSA columns used in this study,23, 36 while the analyte in the mobile
phase (acetohexamide or tolbutamide) was applied at concentrations that ranged from 0
to 20 µM. These studies were performed at 37 ºC on both the HSA and control columns.
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A pH 7.4, 0.067 M potassium phosphate buffer was used as the mobile phase and to
prepare all solutions of the injected analytes and competing agents. The elution of Rwarfarin and L-tryptophan was monitored at 308 and 280 nm, respectively. The central
moments of the resulting peaks were determined by using PeakFit v.4.12 and an
exponentially-modified Gaussian curve fit. The resulting values were used along with
the measured void time of the system, as determined by injecting 20 µL of 20 µM sodium
nitrate (i.e., a non-retained solute on HSA columns), to obtain the retention factors for
each probe compound. Sodium nitrate was monitored at 205 nm.

Results and Discussion
Frontal analysis studies using acetohexamide
In these studies, frontal analysis was used to estimate the association equilibrium
constants (Ka) for acetohexamide and the number of binding sites of this drug with HSA
by using HPAC and columns that contained immobilized HSA. This was done by
measuring the binding capacity of this column (mL) as the concentration of
acetohexamide that was applied to the column was varied. Some typical breakthrough
curves that were obtained in these experiments are shown in Figure 3-2.

If fast

association/dissociation kinetics are present for the binding of the applied analyte with
the immobilize protein (i.e., as is typically present during drug-HSA interactions), the
mean position of the resulting breakthrough curve can be related to Ka, mL, and the
applied concentration of the analyte [A].27, 28 For an analyte that binds to only a single
type of site within the column, the following equations can be used to describe this
relationship.24, 27
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Figure 3-2.

Breakthrough curves for acetohexamide on an immobilized HSA column
at applied concentrations (from left to right) of 10, 7.5, 5, 2.5, and 1 µM.
Alternative detection wavelengths were used for some of the higher
concentrations of analyte solutions to maintain a linear response in
absorbance versus concentration during these studies, as described in the
Experimental Section. Other conditions are given in the text.
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1
m Lapp

=

1
1
+
( K a m L [A]) m L

(3-1)

or

m Lapp =

m L K a [A]
(1 + K a [A])

(3-2)

In these equations, mLapp is the apparent moles of analyte required to saturate the column
at a particular concentration. Equation 3-1 indicates for a system with a single type of
binding site that a plot of 1/mLapp versus 1/[A] should provide a linear relationship from
which the values of Ka and mL can be determined from the slope and intercept. If multisite binding is present, such a plot should approach a linear response at low
concentrations (i.e., high values for 1/[A]) and give a curved response and negative
deviations at high analyte concentrations (i.e., low values for 1/[A]), as illustrated in
Figure 3-3.
In the case of multi-site binding, Equation 3-1 can be expanded to allow for more
than one class of binding sites. For example, a system containing two binding sites
would have the following relationship,24, 27
1
m Lapp

=

1 + K a1 [A] + β 2 K a1 [A] + β 2 K a21 [A] 2
m Ltot {(α 1 + β 2 − α 1 β 2 ) K a1 [A] + β 2 K a21 [A] 2 }

(3-3)

where Ka1 is the association equilibrium constant for the binding site with the highest
affinity (L1) and α1 is the fraction of all binding regions that make up the high affinity
binding sites (i.e., α1 = mL1,tot/mLtot).

The term β2 is the ratio of the association

equilibrium constants for any lower affinity site (e.g., Ka2) versus the highest affinity site,
where β2 = Ka2/Ka1 and 0 < Ka2 < Ka1. Equation 3-3 can also be written in a nonreciprocal form, as given below.24, 27
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m Lapp =

m L1 K a1 [A]
m K [A]
+ L2 a2
(1 + K a1 [A]) (1 + K a 2 [A])

(3-4)

Using this latter equation it is possible to find both Ka and mL values for an analyte by
plotting mLapp versus [A], from which the values of the individual association equilibrium
constants and binding capacities for each site can be obtained by non-linear regression.
Although Equation 3-3 would be expected to produce a non-linear response throughout a
broad range of concentrations, it is known at low analyte concentrations that a linear
response can still be observed even for a system with multi-site binding, as demonstrated
by the following equation.37

lim

[A]→0

1
m Lapp

2

2

α1 + β 2 − α1β 2
1
=
+
m Ltot (α 1 + β 2 − α 1 β 2 ) K a1 [A] m Ltot (α 1 + β 2 − α 1 β 2 ) 2

(3-5)

Equation 3-5 indicates that a linear relationship will be approached even for a multi-site
system for a plot of 1/mLapp versus. 1/[A] at low analyte concentrations, or high values for
1/[A].37 The values of mLtot and Ka1 in this relationship will now be a function of the
relative amount of each type of binding site in the column and their relative affinities for
the analyte, as described by the terms α1 and β2 in the Equation 3-5. However, it has also
been shown in previous theoretical studies that the ratio of the intercept versus slope for
this plot can still be used to provide a good estimate of Ka1 (i.e., the association
equilibrium constant for the highest affinity sites).37
From the breakthrough curves that were obtained for acetohexamide (see
examples in Figure 3-2), double-reciprocal plots were first made of 1/mLapp versus 1/[A]
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Figure 3-3.

A double-reciprocal plot for frontal analysis studies examining the binding
of acetohexamide to an immobilized HSA column. When comparing this
response to the linear relationship that is predicted by Equation 3-1, it was
apparent that negative deviations occurred at high analyte concentrations
(i.e., low values of 1/[A]), indicating that multiple binding regions for
acetohexamide were present. The dashed line shows the linear response
that was obtained for the data at relatively low analyte concentrations (i.e.,
high 1/[A] values), which can still be used in such a case to estimate the
association equilibrium constant for the highest affinity binding sites in
such a system.
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and compared to the responses predicted by Equations 3-1 and 3-3. Some curvature was
noted at high analyte concentrations (i.e., low values for 1/[A]), indicating that more than
one type of binding site was present for acetohexamide on HSA (Figure 3-3).

In

addition, a linear response was approached at high values of 1/[A], as predicted by
Equation 3-5. By using the best-fit line to the linear region of this data set (as occurred at
1-10 µM acetohexamide), an estimate of 2.0 (± 0.1) x 105 M-1 was obtained for the
association equilibrium constant for the highest affinity sites (Ka1) in this system with an
mL value of 1.9 (± 0.1) x 10-8 mol.37
The frontal analysis data for acetohexamide were also examined by using a nonreciprocal plot. Figure 3-4 shows the results that were obtained when these results were
compared to the best-fit response predicted by Equation 3-4 for a two-site binding model.
Using a two-site model, acetohexamide was found to have a relative high affinity group
of sites with an average Ka of 1.3 (± 0.2) x 105, as well as a group of low affinity sites
with an average Ka of 3.5 (± 2.9) x 102 M-1. The corresponding best-fit values of mL for
these sites were 2.4 (± 0.1) x 10-8 and 9.3 (± 5.5) x 10-8 mol, respectively. The result for
the high-affinity binding site in this two-site model showed good agreement with the
estimate of Ka made for the high affinity site using the linear region of Figure 3-3 when
this previous plot was examined according to Equation 3-5.
For the sake of comparison, the acetohexamide data in the non-linear plot given in
Figure 3-4 were also analyzed directly according to a one-site binding model.

As

expected for the results in Figures 3-3 and 3-4, the two-site model gave a higher
correlation coefficient versus the one-side model (i.e., r = 0.998 versus 0.964 for n = 15)
and a smaller sum of the square of the residuals (i.e., 1.2 x 10-17 versus 2.2 x 10-16). In
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Figure 3-4.

Non-linear regression of the acetohexamide frontal analysis data using a
two-site binding model, as described by Equation 1-4. The data used in
this plot were the same as utilized for the double-reciprocal plot in Figure
3-3.

mLapp (x 10 mol)

9

0

10

20

30

40

50

0

250

500

250

6

-1

500

750

Residual Plot

[Acetohexamide] (x 10 M )

-2
0

-1

0

1

2

750

1000

1000

121

122
addition, a residual plot that was prepared for the fit of these data to a two-site model
appeared to give only random variations about the predicted best-fit response, while the
residuals for the one-site fit followed a non-random pattern. All of these results indicated
that acetohexamide was binding to HSA through at least two general groups of sites: a set
of high affinity regions and a set of low affinity regions. This conclusion fits with the
fact that many sulfonylurea drugs are known to bind to more than one binding site on
HSA and bovine serum albumin (BSA) simultaneously (e.g., as noted when using
equilibrium dialysis methods to examine the binding of acetohexamide).4, 38 This overall
result also gave good agreement with previous ultrafiltration studies performed at pH 7.4
and 37°C with soluble HSA, which identified a general group of high affinity sites on
HSA for acetohexamide (Ka1 = 5.9 (± 1.9) x 104 M-1) and a group of lower affinity sites
(Ka2 = 3.4 (± 3.3) x 103 M-1).39
A comparison of the measured binding capacities with the known protein content
of the column, 1.78 (± 0.09) x 10-8 mol HSA, indicated that each of the two groups of
binding sites actually involved more than one region of interaction for acetohexamide
with HSA. For example, the best-fit value of mL for the high affinity sites represented a
relative activity of 1.35 (± 0.08) mol acetohexamide/HSA, which suggested that at least
two regions contributed to this group of interactions (e.g., this might correspond to two
sites each with relative activities of 0.55-0.8, as is often seen with HSA columns).39 In the
same manner, the weak affinity sites had a binding capacity that gave a relative activity
of 5.2 (± 3.1) mol/mol HSA, a result which is similar to results that have been obtained
when examining the non-specific binding regions for other drugs with this protein.39
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Based on the binding capacity data, an attempt was made to re-examine the
frontal analysis data to test the fit of a three-site binding model to see if any distinction
could be made between multiple high affinity sites. The corresponding equation that was
employed for this model is shown in Equation 3-6.

m Lapp =

m L1 K a1 [A] m L 2 K a 2 [A] m L 3 K a 3 [A]
+
+
(1 + K a1 [A]) (1 + K a 2 [A]) (1 + K a 3 [A])

(3-6)

At first glance, the three-site model appeared to give a reasonable fit to the data. The
correlation coefficient (r = 0.998) was comparable to that of the two-site model and the
sum of the square of the residuals was slightly smaller (i.e., 9.2 x 10-18 versus 1.2 x 10-17).
However, the best-fit parameters for the three-site model had high levels of uncertainty
associated with them. For instance, the Ka values obtained with this model were 3.6 (±
5.9) x 105, 4.9 (± 6.5) x 104, and 4 (± 39) x 101 M-1 with corresponding mL values of 9.0
(± 15.4) x 10-9, 1.9 (± 1.3) x 10-8, and 5 (± 44) x 10-7 mol (see Table 3-1). This greater
uncertainty indicated that, if more than one type of high affinity sites were present, the
difference in the binding parameters for these sites could not be reliably determined by
using the frontal analysis results alone.

This issue was examined again later after

additional information had been obtained on these interactions through site-selective
zonal elution experiments (see Zonal elution studies using acetohexamide).

Frontal analysis studies using tolbutamide
Frontal analysis studies with tolbutamide were conducted in the same fashion as
the work described for acetohexamide in the previous section to estimate the total the
number of binding sites and affinities of this drug with HSA. When these tolbutamide
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Table 3-1. Binding parameters obtained by frontal analysis for acetohexamide with HSA

One-Site Model

Two-Site Model

Three-Site Model

Ka1 (M-1)

2.0 (± 0.1) x 105

1.3 (± 0.2) x 105

3.6 (± 5.9) x 105

mL1 (mol)

1.9 (± 0.1) x 10-8

2.4 (± 0.1) x 10-8

9.0 (± 15.4) x 10-8

Ka2 (M-1)

3.5 (± 3.0) x 102

4.9 (± 6.5) x 104

mL2 (mol)

9.3 (± 5.5) x 10-8

1.9 (± 1.3) x 10-8

Ka3 (M-1)

4 (± 39) x 101

mL3 (mol)

5 (± 44) x 10-7

The values in parentheses represent a range of ± 1 S.D.
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results were examined according to a double-reciprocal plot, deviations at high analyte
concentrations (or low values of 1/[A]) were again seen, indicating that multiple binding
sites were present (data now shown). When the linear region of this plot was analyzed
according to Equation 3-5, the estimate obtained for Ka of the high affinity sites was 8.2
(± 0.4) x 104 M-1 with a corresponding mL value of 2.4 (± 0.1) x 10-8 mol (r = 0.999, n =
6).
These data were next examined by using non-reciprocal plots and fits to both onesite and two-site models according to Equations 3-2 and 3-4. Using a single-site model,
this type of regression gave a Ka value of 4.7 (± 0.4) x 104 M-1 and an mL of 3.2 (± 0.1) x
10-8 mol. Fitting the data to a two-site model, tolbutamide had a Ka value for its major
binding site of 8.7 (± 0.6) x 104 M-1 and a value of 8.1 (± 1.8) x 103 M-1 for the second set
of binding sites; the corresponding mL values for tolbutamide at these sites were 2.0 (±
0.1) x 10-8 and 1.8 (± 0.1) x 10-8 mol, respectively. This model gave a correlation
coefficient of 0.999 with randomly distributed residuals and a sum of the square of the
residuals of 4.3 x 10-20, (versus values of r = 0.998 and 3.9 x 10-18 for the fit of the onesite model). The Ka estimated for the high affinity binding site when using either model
were within the range of 0.4 to 3.0 x 105 M-1 that has been reported in the literature for
this interaction.15-20
The binding capacities estimated for these sites were compared to the protein
content of the HSA column. A relative activity of 1.12 (± 0.08) mol tolbutamide/mol
HSA was calculated for the higher affinity binding sites. Given the fact that not all of the
binding sites on HSA are probably active,39 this result suggested that more than one
group of binding sites was involved in these particular interactions. The lower affinity
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regions gave a relative activity of 1.01 (± 0.08) mol tolbutamide/mol HSA. This latter
result indicated that only a few regions on HSA were taking part in these weaker
interactions.
The use of a three-site model was also attempted for tolbutamide but gave results
similar to those for acetohexamide. The sum of the square of the residuals decreased
slightly in going from the two-site to three-site model (i.e., decreasing from 4.3 x 10-20 to
2.9 x 10-20), but the correlation coefficient of 0.999 was comparable to that found for the
two-site binding model. The Ka values found using the three-site binding model were 1.1
(± 0.9) x 105, 2.6 (± 6.5) x 104, and 5 (±149) x 102 M-1 with mL values of 1.3 (± 2.0) x 108

, 1.7 (± 0.6) x 10-8, and 4 (± 97) x 10-8 mol (see Table 3-2). The variations in many of

these parameters were again quite large, which indicated that if more than two groups of
sites were present they could not be differentiated with just the frontal analysis data.
These data were again examined with a three-site model later in this study once
additional information had been collected on site-specific interactions by using the
method of zonal elution (see Zonal elution studies using tolbutamide).

Zonal elution studies using acetohexamide
Competition studies using zonal elution were next performed to determine the
specific binding regions on HSA that were interacting with each of these tested drugs. In
this technique a mobile phase containing a known concentration of competing agent ([I])
was applied to the column while a small plug of analyte was injected onto the column
(see Figure 3-5). The retention time for the analyte was then measured and used to
calculate the retention factor (k), where k = (tR – tM)/tM, tR is the retention time of the
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Table 3-2. Binding parameters obtained by frontal analysis for tolbutamide with HSA

One-Site Model

Two-Site Model

Three-Site Model

Ka1 (M-1)

8.2 (± 0.4) x 104

8.7 (± 0.6) x 104

1.1 (± 0.9) x 105

mL1 (mol)

2.4 (± 0.1) x 10-8

2.0 (± 0.1) x 10-8

1.3 (± 2.0) x 10-8

Ka2 (M-1)

8.1 (± 1.7) x 103

2.6 (± 6.5) x 104

mL2 (mol)

1.8 (± 0.1) x 10-8

1.7 (± 0.6) x 10-8

Ka3 (M-1)

5 (± 149) x 102

mL3 (mol)

4 (± 97) x 10-8

The values in parentheses represent a range of ± 1 S.D.
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Figure 3-5.

Competition studies based on zonal elution for the injection of (a) Ltryptophan or (b) R-warfarin as site-selective probes onto HSA columns
and in the presence of various concentrations of tolbutamide in the mobile
phase. The concentration of tolbutamide in these examples (from left to
right) was 20, 15, 10, 5, or 1 µM. The injected concentration of each
probe, L-tryptophan and R-warfarin, was 5 µM and the injection volume
was 20 µL. Other conditions are given in the text.
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injected solute’s peak, and tM is the retention time of a non-retained solute (e.g., sodium
nitrate). The results are often first examined by making a plot of 1/k versus [I]. The
following equation predicts that such a plot will give a linear response if A and I compete
at a single type of site on the immobilized protein and I has no other types of binding
sites with the column.27, 28

VM
1 K aI VM [I]
=
+
k
K aA m L
K aA m L

(3-7)

In this equation, KaA and KaI are the association equilibrium constants for the analyte and
the competing agent, respectively, at their site of competition and VM is the void volume.
According to Equation 3-7, if a plot of 1/k versus [I] is linear, the association equilibrium
constant for I at the site of competition can then be calculated from the ratio of the slope
versus the intercept of this plot. This is a useful tool in that it can allow information to be
obtained on site-selective interactions and local association equilibrium constants for
analytes that may have multiple binding sites to an immobilized ligand.27
In the competition studies that were conducted in this study, R-warfarin was used
as a site-selective probe for Sudlow site I and L-tryptophan was used as a site-selective
probe for Sudlow site II, as employed in previous studies examining the binding of HSA
with other drugs and solutes.21, 23, 24, 36 It was found in these experiments when using
acetohexamide as the competing agent that plots of 1/k versus [I] gave a linear response
for the injection of both R-warfarin and L-tryptophan (see Figure 3-6), with correlation
coefficients of 0.991 and 0.996, respectively (n = 6).
The predicted value of k (as calculated by taking the inverse of the intercept) for
R-warfarin when no acetohexamide was present in the mobile phase was 54.3 (± 1.7),
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Figure 3-6.

Plots of 1/k versus [Acetohexamide] for competition studies performed by
zonal elution using (a) L-tryptophan or (b) R-warfarin as site-selective
probes injected onto HSA columns in the presence of various
concentrations of acetohexamide as a competing agent. The equations for
the best-fit lines in these plots are as follows: (a) y = 18,100 (± 800) x +
0.137 (± 0.009), with a correlation coefficient of 0.996 (n = 6); and (b) y =
780 (± 50) x + 0.0184 (±0.0006), with a correlation coefficient of 0.991 (n
= 6).
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which showed good agreement with the actual measured value of 55.1 (± 0.1). The
retention factor for L-tryptophan when no competing agent is present in the mobile phase
is 7.13 (± 0.02), while the predicted value is 7.31 (± 0.47). The relative difference in
retention factors between the predicted value (i.e., as obtained from the best-fit intercept)
and the actual value (i.e, k when no competing agent was present in the mobile phase )
was only 1.6% for R-warfarin and 2.4% for L-tryptophan showing little difference
between predicted and actual values.

The agreement of these results is a further

indication that acetohexamide had direct competition with both R-warfarin and Ltryptophan, indicating that acetohexamide also had binding to both Sudlow sites I and II
of HSA. It was possible to use the best-fit lines to the plots in Figure 3-6 along with
Equation 3-5 to determine the site-specific association equilibrium constants for
acetohexamide at Sudlow sites I and II. The Ka values that were obtained through this
process were 4.2 (± 0.3) x 104 M-1 and 1.3 (± 0.1) x 105 M-1, respectively. It was noted
that the Ka value found by this approach for Sudlow site II was similar to that for the
highest affinity site when using a two-site model to examine the frontal data.

Zonal elution studies using tolbutamide
Competition studies in zonal elution experiments were also carried out for
tolbutamide (see Figure 3-5). The results that were obtained when injections of Ltryptophan were made in the presence of tolbutamide are shown in Figure 3-7(a). The
resulting plot of 1/k versus [Tolbutamide] gave a linear relationship with a correlation
coefficient of r = 0.998 (n = 6). This result indicated that direct competition was taking
place between tolbutamide and L-tryptophan at Sudlow site II. By using Equation 3-5 to
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Figure 3-7.

Plots of 1/k versus [Tolbutamide] for competition studies performed by
zonal elution using (a) L-tryptophan or (b) R-warfarin as site-selective
probes injected onto HSA columns in the presence of various
concentrations of tolbutamide as a competing agent. The equations for the
best-fit lines shown in these plots are as follows: (a) y = 8400 (± 300) x +
0.157 (± 0.003), with a correlation coefficient of 0.998 (n = 6); (b) y =
1070 (± 30) x + 0.0194 (± 0.0004), with a correlation coefficient of 0.999
(n = 4).
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analyze this plot (see Table 3-3), it was determined that the association equilibrium
constant for tolbutamide at this site was 5.3 (± 0.2) x 104 M-1, which is similar to the
value calculated for the high-affinity binding site of tolbutamide with HSA when using
frontal analysis.
The plot of 1/k versus [Tolbutamide] that was generated when R-warfarin was the
injected probe compound is shown in Figure 3-7(b). This plot appeared to be linear at
high tolbutamide concentrations but did have some deviations from linearity at
tolbutamide concentrations below 5 µM. One way this behavior may be produced is if
some competition were present between R-warfarin and tolbutamide at both Sudlow site I
and at a few of the weaker affinity regions for tolbutamide on HSA. For instance, the
behavior seen in Figure 3-7(b) is predicted by the following equation that has been
previously derived to predict the response that would be obtained for a plot of 1/k versus
[I] in a system with two groups of bindings sites.37
Vm (1 + K I1 [I] + γ 2 K I1 [I] + γ 2 K I2 [I] 2
1
=
k
m Ltot K a1{(α 1 + β 2 − α 1 β 2 ) + K I1 [I](γ 2α 1 + β 2 − α 1 β 2 )}

(3-7)

In Equation 3-7, Ka1 is the association equilibrium constant for the injected analyte
binding to the highest affinity site of the ligand and KI1 is the association equilibrium
constant for the competing agent at that site. The terms α1 again represents the fraction
of active sites in the column that is due to the high affinity binding sites, and β2 is again
the ratio of the association equilibrium constant for the lower affinity site vs. the highest
affinity region (β2 = Ka2/Ka1). The term γ2 in this equation is similar to β2 but now
represents the ratio of the association equilibrium constant for the competing agent at the
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Table 3-3.

Binding constants obtained by zonal elution and competition studies for

acetohexamide and tolbutamide with HSA

Sudlow Site I (R-warfarin)
( x 104 M-1)

Sudlow Site II (L-tryptophan)
(x 104 M-1)

Acetohexamide

4.2 (± 0.4)

13 (± 1)

Tolbutamide

5.5 (± 0.2) *

5.3 (± 0.2)

The values in parentheses represent a range of ± 1 S.D.

*

Some curvature was noted at

low competing agent concentrations in a plot prepared according to Equation 3-5 when
examining the competition of R-warfarin with tolbutamide. The linear region of this plot
was used to obtain the result given here, based on behavior predicted by Equation 3-8.
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site with the lower affinity for the injected analyte vs. the highest affinity for the injected
analyte (γ2 = KI2/KI1).
At reasonably high values of [I], the response of Equation 3-7 will approach a
linear relationship, which is described by Equation 3-8.
Vm K I 1 [ I ]γ 2
Vm ( β 2 + α 1γ 22 − α 1 β 2 )
1
=
+
[ I ]→∞ k
m Ltot K a1 (γ 2α 1 + β 2 − α 1 β 2 ) m Ltot K a1 (γ 2α 1 + β 2 − α 1 β 2 ) 2
lim

(3-8)

In this relationship, the slope and intercept are now a function of the relative amount and
affinity of each binding site (as described by the terms α1, β2, and γ2) as well as the
values for Vm, Ka1 and mLtot. However, it has been demonstrated in theoretical studies that
the use of the slope versus intercept ratio from this linear region can still be used to
provide a reasonable estimate of KI1 in a system with multisite interactions. A linear fit
was made to the data for tolbutamide and warfarin in Figure 3-7(b) at tolbutamide
ranging from 5-20 µM, this approach gave an estimate for KI1 of 5.5 (± 0.2) x 104 M-1,
which would represent the binding of tolbutamide at its highest affinity site of
competition with R-warfarin. This value is similar to the value calculated for the highaffinity binding site when using frontal analysis, and direct binding by tolbutamide at
Sudlow site I is consistent with previous information reported in the literature.3, 30 It is
interesting to note that this value is also quite close to the association equilibrium
constant that was determined for tolbutamide at Sudlow site II. This later observation
explains why a two-site model using only a single group of higher affinity sites plus a
group of weaker affinity sites appeared to give a good fit in the frontal analysis work
described for tolbutamide with HSA in the frontal analysis studies. Even when the
results of these zonal studies were combined with the previous frontal analysis data, no
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further distinction between the interactions of tolbutamide at the two proposed high
affinity sites could be made when using the overall binding isotherm because of the
similarity in these values. This behavior demonstrates the value of using both frontal
analysis and site-selective competition studies in zonal elution to examine such
interactions.
Another possible explanation for the deviations from linearity that were noted in
Figure 3-7(b) is that some allosteric effects were occurring between R-warfarin at Sudlow
site I and some other region that was interacting with tolbutamide. This possibility was
explored by using the following that has been developed in previous work to describe
such an interaction.40

 1

k0
1
=
× 
+ 1
k − k 0 β I → A − 1  K IL [I] 

(3-9)

This equation includes the retention factor k that is observed for the injected analyte A,
the mobile phase concentration of the competing agent ([I]) and the association
equilibrium constant KIL for the binding of competing agent I to the immobilized ligand
L. Other terms in this equation include k0, which is the retention factor for A in the
absence of any competing agent, and βIA, which is the coupling constant for the
allosteric interaction, as given by βIA = KaL’/KaL (where KaL is the initial association
equilibrium constant for A with L, and KaL’ is the association equilibrium constant for A
with I after I has been bound to L, also resulting in a change in the binding of A to L).
Equation 3-9 predicts that a plot of k0/(k – k0) will give a linear relationship for a simple
allosteric interaction, where the intercept is equal to 1/(βIA - 1) and the slope is 1/[(βIA 1) KIL]. From the slope and intercept it is possible to determine the values of βIA and
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Figure 3-8.

Change in the retention of R-warfarin in the presence of tolbutamide
during zonal elution studies, as examined according to Equation 1-9. The
best-fit line shown in this plot is described by the equation y = [7.60 (±
0.17) x 10-6] x – 1.44 (± 0.08) and had a correlation coefficient of 0.999 (n
= 5). The error bars represent a range of ±1 S.D.
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KIL. A value of βIA > 1 will occur if positive allosteric effects are present between I and
A and a value of 0 < βIA < 1 will occur if negative allosteric effects are taking place. If

βIA is equal to zero, then direct competition is taking place between I and A, while a
value of one for βIA indicates that there is no effect of I on A as these agents bind to L.
A plot of k0/(k-k0) versus. 1/[I] was prepared according to Equation 3-9 to further
explore the observed change in retention for R-warfarin by HSA in the presence of
tolbutamide. The result that was obtained is shown in Figure 3-8. This plot appeared to
have a good correlation coefficient for a linear fit (r =0.999, n = 5); however, some
curvature did appear to be present in this plot. If these deviations were ignored, a βIA
value of 0.31 (± 0.02) would be obtained for the coupling constant, which would
represent a negative allosteric effect for tolbutamide on the binding of R-warfarin at
Sudlow site I. The value of KIL that would be obtained from the same fit is 1.9 (± 0.1) x
105 M-1 for the binding of tolbutamide to HSA. This latter result is similar to some
previously reported values for the binding of tolbutamide with HSA,15-18 but is higher
than the Ka value for the high affinity site that was determined in this current work when
using frontal analysis. Based on these observations, the curved behavior noted for the
plot in Figure 3-8, and the results that were obtained for acetohexamide, it was concluded
that a multi-site model was a more likely explanation than allosteric interactions for the
curvature seen in Figure 3-7(b).

Conclusion
These studies showed that frontal studies and zonal studies compliment each other
as a means for gleaning a better understanding of the overall binding of drugs such as
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sulfonylureas to proteins like HSA.

Using frontal analysis alone, it was initially

determined that acetohexamide was interacting with HSA at two general classes of
binding sites, including a set of higher affinity regions and a group of weaker affinity
regions (Note: this binding can occur simultaneously at both classes of sites). The use of
more detailed competitive binding studies and zonal elution studies indicated that
acetohexamide was binding with a relatively high affinity to both Sudlow sites I and II.
It was also possible through these measurements to obtain site-selective equilibrium
constants for these interactions (1.3 (± 0.1) x 105 and 4.3 (± 0.3) x 104 M-1) and to
combine the zonal elution and frontal analysis data to further refine the overall binding
model and estimates of the weak affinity interactions of acetohexamide with HSA.
Tolbutamide was also determined by frontal analysis to bind with HSA at both
high affinity and lower affinity regions.

Zonal elution studies and work with site-

selective probes indicated that the high affinity interactions probably involved binding at
both Sudlow sites I and II, with interactions that were quite similar in strength. The Ka
values estimated for tolbutamide at Sudlow sites I and II were 5.5 (± 0.2) x 104 and 5.3 (±
0.2) x 104 M-1, respectively, and were again used with the frontal analysis results to refine
a model for describing the overall binding of this drug to HSA. This study demonstrates
that using both frontal analysis and zonal elution can be extremely valuable in obtaining a
good quantitative description of how drugs such as sulfonylureas are interacting with
HSA. The same approach should also be useful when employing HPAC to examine
other complex drug-protein interactions.
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CHAPTER 4
THE BINDING OF WARFARIN AND L-TRYPTOPHAN TO GLYCATED HSA

Introduction
Diabetes is a growing problem in the United States. In 2007, over 23 million
people within the U.S. (7.8% of the population) were reported to have this disease, with
over 1 million people being diagnosed every year.1 The most common form of diabetes
is type 2 (non-insulin dependent) diabetes, where the body suffers from a shortage of
insulin. Diabetes is characterized by an elevated level of glucose in the blood.

This

glucose can form covalent adducts with proteins in blood through a non-enzymatic
process known as glycation.2-4 For example, glycated hemoglobin is now commonly
used by physicians to monitor the long-term control of diabetes by a patient.2 However,
many other blood proteins also become glycated including human serum albumin (HSA).
Because HSA has a shorter half-life than hemoglobin in blood, monitoring the extent of
HSA glycation has been considered as a way to look at short-term diabetes management.2
HSA is the most prominent protein in human plasma. This protein is synthesized
in the liver and contains 585 amino acids with a total molar mass of 66,438 Da.5-7 Twothirds of HSA is made up of α-helix structures while 10% of the protein contains β-turns.
This protein has three homologous domains (I, II, and III) that each contain two subunits
(A and B). Approximately 6-13% of this protein is glycated in normal individuals,2-5 but
this level can increase to over 20-30% in individuals with diabetes.2, 3, 5 Glycation occurs
by a condensation reaction of glucose with a lysine residue or the N-terminus of HSA to
first form a Schiff base.3, 6-8 Rearrangements of this product create a ketoamine (i.e., an

148
Amadori product).3,

6, 8

Further rearrangements of this adduct can create advanced

glycation end-products (AGEs). Increased levels of these adducts and products can lead
to severe health complications in diabetic individuals.3
HSA is a major transport protein in blood for carrying various endogenous and
exogenous compounds throughout the body. It greatly influences drug distribution and
can play a major role in affecting drug absorption, distribution, metabolism, and
excretion.4,

9-11

Binding to HSA also allows hydrophobic drugs to be more soluble in

blood and increases the overall lifetime of a drug before it is metabolized.4,

11

It has

previously been determined that HSA has two major binding sites for drugs (i.e., Sudlow
sites I and II, located in subunits IIA and IIIB of HSA), as well as additional minor
binding sites.12-14 Sudlow site I binds anti-coagulant drugs such as warfarin and antiinflammatory drugs such as azapropazone, phenylbutazone, and salicylate. Sudlow site II
binds drugs such as ibuprofen, fenoprofen, ketoprofen, and benzodiazepines, along with
the essential amino acid L-tryptophan.9
The purpose of this study was to see if the binding of HSA to warfarin and Ltryptophan (see structures in Figure 4-1) is altered as the level of HSA glycation is
increased, as occurs in diabetes. Warfarin and L-trytophan were of interest to this work
because they are often used as site-selective probes for Sudlow sites I and II, respectively,
in examining the binding of other drugs to HSA at these sites.15-17 Glycation has been
noted in previous work to occur at locations that are near both Sudlow sites I and II.2, 3, 8,
16, 17

It has been suggested in earlier studies that the binding of HSA to some drugs and

other solutes,5,18,19 including both warfarin5 and L-tryptophan,19 can be affected by
modifications resulting from glycation. However, past studies examining the binding of

149

Figure 4-1.

Structures of warfarin and L-tryptophan.
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Warfarin

L-tryptophan
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warfarin with glycated HSA have resulted in apparently conflicting results, in which
some authors have reported an increase in binding while others reported a decrease.2, 5
Previous work with L-tryptophan and glycated HSA have suggested that there may be a
fluctuation in the binding constants for this interaction at 4ºC when increasing levels of
glycation are present in HSA.19 Thus, there is still a need for a clearer understanding of
how glycation affects the binding of both warfarin and L-tryptophan with HSA,
especially under physiological conditions (i.e., 37°C and pH 7.4).
The goal of this current study was to obtain binding information on these probe
compounds by using high-performance affinity chromatography (HPAC). HPAC is a
chromatographic technique that can make use of an immobilized protein (e.g., HSA) to
provide a precise, reproducible, and convenient means of examining drug-protein
binding, while also being capable of automation.20 This approach has been utilized
successfully in the past to obtain drug-protein binding data on interactions of both
warfarin and L-tryptophan with normal HSA.21-24 This current report employed HPAC to
also examine the interactions of these solutes with in vitro glycated HSA. This was
accomplished by preparing HPAC columns that contained HSA with various known
levels of glycation.

The binding parameters that were found with warfarin and L-

tryptophan on these columns were then compared to those noted with normal HSA.
Knowledge of how these interactions are affected by glycation should be valuable in
future work that uses warfarin or L-tryptophan as probes to examine the binding of other
drugs of solutes with glycated HSA. This information, in turn, could be important in the
future in obtaining a better picture of how such compounds bind to serum proteins such
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as HSA during diabetes and in how these interactions affect properties such as the
metabolism, excretion and distribution of these drugs in this disease state.

Experimental
Reagents
Racemic warfarin (98% pure), L-tryptophan (98%), monobasic and dibasic
potassium phosphate salts, D-(+)-glucose (99.5%), sodium azide (>95%), acetohexamide,
sodium chloride, sodium nitrate, sodium phosphate salts, HSA (essentially fatty acid free
albumin from human serum, ≥ 96%), and in vitro glycated HSA used to make the gHSA1
column (Lot 058K6087) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Reagents used in the bicinchoninic acid (BCA) protein assay were from Pierce
(Rockford, IL, USA).

Nucleosil Si-300 silica (300 Å pore size, 7 micron particle

diameter) was obtained from Macherey-Nagel (Düren, Germany). The enzymatic assay
kits for fructosamine were from Diazyme Laboratories (San Diego, CA, USA). Sterilized
17 x 100 mm culture tubes were purchased from Fisher Scientific (Pittsburg, PA, USA).
Slide-A-Lyzer 7K dialysis cassettes (7 kDa MW cutoff; 0.5-3, 3-12, and 12-30 ml sample
volume) were acquired from Thermo Scientific (Rockford, IL, USA). Econo-Pac 10 DG
disposable chromatography desalting columns were purchased from Bio-Rad
Laboratories (Hercules, CA, USA). Solutions were made using water from a Nanopure
system (Barnstead, Dubuque, IA, USA) and filtered with a 0.20 µm GNWP nylon
membrane from Millipore (Billerica, MA, USA).
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Apparatus
The chromatographic system consisted of a Jasco DG-2080-53 three-solvent
degasser (Tokyo, Japan), two Jasco PU-2080 isocratic HPLC pumps, a Rheodyne
Advantage PF six-port valve (Cotati, CA, USA), a Jasco AS-2055 autosampler, a Jasco
CO-2060 column oven (i.e., to maintain a column temperature of 37 °C), and a Jasco
UV-2075 UV/Vis detector.

This chromatographic system hardware was controlled

through EZChrom Elite software v3.2.1 (Agilent, CA, USA) and a Jasco LC Net
component. The chromatographic data were analyzed using in-house programs written
using Labview 5.1 software (National Instruments, Austin, TX, USA) or using Peakfit
4.12 (Jandel Scientific Software, San Rafael, CA, USA).

Linear regression was

performed using Excel 2003 (Microsoft Corporation, Redmond, WA, USA) and nonlinear regression was performed using DataFit (Oakdale Engineering, PA, USA).

Methods
Studies were performed using three different glycated HSA samples. The first of
which was purchased from a commercial source (Sigma-Aldrich), and the other two
glycated HSA samples were made in vitro using a modified version of previously
published methods.21, 22 To perform in vitro glycation of the HSA samples, all glassware
and spatulas that would come in contact with the glycated HSA solution were previously
sterilized by autoclaving to prevent bacterial growth during the preparation of the
glycated HSA. One liter of pH 7.4, 0.2 M potassium phosphate buffer was prepared and
also sterilized by autoclaving to minimize bacterial growth during this process. Sodium
azide (i.e., a strong antibacterial agent) was added to this buffer once it had cooled to
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make a 1 mM solution of this agent. A 15 mM glucose solution was prepared using this
sterilized sodium azide solution and 20 ml of this solution was then used to dissolve 840
mg of HSA to give a working solution with an HSA concentration of 42 g/L. This
concentration of HSA was within the typical range (40-45 g/L) seen in humans under
normal physiological conditions.4, 23, 24
This HSA solution was placed into a series of sterile culture tubes as 3-4 ml
fractions, covered with the culture tube cap, further sealed with parafilm, and incubated
in a water bath at 37 °C for four weeks.21 After this incubation period, each glycated
HSA solution was passed through a size-exclusion desalting column to separate the
protein from any excess glucose and sodium azide in the solution. The collected protein
fraction was dialyzed against water to remove any remaining glucose and buffer salts.
The water used during dialysis was 200-500 times the volume of the sample. The sample
was placed into a sterile dialysis cassette and allowed to dialyze for 2 h at room
temperature, with gentle stirring using a magnetic stir bar. The water was then changed
and the sample was dialyzed against water again for another 2 h under the same
conditions. The water was changed one last time and the sample was allowed to dialyze,
without stirring, at 4 °C overnight for approximately 14-18 h. The final samples were
stored at -80 °C. Lyophilization was performed until samples were completely dry.
Samples were again stored at -80 °C until use. This procedure was performed once for
each HSA sample. The first time this procedure was carried out, the levels of glucose
were kept around physiological levels. However, the second time a greater level of
glycation was desired so the glucose concentration was increased to ~30 mM to increase
glycation levels.
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A commercial fructosamine assay from Diazyme was modified for use in
determining the overall level of glycation of each batch of HSA that was used in this
study.

A 0.85% (w/v) saline solution was first prepared by dissolving 0.85 g sodium

chloride in 100 ml of water. A pH 7.4, 0.025 M sodium phosphate buffer was also
prepared. Although normal HSA concentrations in serum are around ~40 g/L, an HSA
sample solution of ~20 g/L was prepared to stay within the linear range of the assay (i.e.,
30-1354 µmol/L or 2-90 g/L). Each sample of glycated HSA for this assay was prepared
by weighing out roughly 10 mg of this protein and adding 500 µL of pH 7.4, 0.025 M
sodium phosphate buffer, followed by the solution then being placed on a vortex mixer
for a short period of time. A temperature-controlled UV/vis spectrometer was used to
perform the assay with the temperature held at 37 °C for the entire duration. A 300 µL
portion of Reagent 1 from the kit was added to an empty cuvette. A 30 µL portion of the
sample was then added, the resulting solution was mixed quickly, and placed into the
spectrometer, with absorbance measurements being taken after 5 min at 600 and 700 nm.
A 75 µL portion of Reagent 2 from the kit was then added to the cuvette and mixed
quickly with the other contents, with this mixture then being allowed to react for 5 min
before measurements were again taken at 600 and 700 nm.

Each sample was run in

duplicate or triplicate. A 0.85% (w/v) saline solution was used as a blank to subtract out
the background while calibration standards and a control were measured during this
assay; this procedure was repeated several times using these solutions in place of a 30 µL
sample. The difference in the absorbance readings at 600 nm and 700 nm was calculated
at each time, and the difference in the resulting values for the first and second 5 min
readings was then also found. A calibration curve was made per the manufacturer’s
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instructions using a calibration standard included with the kit. This gave a plot that was
used to find the µmol of fructosamine (i.e., a value equivalent to µmol hexose) in each
protein sample.
Nucleosil Si-300 silica was used to prepare diol-bonded silica according to a
previously published procedure.25

Glycated HSA was immobilized to the resulting

support by using the Schiff-base method, as previously discussed for normal HSA; and a
control support was made in the same manner but with no glycated HSA being added
during the immobilization step.26

A BCA assay was performed in triplicate to

determining the content of each support, using soluble glycated HSA as the standard and
the control support as the blank. The protein content of gHSA 1, 2, and 3 samples were
found by this method to be 29 (± 4), 47 (± 8), and 40 (± 3) mg HSA/g silica, respectively
(see Table 4-1). Each glycated HSA silica sample was downward slurry-packed into a
separate 2.0 cm x 2.1 mm I.D. columns at 3500 psi (24.1 MPa) using pH 7.4, 0.067 M
potassium phosphate buffer as the packing solution. A column with the same dimensions
but packed with the control support was also prepared. All columns were stored at 4 °C
in pH 7.4, 0.067 M potassium phosphate buffer and were used over the course of one
year and for fewer than 500 sample applications or injections per column. HSA columns
have been shown in previous studies to retain good stability for drug-protein binding
studies under such conditions.27
The

warfarin,

L-tryptophan

and

all

other

sample

solutions

for

the

chromatographic studies were prepared in pH 7.4, 0.067 M potassium phosphate buffer.
The same pH 7.4, 0.067 M potassium phosphate buffer was used for application and
elution in the chromatographic studies. All solutions were filtered through a 0.2 µm

157
nylon filter and degassed under vacuum for at least 15 min prior to use. Solutions of Ltryptophan have been found to decrease in stability over 2-9 days (depending on storage
conditions),16 so for this work the L-tryptophan solutions were made fresh daily prior to
use. Racemic warfarin has been shown to have a slow structural conversion over time
from its minor cyclic hemiketal to its major cyclic hemiketal.28 When stored at 5 °C, a
5% conversion occurs in 45-52 hours whereas 95% conversion occurs between 109-127
days.

Warfarin solutions were stored at 4 °C and used within 10 days for these

experiments. All chromatographic experiments described in this report were performed
at 37.0 (± 0.1) °C. Wavelengths of 308 and 280 nm were used to detect R-warfarin and
L-tryptophan, respectively, while sodium nitrate (i.e., a non-retained solute) was
monitored at 205 nm.
The competition studies described later in this report were conducted by using
zonal elution on the columns containing normal HSA or glycated HSA. These studies
were conducted using varying concentrations of acetohexamide (0-20 µM) in the mobile
phase while 20 µL of R-warfarin or L-tryptophan were injected on to the column at a
concentration of 5 µM. These studies were performed for the HSA or gHSA columns
and corresponding control columns. Sodium nitrate was used to determine the void time
of the columns and the system by injecting 20 µL of 20 µM sodium nitrate onto each
column and injecting it onto the system with a zero-volume union. A pH 7.4, 0.067 M
potassium phosphate buffer was used to make all solutions.

PeakFit v.4.12 and an

exponentially-modified Gaussian curve fit were used to determine the central moments of
the eluting peaks.
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All frontal analysis experiments were carried out at 0.5 ml/min. This flow rate
has been shown in similar studies to obtain reproducible binding capacities with the given
analytes and on columns containing normal HSA.29, 30 The concentrations for the applied
analyte solutions ranged from 1 and 10 µM. A six-port injection valve was used to
switch between the mobile phases (i.e. sample application and elution/column
regeneration). The column was first equilibrated using pH 7.4, 0.067 M potassium
phosphate buffer. When performing the frontal analysis experiments, the six-port valve
was programmed to switch from this buffer to the given analyte solution after one minute
from time zero to ensure an initial steady baseline for data analysis. Once the analyte had
fully saturated the column and a breakthrough curve had been obtained, the six-port valve
was switched back to the original pH 7.4 phosphate buffer to wash the retained analyte
from the column and re-equilibrate the column before the next run. All experiments were
performed at each analyte concentration on both the glycated HSA columns and the
control column. The resulting breakthrough curves were analyzed using by Labview 5.1
or Peakfit v.4.12 and were corrected for non-specific binding by the analytes to the
support by subtracting control column data from data for the glycated HSA columns.

Results and Discussion
Preparation and Initial Studies of Glycated HSA
The in vitro glycated HSA used to make the gHSA1 column was determined to
have 1.31 (± 0.05) mol hexose/mol HSA according to a fructosamine assay (see Table 41). The in vitro glycated HSA used to make the gHSA2 column had a glycation level of
2.34 (± 0.13) mol hexose/mol HSA, and the glycated HSA used to make the gHSA3
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Table 4-1. Protein content and level of glycation of HSA supporsts
gHSA1

gHSA2

gHSA3

Protein Content of the
Column (mg HSA/g silica)

29 (± 4)

47 (± 8)

40 (± 3)

mol Hexose per mol HSA

1.31 (± 0.05)

2.34 (± 0.13)

3.35 (± 0.14)

Reported errors represent ± 1 S.D.
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column contained 3.35 (± 0.14) mol hexose/mol HSA. Separate protein assays indicated
that the amount of glycated HSA for all of these samples was comparable to that typically
seen for normal HSA.17, 28 The protein content of the columns ranged from 29 to 47 mg
protein/g silica, or roughly 440 to 710 nmol glycated HSA/g silica.
Preliminary competition studies were first conducted with these supports using
the method of zonal elution. In these studies, similar retention factors (when corrected
for differences in column protein content) were noted to be present for R-warfarin and Ltryptophan in the absence of any competing agents. An example of such a study is shown
in Figure 4-2 for columns containing HSA or glycated HSA. In this type of study, the
retention of these site-selective probe compounds was being examined while varying the
concentration of a mobile phase additive and possible competing agent (i.e.,
acetohexamide, in this case). In this type of experiment, Equation 4-1 describes the
predicted change in retention of the injected analyte (A) if it has competition at a single
type of site on an immobilized ligand with the competing agent (I).

VM
1 K aI VM [I]
=
+
k
K aA m L
K aA m L

(4-1)

In this equation, the retention factor (k) is determined by using the retention time of the
analyte (tR) and the void time of the system (tM), where k = (tR – tM)/tM. KaA and KaI are
the association equilibrium constants for the analyte and the competing agent,
respectively, at their site of competition on the immobilized ligand and VM is the void
volume. If direct competition is present between A and I at a single type of binding site,
a plot of 1/k versus [I] should be linear, as occurs for the plots in Figure 4-2. In addition,
the value of k at the intercept will be directly related to the equilibrium constant and
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Figure 4-2.

(a) Competition studies for the injection of R-warfarin onto gHSA1
column

with

acetohexamide

solutions

in

the

mobile

phase.

Acetohexamide concentrations from left to right: 20, 15, 10, 5, and 1 µM.
R-warfarin injections were 5 µM and the injection volume was 20 µL. (b)
Plots of 1/k vs. [Acetohexamide] while injecting R-warfarin on to a
normal HSA column (●) and gHSA1 column (■). The best-fit line for the
normal HSA column was determined to be y = 779 (± 51) x + 0.0184 (±
0.0006), r = 0.991.

The equation for the glycated HSA column was

calculated to be y = 1075 (± 72) x + 0.0183 (± 0.0008), r = 0.991.
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relative activity of the immobilized ligand for the injected analyte (i.e., at [I] = 0, 1/k =
VM/{KaA mL} or k = KaA mL/VM).
The similarities of the retention factors noted when [I] = 0 in plots such as Figure
4-2 for the normal HSA and glycated HSA columns suggested that warfarin and Ltryptophan (data not shown) had relatively consistent binding to Sudlow sites I and II,
respectively. This appeared to be the case even though the competition of these probes
with drugs like acetohexamide did create a change in the response of these plots.
Additional studies based on frontal analysis were next undertaken (see following
sections) to further examine the interactions of warfarin and L-tryptophan with these
columns prior to more in depth studies using these compounds as probes in competition
studies with additional drugs on glycated HSA.

Binding of Warfarin to Glycated HSA
Frontal analysis studies were performed to obtain a more detailed analysis of the
binding parameters for glycated HSA with warfarin.

This method is performed by

continuously applying a solution with a known amount of analyte to a column with an
immobilized ligand. As the analyte binds to the ligand, the column becomes saturated
and a characteristic breakthrough curve is formed (Figure 4-3). A breakthrough time can
be calculated when the area under the first half of the curve equals the area above the
second half of the curve.20 The middle point represents the breakthrough time. When
fast association/dissociation kinetics are present, the breakthrough time can be related to
the concentration of the analyte [A], the association equilibrium constant for the analyteligand system (Ka), and the moles of active binding sites on the column for the analyte
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(mL). The following equations show this relationship for a system where there is a single
type of binding site on the ligand for the analyte (single-site model),20

m Lapp =
1
m Lapp

=

m L K a [A]
(1 + K a [A])

(4-2)

1
1
+
( K a m L [A]) m L

(4-3)

in which mLapp is the apparent moles of analyte that are required to reach the mean
position of the breakthrough curve at any given concentration of applied analyte and [A]
is the molar concentration of the applied analyte. Equation 4-3 would be expected to
produce a linear relationship for a 1:1 binding model when a plot is made of 1/mLapp
versus 1/[A], while a non-linear fit and a plot of mLapp versus [A] would be used when
applying Equation 4-2 to the same data. Either type of fit make it possible to determine
Ka and mL simultaneously for the interaction, which can be used to provide information
on how a change in the ligand might affect its affinity or relative activity for the applied
analyte.31 In this current study, this approach was used to monitor any changes that
occurred in binding as the degree of glycation was varied for HSA.
Some typical frontal analysis results that were obtained for warfarin on the
glycated HSA columns are shown in Figures 4-3 and 4-4.

In each case, warfarin

produced breakthrough curves that shifted to shorter breakthrough times as the
concentration of the applied analyte was increased (see Figure 4-3). The data obtained
from these breakthrough curves were then analyzed according to Equation 4-3. Some
typical results are shown in Figure 4-4. It was found for each of the glycated HSA
columns that there was good agreement with the linear behavior predicted by Equation 43 at the concentration range which was examined in this study. The correlation
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Figure 4-3.

Breakthrough curves for warfarin at applied concentrations 10, 5, 2.5, 1.5,
and 1 µM (from left to right) on the gHSA1 column. Conditions for these
studies are given in the text.
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Figure 4-4.

Double reciprocal plots of warfarin binding to affinity columns containing
glycated HSA for the gHSA1 column (▲), gHSA2 column (■), and
gHSA3 column (●). The solid line shows the best-fit line for each data
set. The error bars represent a range of ± 1 S.D. The best-fit line for the
gHSA1 column was determined to be y = 424 (± 15) x + [9.62 (± 0.87)] x
107, r = 0.998. The best-fit line for the gHSA2 column was determined to
be y = 270 (± 10) x + [6.10 (± 0.56)] x 107, r = 0.998. The best-fit line for
the gHSA3 column was determined to be y = 287 (± 13) x + [7.80 (±
0.77)] x 107, r = 0.997.
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coefficients ranged from 0.997 to 0.998 (n = 5), with only random variations generally
being noted in each of the plots about the best-fit line (Note: a small amount of curvature
may have been present in the results for the gHSA3 column, but using a higher-order fit
such as a two-site model did not give any further improvement in the quality of the
overall fit to this set of results). Similar agreement between the data and a one-site
binding model was obtained when fitting a plot of mLapp versus [A] according to Equation
4-2, as demonstrated in Figure 4-5.
Table 4-2 summarizes the association equilibrium constants that were obtained
when plotting the data according to Equation 4-3 and using a single-site model. These
values ranged from 2.3 x 105 M-1 to 2.7 x 105 M-1, and had relative precisions of ± 910%. These results did not show any significant variations between the various glycated
HSA columns that were examined in this study, with all Ka values agreeing within 1720% and within ± 2 S.D. of any other Ka value for warfarin in this same data set. This
range of values also agreed within an average association equilibrium constant of 2.35 x
105 M-1 that was determined based on previous results reported for the separate R- and Senantiomers of warfarin on a similar column that contained normal HSA and using the
same method of data analysis.29 These results indicated that glycation did not have any
observable effect on the average Ka that was measured for R/S-warfarin on these columns
as the level of glycation of HSA was increased up to the level present in the gHSA
column (i.e., 3.35 mol hexose/mol HSA, as shown in Table 4-1).
It was also possible from the results in Figure 4-4 to determine the binding
capacity of each affinity column for warfarin. This information could then be combined
with the known protein content to obtain the specific activity of each type of HSA for the
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Figure 4-5.

Plot of mLapp vs. [warfarin] using Equation 4-2 for the gHSA1 column
(▲), gHSA2 column (■), and gHSA3 column (●). The best-fit line for the
gHSA1 column was determined to be: y = [{1.81 (± 0.15)} × 105 × {1.19
(± 0.05) × 10-8 x] /[1 + {1.81 (± 0.15)} × 105 x], r = 0.999. The best-fit
line for the gHSA2 column was determined to be: y = [{1.89 (± 0.09)} ×
105 × {1.83 (± 0.05) × 10-8 x] /[1 + {1.89 (± 0.09)} × 105 x], r = 0.999.
The best-fit line for the gHSA3 column was determined to be: y = [{2.01
(± 0.20)} × 105 × {1.52 (± 0.05) × 10-8 x] /[1 + {2.01 (± 0.20)} × 105 x], r
= 0.998.
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Table 4-2. Calculated binding constants for warfarin and L-tryptophan on each of the
glycated HSA columns

Racemic Warfarin
(Values using Eqn 4-3)

HSA

gHSA1

gHSA2

gHSA3

Ka (x 105 M-1)

2.35 (± 0.35)a

2.27 (± 0.22)

2.26 (± 0.22)

2.72 (± 0.29)

mL (x 10-8 mol)

1.29 (± 0.13)

1.04 (± 0.09)

1.64 (± 0.15)

1.28 (± 0.13)

73 (± 9)

76 (± 12)

74 (± 14)

68 (± 9)

Ka (x 104 M-1)

1.1 (± 0.3)b

5.18 (± 0.92)

6.36 (± 1.66)

5.67 (± 0.54)

mL (x 10-9 mol)

NA

5.0 (± 0.9)

6.7 (± 1.8)

5.8 (± 0.6)

Activity (%)

NA

36 (± 8)

30 (± 5)

31 (± 4)

Activity (%)

L-Tryptophan
(Values using Eqn 4-3)

a

Value from Ref. 29.

b

Value from Ref. 30; NA, not available.

All reported errors represent ± 1 S.D.
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applied analyte. These results are also summarized in Table 4-2. When the binding
capacities were normalized for the protein content, it was found that comparable specific
activities were present on each of the columns for warfarin. These values ranged from 68
to 76% with the activities decreasing slightly with increasing levels of glycation. The
precision of these measurements were ±12-19% of the reported activities while the
activities were within 11% of one another. Although an initial decrease of activity was
noted as glycation levels were increased, overall precision of these values reveal them to
be comparable to each other. Calculations performed for the normal HSA column using
the data collected from the competition studies between R-warfarin and acetohexamide
and Equation 4-1 also shows an activity of 73 (± 9)% which is also well within the range
of the measurements determined for the glycated HSA columns. Therefore, there does
not seem to be a significant change in the binding constant or the activity as the level of
glycation is increased.

Binding of L-Tryptophan to Glycated HSA
Similar frontal analysis studies were also done for L-tryptophan to examine the
binding of this compound to Sudlow site II as glycation levels were increased. Frontal
analysis studies were again performed at low concentrations of L-tryptophan because low
concentrations offer only single-site binding to HSA.
characteristic breakthrough curves for L-tryptophan binding.

All columns produced
The data were fit to

Equation 4-2 with linear results obtained on all three glycated HSA columns and
correlation coefficients of 0.999 (n = 5) for all data. These data also produced residual
plots with random variation.
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Table 4-2 again summarizes association constants and activities calculated for Ltryptophan binding to glycated HSA. Association constants for this compound ranged
from 5.18 104 M-1 to 6.36 x 104 M-1 with precisions of ±9-26% (Figure 4-6). These
results did not show any significant variations between the columns and were within 2
S.D.s of one another. These values did appear 5-6 times higher than the reported value
for normal HSA determined using a similar column.30 Studies done by Okabe and
Hashizume also found that the binding of low concentrations of flufenamic acid, a
compound that binds to site II, also increased its binding to glycated HSA.32 However,
they also found that the site II-ligands dansylproline and ibuprofen decreased in binding
due to the glycation of HSA compared to non-glycated HSA. Nakajou et. al. also saw a
decrease in binding of dansylsarcosine to glycated HSA.2 Bohney and Feldhoff found no
binding changes in L-tryptophan with increased levels of glycation on HSA33 while
Barzegar, et. al. reported a decrease followed by an increase of the binding constant as
glycation increases.19 It is possible that differences in experimental conditions led to
variations in results. Also, although major glycation sites are close in proximity to
Sudlow site I, no major glycation sites have been noted to be close to Sudlow site II. It is
probable that the conformational changes that occur when HSA undergoes glycation
affect the binding at site II. These changes could lead to differences in the binding of site
specific compounds depending on how they bind in the binding pocket of that site. This
was also suggested by Barzegar, et. al. who proposed that a small amount of glycation
induces a change in the tertiary structure of HSA causing local unfolding of the protein
around the binding site while higher levels of glycation are able to stabilize the protein
structure in order to facilitate binding again.19
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Figure 4-6.

Double reciprocal plots of L-tryptophan binding to affinity columns
containing glycated HSA. These results are for the gHSA1 column (▲),
gHSA2 column (■), and gHSA3 column (●). The solid line shows the
best-fit line for each data set. The error bars represent a range of ± 1 S.D.
The best-fit line for the gHSA1 column was determined to be y = [3.89 (±
0.06)] × 103 x + [2.02 (± 0.36)] x 108, r = 0.999. The best-fit line for the
gHSA2 column was determined to be y = [2.34 (± 0.07)] × 103 x + [1.49
(± 0.39)] x 108, r = 0.999. The best-fit line for the gHSA3 column was
determined to be y = [3.04 (± 0.04)] × 103 x + [1.72 (± 0.16)] x 108, r =
0.999.
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The binding capacity and the protein content were used to determine the activity
of L-tryptophan on each glycated HSA column.

These values have also been

summarized in Table 4-2. When the binding capacities had been normalized for the
amount of protein on the column, the activities of L-tryptophan were comparable
between the columns. The activities ranged from 30.5 to 36.5% with precisions of ±1222%. The highest and the lowest values differed from each other by approximately 16%
but were within 1 S.D. Although an initial decrease in activity appeared to be apparent,
the precisions of these values show that they are statistically comparable at the 95%
confidence level.

Conclusion
Uncontrolled diabetes increases blood sugar levels which facilitates a boost in the
level of glycation that blood proteins undergo. This increase in glycation can potentially
alter the binding of drugs to the protein thereby changing the transport of the drug around
the body. These studies examined the binding of two drugs to the two major binding
sites on HSA, Sudlow sites I and II. As glycation levels are increased, the association
equilibrium constants of warfarin remain constant while the percent of bound drug
decreases as glycation increases. However, when taking into account the standard errors
associated with the activities, the values are in fact comparable.

The association

equilibrium constants for L-tryptophan appear to increase slightly but then return to
normal as glycation levels are increased.

Yet again, when taking into account the

standard errors associated with the binding constants, the binding constants remain the
same as glycation increases. L-Tryptophan also shows similar activities for the protein as
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the levels of glycation are increased, with no appreciable difference in either the binding
constants or the activity with glycation but higher binding constants for glycated HSA
than for normal HSA.

In general, both probe compounds show steady association

equilibrium constants when glycation levels were increased and overall activities that
were comparable when taking into account the standard errors for these values. These
findings are important when determining drug binding to Sudlow sites I and II because it
can help to identify the cause behind a change in binding to these sites. HPLC using the
method of frontal analysis is a useful tool to examine these binding changes because it
can differentiate between the two factors, Ka and mL, that attribute to the binding of
compounds to HSA using only one type of experiment.
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CHAPTER 5
THE BINDING OF SULFONYLUREAS TO GLYCATED HSA

Introduction
Human serum albumin (HSA) is the most abundant protein in human plasma.
HSA is produced in the liver and exported as a single chain of 585 amino acids, reaching
a serum concentration of ~40 g/L.1-8

It is a globular protein made up of three

homologous domains, I-III, each containing two subdomains, A and B.3-7, 9 This protein
is known to have two major binding sites for drugs (i.e., Sudlow sites I and II), which are
found in subdomains IIA and IIIA, respectively.10, 11 Sudlow site I, also known as the
warfarin-azapropazone site, binds to bulky heterocyclic compounds such as coumarin
compounds, sulfonamides, and salicylate.3, 6, 8, 9 Sudlow site II, also known as the indolebenzodiazapine site, binds aromatic carboxylic acids and is known for binding profens
such as ibuprofen and ketoprofen.3, 6, 8, 9 HSA binds many endogenous and exogenous
compounds, acting as the major transport protein for these compounds in the circulation.8
The binding of drugs to HSA can greatly affect the pharmacologic and
pharmacokinetic properties of such drugs. This can influence the activity of a drug by
altering the drug’s free fraction in blood.8,

12

It is commonly believed that this free

fraction is the portion that interacts at receptor sites, allowing drug delivery and uptake
by cells.8, 13 The binding of drugs to HSA can be affected by competition for binding
sites with co-administered drugs, fluctuations in endogenous compounds that bind to this
protein, and post-translational modifications of HSA, such as glycation.8,

14

Glycation

occurs when a protein becomes non-enzymatically linked to sugar molecules.

This
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process is especially prevalent in diabetes, where blood sugar levels are elevated. The
normal level of HSA glycation is around 6-13%, while a diabetic individual may have
20-30% of HSA glycated in the circulation.1, 2, 8 Some of the primary glycation sites have
been shown to be at or near Sudlow sites I and II, potentially creating interferences with
drug-protein binding at these sites.2, 15, 16
Drugs such as sulfonylureas are often used to treat type II, or non-insulin
dependent, diabetes. Sulfonylureas have been used since their discovery in 1942 in
monotherapy and in combination therapy with other drugs to treat diabetes.17-19 Firstgeneration sulfonylureas include tolbutamide, chlorpropamide, acetohexamide, and
tolazamide. These drugs are of particular interest in drug-binding studies because they
are thought to be more easily displaced from HSA than their next-generation
counterparts.20 Displacement of these drugs could be particularly problematic due to
their high degree of binding to HSA. For instance, tolbutamide is 90% bound to HSA at
therapeutic levels and even a small change in the free fraction of this drug can lead to
severe hypoglycemia.8, 21
This study used high-performance affinity chromatography (HPAC) to examine
the binding of two first-generation sulfonylurea drugs, tolbutamide and acetohexamide, to
HSA with various levels of glycation. Past studies using equilibrium gel filtration have
found that the amount of sulfonylureas bound to glycated HSA decreases compared to
binding of the same drugs with normal HSA.22

Also, work with a fluorescence

quenching method has shown that there is a decrease in the apparent binding constants of
glycated HSA vs. normal HSA.21

The benefits of using HPAC over these more

traditional methods include the good precision and reproducibility of HPAC plus its small
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sample requirements, and ease of automation. These current studies were performed to
determine how the association equilibrium constants and binding capacities of
sulfonylurea drugs on HSA were affected with increasing levels of glycation as
determined by using frontal analysis.23, 24 Zonal elution studies were also performed to
examine the binding of these drugs at Sudlow sites I and II of HSA as the levels of
glycation were increased. The knowledge gained from these studies should aid in the
development of personalized medicine for patient drug therapy regiments in diabetes.

Theory
Frontal Analysis
The method of frontal analysis was used to determine the association equilibrium
constant(s), Ka, and moles of binding sites, mL, for acetohexamide and tolbutamide on
glycated HSA. If fast association/dissociation kinetics are present in a drug-protein
system, the resulting breakthrough curve can be related to Ka, mL, and the concentration
of the applied analyte, [A].23 Examples of breakthrough curves that were obtained for
acetohexamide in this study are shown in Figure 5-1. The following equations can be
used to describe the response in this method for a drug with a single type of binding site
on an immobilized protein:23, 24

1
m Lapp

=

1
1
+
( K a m L [A]) m L

(5-1)

or

m Lapp =

m L K a [A]
(1 + K a [A])

(5-2)
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In the above equations, mLapp is the apparent moles of analyte required to saturate the
column at a given concentration of applied analyte. Using Equation 5-1, a plot of 1/mLapp
vs. 1/[A] should give a linear relationship if the drug binds to only one type of binding
site on the protein. The intercept divided by the slope of the best-fit line can be used to
calculate Ka, while taking the inverse of the intercept will give mL. Deviations from
linearity at high concentrations (low 1/[A]) in this type of plot indicate that the drug is
binding to more than one type of binding site on the protein in the column.23
Equations 5-1 and 5-2 can be expanded for systems with more than one type of
binding site with a ligand. An expansion of Equation 5-1 for a two-site binding model is
shown in Equation 5-3, while a similar expansion for Equation 5-2 is given in Equation
5-4:23, 24
1
m Lapp

=

1 + K a1 [A] + β 2 K a1 [A] + β 2 K a21 [A] 2
m Ltot {(α 1 + β 2 − α 1 β 2 ) K a1 [A] + β 2 K a21 [A] 2 }

m Lapp =

m L1 K a1 [A]
m K [A]
+ L2 a2
(1 + K a1 [A]) (1 + K a 2 [A])

(5-3)

(5-4)

In these equations, Ka1 and Ka2 are the association equilibrium constants of A at binding
sites 1 and 2, and mL1 or mL2 are the binding capacities that correspond to these sites. The
term α1 is the fraction of all binding regions that make up the high affinity binding sites
(i.e., α1 = mL1,tot/mLtot), while β2 is the ratio of the association equilibrium constants for
any lower affinity site (e.g., Ka2) versus the highest affinity site, where β2 = Ka2/Ka1 and 0
< Ka2 < Ka1. Equation 5-4 can be used to make of plot of mLapp vs. [A] in order to
calculate binding constants for the two binding sites. Similar models can be used for
systems with more than two binding sites.24
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Using these equations, a non-linear plot of 1/mLapp vs. [A] would be expected
throughout a broad range of concentrations for a system with multi-site binding.
However, at low concentrations a linear response would still be observed. In this case,
Equation 5-3 can be simplified and used to calculate binding constants for the highest
affinity binding site, as occurs when using low concentrations of the analyte and as
shown by the linear approximation in Equation 5-5.25

lim

[A]→0

1
m Lapp

2

2

α1 + β 2 − α1β 2
1
=
+
m Ltot (α 1 + β 2 − α 1 β 2 ) K a1 [A] m Ltot (α 1 + β 2 − α 1 β 2 ) 2

(5-5)

A plot of 1/mLapp vs. 1/[A] according to Equation 5-5 has been shown in previous
theoretical studies to provide a good estimate for Ka1 and mLtot in multi-site systems.25

Zonal Elution
HPAC and the method of zonal elution were used to examine the binding of
acetohexamide and tolbutamide to glycated HSA at specific binding sites.

In this

method, a competing agent I (in this case, acetohexamide or tolbutamide) is present in the
mobile phase at a known concentration while a small plug of analyte A (either R-warfarin
or L-tryptophan) is injected onto the column. This technique is often used to examine the
binding interactions of the analyte and the competing agent. Observations can often be
put into three categories for these interactions: 1) the pair directly competes for the same
binding site, 2) the compounds affect the binding of one another through allosteric
effects, or 3) no direct competition is observed. The retention time of the resulting
analyte peaks can be used to determine the retention time of the analyte, tR, which can
then be used to calculate the retention factor k, where k = (tR-tM)/tM) and tM is the elution
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time of a non-retained solute (e.g., sodium nitrate). The following equation can be used
to describe the relationship between the retention factor of the analyte and the
concentration of the competing agent, [I].23, 24

VM
1 K aI VM [I]
=
+
k
K aA m L
K aA m L

(5-6)

In Equation 5-6, KaI and KaA are the association equilibrium constants for the competing
agent and analyte, respectively, at their site of competition and VM is the void volume. A
plot of 1/k vs. [I] for this equation should yield a linear response if A and I have direct
competition for one binding site on the ligand. The best-fit line for a system with these
interactions can be used to determine the association equilibrium constant for the
competing agent by dividing the slope by the intercept. This can be a useful tool to
determine site-selective interactions for a compound at a particular binding site on a
ligand.23

Experimental
Reagents
The acetohexamide, tolbutamide (≥ 99.9%), warfarin (≥ 97%), L-tryptophan
(98%), monobasic and dibasic potassium phosphate salts, D-(+)-glucose (99.5%), sodium
azide (>95%), sodium chloride, sodium phosphate salts, HSA (essentially fatty acid free,

≥ 96%), and commercial glycated HSA (Lot 058K6087) were purchased from SigmaAldrich (St. Louis, MO, USA). The Nucleosil Si-300 (7 micron particle diameter, 300 Å
pore size) was purchased from Macherey-Nagel (Düren, Germany). Reagents used in the
bicinchoninic acid (BCA) protein assay were from Pierce (Rockford, IL, USA). The
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enzymatic assay kits for fructosamine (used here for glycated serum proteins) were from
Diazyme Laboratories (San Diego, CA, USA). Sterilized 17 x 100 mm culture tubes
were purchased from Fisher Scientific (Pittsburg, PA, USA). Slide-A-Lyzer 7K (7 kDa
MW cutoff) dialysis cassettes with varying sample volume sizes (0.5-3, 3-12, and 12-30
ml) were acquired from Thermo Scientific (Rockford, IL, USA). The Econo-Pac 10 DG
disposable chromatography 30 x 10 ml desalting columns were from Bio-Rad
Laboratories (Hercules, CA, USA).

All solutions were made using water from a

NANOpure system (Barnstead, Dubuque, IA, USA) and filtered with a 0.20 µm GNWP
nylon membrane from Millipore (Billerica, MA, USA).

Apparatus
The HPLC system consisted of a Jasco DG-2080-53 three-solvent degasser
(Tokyo, Japan), two Jasco PU-2080 isocratic pumps, a Rheodyne Advantage PF six-port
valve (Cotati, CA, USA), a Jasco AS-2055 autosampler, a Jasco CO-2060 column oven,
and a Jasco UV-2075 UV/Vis detector. The HPLC system hardware was controlled by
EZChrom Elite software v3.2.1 (Scientific Software, Inc., Pleasanton, CA, USA) via
Jasco LC Net hardware.

An in-house version of Labview 5.1 software (National

Instruments, Austin, TX, USA) was used to analyze the frontal analysis breakthrough
curves while PeakFit 4.12 (Jandel Scientific Software, San Rafael, CA, USA) was used to
determine the central moments of peaks obtained from zonal elution experiments. Linear
regression was performed using Excel 2003 (Microsoft Corporation, Redmond, WA,
USA) and non-linear regression was performed using DataFit (Oakdale Engineering, PA,
USA).
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Methods
Diol silica was made using Nucleosil Si-300 silica and HSA was immobilized to
the diol silica by the Schiff base method according to a previously-published
procedures.26-28 Control silica was also made using this method but with no added HSA.
A BCA assay was performed in triplicate to determine the protein content of the supports,
using soluble glycated HSA as the standard and the control support as the blank. These
studies used three batches of HSA for immobilization, with each batch having a different
level of glycation. The first HSA sample was purchased from Sigma (gHSA1), while the
second and the third were made in vitro using low or medium levels of glucose (gHSA2
and gHSA3, respectively).
HSA was glycated in vitro using a modified version of previously-published
methods.29, 30 In order to make the gHSA2 sample, a 20 mL solution containing 1 mM
sodium azide, 15 mM glucose, and 42 g/L HSA was made in sterile pH 7.4, 0.2 M
potassium phosphate buffer. This solution was put into sterile culture tubes in 3-4 ml
fractions, capped, sealed with parafilm and allowed to incubate in a water bath for 4
weeks at 37 °C. The solutions were then filtered using a size exclusion desalting column
to remove excess glucose and sodium azide from the protein solution. The protein
fraction was then dialyzed against water to remove buffer salts. This protein solution was
placed into sterile dialysis cassettes and dialyzed against water at a volume 200-500x that
of the sample for 2 h with gentle stirring at room temperature; the water outside of the
cassettes was removed and replaced with fresh water, followed by another 2 h of dialysis
under the same conditions. The water was again replaced with fresh water and dialysis
was allowed to continue at 4 °C for ~14-18 h with no stirring. The resulting protein
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solution was stored at -80 °C until further use. Lyophilization was performed on the
protein solution until the protein was dry. The HSA was then stored at -80 °C until it was
used for immobilization. The same procedure was used to make the gHSA3 sample but
with the glucose levels being increased to ~30 mM during incubation to elevate the level
of HSA glycation.
After immobilization, the glycated HSA supports were downward slurry-packed
into separate 2.0 cm x 2.1 mm I.D. columns at 3500 psi (24 MPa) using pH 7.4, 0.067 M
potassium phosphate buffer as the packing solution. The control supports for each gHSA
sample were packed into separate columns under the same conditions. These columns
were stored at 4 °C in the packing solution and used over a period of one year and fewer
than 500 sample applications per column. Similar columns containing normal HSA have
been found in previous studies to retain good stability for drug-protein binding studies
under such conditions.31
A fructosamine assay kit from Diazyme Laboratories was used to determine the
mol hexose (sugar)/mol HSA as a measure of glycation. This kit contained a calibrator, a
control, Reagent 1, and Reagent 2. This assay is meant to be used for serum samples and
was modified from the original instructions per the manufacturer’s advice for use with
the protein solution. A 20 g/L HSA solution was prepared from a glycated HSA sample
by dissolving ~10 mg of protein in 500 µL of pH 7.4, 0.025 M potassium phosphate
buffer. A 300 µL portion of Reagent 1 was placed into an empty cuvette and 30 µL of
the protein solution was added to the cuvette. This mixture was stirred quickly and
placed into a temperature-controlled UV/vis spectrometer at 37 °C for 5 min.
Absorbance values were collected at 600 and 700 nm at this time. A 75 µL portion of
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Reagent 2 was quickly added to the cuvette, mixed, and allowed to react for 5 more
minutes, after which the absorbance values were again measured. This procedure was
repeated for the control, calibration standard, and a saline solution sample in place of the
protein sample. The assay was performed in duplicate or triplicate. A 0.85% sodium
chloride saline solution was used as a blank for the calibration curve, while the assay kit
provided a calibration standard of 613 µmol/L fructosamine for the second point of the
curve. A control provided with this kit was used to test for the accuracy of the method.
The original procedure called for only one absorbance reading to be taken at 600 nm,
while this modified procedure required the use of a difference in absorbance readings at
600 and 700 nm. Other than this change, the assay followed the manufacturer’s protocol.
The value of mol hexose/mol HSA was calculated for each glycated HSA sample using
the resulting data and calibration plot. The assay was repeated with fresh reagents and
solutions when new batches of glycated HSA were analyzed.
The acetohexamide, tolbutamide, R-warfarin, and L-tryptophan solutions were
made in pH 7.4, 0.067 M potassium phosphate buffer. This buffer was also used as the
application and elution buffer in the chromatographic studies. All solutions were filtered
through a 0.2 µM nylon filter and degassed for 10-15 min prior to use. A flow rate of 0.5
ml/min was used for both the frontal analysis and zonal elution studies. This flow rate
has been shown in previous studies to give reproducible retention factors and binding
capacities for drug binding studies conducted on similar columns containing normal
HSA.32, 33
Frontal analysis studies were performed at 37 °C. In these experiments, the
column was first equilibrated with pH 7.4, 0.067 M potassium phosphate buffer, with
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equilibration being completed between each successive run. The solutions were switched
quickly between the pH 7.4 buffer and sample solution using an automated six-port
valve. Once the analyte had saturated the column and produced a breakthrough curve,
the valve was switched again and buffer was used to elute the remaining analyte from the
column. For the frontal analysis studies, the analyte solutions contained acetohexamide
at a concentration of 1-1000 µM or tolbutamide at a concentration of 1-200 µM. The
analyte was monitored using absorbance readings at 248 nm for acetohexamide at 1-7.5
µM, 315 nm for acetohexamide at 10-1000 µM, and 250 nm for tolbutamide at 1-200
µM. (Note: the wavelength was changed for acetohexamide in going from 1-7.5 µM to
10-1000 µM to keep the absorbance values within a linear range of response). Runs were
performed in triplicate for each analyte concentration and the resulting breakthrough
curves were analyzed using Labview 5.1 and the equal areas method.23 Non-specific
binding was corrected by subtracting the results for the control column from the protein
column results.
Zonal elution competition studies were performed using two well-characterized
probe compounds for HSA: R-warfarin, known to bind to Sudlow site I, and Ltryptophan, known to bind to Sudlow site II.10,

11

Varying concentrations of

acetohexamide or tolbutamide (ranging from 1-20 µM) were placed in the mobile phase.
A series of 20 µL injections of 5 µM R-warfarin or L-tryptophan were made at 37 °C.
The concentration of these samples has been shown in the past to be within linear elution
conditions for similar HSA columns.34, 35 The elution of R-warfarin and L-tryptophan
was monitored at 308 and 280 nm, respectively. Injections of 20 µM sodium nitrate were
also made at 20 µL under the same conditions using only the pH 7.4 buffer as the mobile
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phase. Sodium nitrate was used as a non-retained solute to determine column and system
void times, with the elution of sodium nitrate being monitored at 205 nm. The resulting
peaks were analyzed using PeakFit v4.12 software and fit to an exponentially-modified
Gaussian curve.

Results and Discussion
Preparation of Glycated HSA
A fructosamine assay was used to determine the amount of glycation present in
each HSA sample. The first glycated HSA column (gHSA1) was determined to contain
1.31 (± 0.05) mol hexose/mol HSA. The second glycated HSA column (gHSA2) had
HSA with a glycation level of 2.34 (± 0.13) mol hexose/mol HSA. The third column
(gHSA3) was made with HSA that had a glycation level of 3.35 (± 0.14) mol hexose/mol
HSA. The protein content of these columns was between 29 and 47 mg protein/g silica
(or ~440-710 nmol HSA/g silica).

These levels were comparable to protein levels

previously noted for normal HSA supports prepared by the same method.28 The protein
content and glycation levels for each of the supports are summarized in Table 5-1.

Acetohexamide Binding to gHSA1
Breakthrough curves were collected for acetohexamide on each glycated HSA
column. The first analysis was performed using the gHSA1 column (see Figure 5-1).
Breakthrough times were calculated from the curves and mLapp values were determined at
each analyte concentration. Double reciprocal plots were prepared according to Equation
5-1. Previous studies have indicated that acetohexamide binds to normal (non-glycated)
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Table 5-1. Protein content and level of glycation of HSA supports

Protein Content
(mg HSA/g silica)
Level of glycation
(mol Hexose per mol HSA)

gHSA1

gHSA2

gHSA3

29 (± 4)

47 (± 8)

40 (± 3)

1.31 (± 0.05)

2.23 (± 0.13)

3.22 (± 0.14)

The values in parenthesis represent ± 1 S.D.

195

Figure 5-1.

Breakthrough curves for acetohexamide on the gHSA1 column.
Concentrations from left to right: 1000, 500, 300, 100, 50 µM
acetohexamide.
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HSA at more than one type of binding site (see Chapter 3), so deviations from linearity at
high concentrations were expected for this type of plot, as seen in Figure 5-2. The data
over the linear range (acetohexamide concentrations 1-10 µM) were fit to Equation 5-5.
From this linear region (r = 0.998, n = 7), Ka1 and mL1 values for the high-affinity binding
regions of acetohexamide with the glycated HSA were found to be 2.0 (± 0.2) x 105 M-1
and 1.35 (± 0.10) x 10-8 mol.
Due to the curvature of the results in Figure 5-2, the overall data in Figure 5-3
were also fit to a two-site model using Equation 5-4. The data fit well to this model and
gave only random residuals and a small sum of square of the residuals. The Ka value for
the high-affinity interactions was calculated from this fit to be 1.2 (± 0.2) x 105 M-1, and
these sites had an mL value of 1.7 (± 0.1) x 10-8 mol. The second, lower-affinity binding
sites gave a Ka value of 1.4 (± 0.8) x 103 M-1 and a corresponding mL value of 1.7 (± 0.4)
x 10-8 mol. The Ka value calculated for the group of high-affinity binding sites was
similar to the value obtained when using Equation 5-5. The association equilibrium
constant for the high-affinity sites is comparable to those obtained for acetohexamide on
a normal HSA column, which had a Ka value of 1.3 (± 0.2) x 105 M-1. The lower-affinity
binding site appears to increase from 3.5 (± 0.3) x 102 M-1 on the normal HSA column to
1.4 (± 0.8) x 103 M-1 on the gHSA1 column; however, the error associated with these
values makes them indistinguishable at the 95% confidence level. These results are
summarized in Table 5-2.
A comparison of the binding capacity and protein content of the gHSA1 column
was also made. This comparison was used to estimate the number of binding regions.
Using the results from the two-site binding model, the high-affinity sites had a calculated
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Figure 5-2.

Reciprocal plot for acetohexamide using Eqn. (1).

Best-fit line was

calculated using concentrations 1-10 µM acetohexamide according to Eqn.
(5): y = 360 (± 10) x + [7.4 (± 0.5) x 107], r = 0.998, n = 7. The error bars
represent a range of ± 1 SD.
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Figure 5-3.

Plot of mLapp vs. [Acetohexamide] for the gHSA1 column with a fit using
Eqn. (4).
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Table 5-2. Binding constants calculated for acetohexamide and tolbutamide using frontal
analysis and a two-site binding model.

Ka1
(x 105 M-1)

mL1
(x 10-8 mol)

Activity

Ka2
(x 103 M-1)

mL2
(x 10-8 mol)

Activity

HSA

1.3
(± 0.2)

2.4
(± 0.1)

1.3
(± 0.1)

0.35
(± 0.03)

9.3
(± 5.5)

5.2
(± 3.1)

gHSA1

1.2
(± 0.2)

1.7
(± 0.1)

1.3
(± 0.2)

1.4
(± 0.8)

1.7
(± 0.4)

1.3
(± 0.3)

gHSA2

2.0
(± 0.6)

1.8
(± 0.3)

0.80
(± 0.20)

11
(± 3)

2.4
(± 0.3)

1.1
(± 0.2)

gHSA3

2.0
(± 0.3)

1.5
(± 0.1)

0.80
(± 0.09)

4.1
(± 0.7)

3.0
(± 0.1)

1.6
(± 0.5)

HSA

0.87
(± 0.06)

2.0
(± 0.1)

1.1
(± 0.1)

8.1
(± 1.7)

1.8
(± 0.1)

1.0
(± 0.1)

gHSA1

1.2
(± 0.2)

1.1
(± 0.2)

0.82
(± 0.18)

9.5
(± 3.2)

1.7
(± 0.1)

1.2
(± 0.2)

gHSA2

0.84
(± 0.16)

2.2
(± 0.4)

1.0
(± 0.3)

7.8
(± 5.1)

1.9
(± 0.2)

0.87
(± 0.18)

gHSA3

0.89
(± 0.06)

1.9
(± 0.1)

1.1
(± 0.1)

1.7
(± 1.1)

3.6
(± 1.4)

1.9
(± 0.8)

Acetohexamide
Column

Tolbutamide
Column

The values in parenthesis represent ± 1 S.D.
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activity of 1.3 (± 0.2), while the lower-affinity sites had an activity of 1.3 (± 0.3). When
compared to a typical value of 0.55-0.8 for single-site binding to immobilized HSA, these
values suggest that at least two regions are involved in binding at each of these groups of
sites. Similar results for the high-affinity sites were found for acetohexamide binding to
normal HSA in previous studies.
Zonal elution competition studies were performed to examine binding at Sudlow
sites I and II using the site-selective probe compounds R-warfarin (see Figure 5-4) and Ltryptophan, respectively. When plotting 1/k vs. [acetohexamide], a linear response was
obtained for each probe compounds as seen in Figure 5-5. These plots gave a correlation
coefficient of 0.991 for both L-tryptophan and R-warfarin, indicating there was direct
competition of both these probe compounds with acetohexamide. Previous zonal elution
competition studies performed using normal HSA also displayed direct competition of
these probes with acetohexamide. This indicates that acetohexamide had binding at both
Sudlow sites I and II on HSA when low levels of glycation were present.
The experimental retention factor for L-tryptophan determined by this method
was 3.9 (± 0.1) when no competing agent was present in the system. A predicted value
for the retention factor was also calculated by taking the inverse of the intercept from the
best-fit line. This value was determined to be 3.7 (± 0.2). With a calculated 3.2%
difference, the experimental value showed good agreement to the predicted value. The
same was true for R-warfarin. This compound had an experimental retention factor of 59
(± 1) and a predicted value of 55 (± 2) in the absence of any acetohexamide. These
values are within two standard deviations of one another, with only a slightly larger
difference (7.3%) than seen with L-tryptophan.
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Figure 5-4.

Zonal elution competition studies for R-warfarin and acetohexamide on
the gHSA1 column.

R-Warfarin was injected onto the column while

known amounts of acetohexamide were present in the mobile phase.
Acetohexamide concentrations from top to bottom: 20, 15, 10, 5, and 1
µM. Injections were made using 20 µL of 5 µM R-warfarin.
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Figure 5-5.

Determination of the (a) R-warfarin and (b) L-tryptophan retention on the
gHSA1 column in the presence of acetohexamide as analyzed using
Equation 5-6. The best-fit line for R-warfarin was y = 1100 (± 100) x +
0.018 (± 0.001), r = 0.991, n = 6. The best-fit line for L-tryptophan was y
= [2.1 (± 0.1) x 104] x + 0.27 (± 0.02), r = 0.991, n = 6. The error bars
represent a range of ± 1 SD.
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The association equilibrium constants were calculated for acetohexamide at
Sudlow sites I and II by taking the ratio of the slope to the intercept for plots of 1/k vs.
[acetohexamide]. Values of 5.9 (± 0.5) x 104 M-1 and 7.9 (± 0.7) x 104 M-1 were
calculated for the interactions at Sudlow site I and site II, respectively. It was noted that
these values were both slightly lower than the high-affinity set of binding sites found for
acetohexamide using frontal analysis, but much higher than the value for the loweraffinity sites. It is possible that frontal analysis was grouping both of these regions in the
group of high-affinity sites.
Compared to a normal HSA column, the association equilibrium constant
calculated for Sudlow site I increased from 4.2 (± 0.4) x 104 M-1 to 5.9 (± 0.5) x 104 M-1
on the gHSA1 column. This value remained within two standard deviations of the Ka for
the normal HSA column. The opposite was true for the interactions at Sudlow site II,
where the binding constant decreased from 1.3 (± 0.1) x 105 M-1 to 7.9 (± 0.7) x 104 M-1
in going from a normal HSA column to the gHSA1 column (see Table 5-3). Perhaps
these opposing binding changes are why there was no apparent change in the overall Ka
value at the high-affinity sites for these two columns when examined by frontal analysis.

Acetohexamide Binding to gHSA2
The HSA that had the next highest level of glycation was gHSA2. The same
studies that were performed using the gHSA1 column were performed with a gHSA2
column.

First, frontal analysis was performed to investigate the binding of

acetohexamide to glycated HSA. A reciprocal plot of 1/mLapp vs. 1/[acetohexamide] was
again made for these data and examined using a single-site binding model. Like the
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Table 5-3. Binding constants for acetohexamide and tolbutamide determined using zonal
elution competition studies

Sudlow Site I
(R-warfarin)
( x 104 M-1)

Sudlow Site II
(L-tryptophan)
(x 104 M-1)

HSA

4.2 (± 0.4)

13 (± 1)

gHSA1

5.9 (± 0.5)

7.9 (± 0.7)

gHSA2

3.8 (± 0.3)

11 (± 1)

gHSA3

4.1 (± 0.6)

12 (± 1)

HSA

5.5 (± 0.2)

5.3 (± 0.2)

gHSA1

6.9 (± 0.2)

5.9 (± 0.3)

gHSA2

6.6 (± 0.5)

7.2 (± 0.3)

gHSA3

6.5 (± 0.2)

6.4 (± 0.3)

Acetohexamide
Column

Tolbutamide
Column

The values in parenthesis represent ± 1 S.D.
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gHSA1 column, non-linear results were seen for this column at high concentrations (low
1/[A] values), implying that acetohexamide binds to the gHSA2 column at more than one
type of binding site. Linear regression was performed for the lower acetohexamide
concentrations (1-10 µM, r = 0.999, n = 6) using Equation 5-5 to estimate the binding
constants for the high-affinity binding sites. This gave a Ka of 2.0 (± 0.2) x 105 M-1 and a
corresponding mL of 2.0 (± 0.1) x 10-8 mol. These results are similar to those calculated
for the gHSA1 column for its high affinity sites.
The data were then fit to a two-site model using Equation 5-4. Association
equilibrium constants of 2.0 (± 0.6) x 105 M-1 and 1.1 (± 0.3) x 104 M-1 were calculated
for the high- and lower-affinity binding regions.

The high-affinity binding regions

showed strong agreement with the one-site model results using only low concentrations
and Equation 5-5. This again supported the use of Equation 5-5 in determining binding
constants for the high-affinity regions. Acetohexamide appeared to have stronger affinity
to the lower-affinity binding sites with the gHSA2 column then with the gHSA1 column.
Further investigation was done using zonal elution to explore these interactions.
The binding capacities for the high- and lower-affinity regions were 1.8 (± 0.3) x
10-8 mol and 2.4 (± 0.3) x 10-8 mol, respectively. At first glance, the high-affinity site
seemed to have the same activity level as seen using the gHSA1 column, while the loweraffinity site appeared to increase. However, since the protein content was higher for the
gHSA2 column than the gHSA1 column, the binding capacities alone can be misleading
in this instance. In fact, the specific activities at both the high affinity and low affinity
regions appeared to decrease for the gHSA2 column, with the high-affinity binding sites
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having an activity of 0.79 (± 0.20) and the lower-affinity sites having an activity of 1.1 (±
0.2).
Zonal elution studies were performed to examine the binding of acetohexamide at
Sudlow sites I and II for the gHSA2 column. Using Equation 5-6, plots of 1/k vs.
[acetohexamide] were made for the competition of acetohexamide with R-warfarin and
L-tryptophan.

Both plots appeared to be linear when fit to Equation 5-6.

The

experimental retention factor for the competition of L-tryptophan and acetohexamide
when no acetohexamide was present in the mobile phase was 5.6 (± 0.3), while the
predicted value from the best-fit line was calculated to be 5.8 (± 0.1). These values were
within two standard deviations of one another and had only a 5% difference. The
competition between R-warfarin and acetohexamide had similar results, with an
experimental retention factor of 64 (± 1) and a predicted value of 62 (± 2) in the absence
of acetohexamide. These values only differed by 3% and were also within two standard
deviations of one another. These retention factors were higher on the gHSA2 column
than the gHSA1 column due to the increased protein content within the gHSA2 column.
Association constants for acetohexamide were also calculated using the zonal
elution data. The competition with L-tryptophan produced a Ka value of 1.1 (± 0.1) x 105
M-1, while the competition with R-warfarin resulted in a Ka of 3.8 (± 0.3) x 104 M-1.
These values both shifted from those calculated for the gHSA1 column. Using higher
levels of glycation, it appears as though the Ka value at Sudlow site II increased while the
Ka value at Sudlow site I decreased. These values were both lower than the frontal
analysis estimate for the high-affinity binding site; however, the Ka value calculated for
Sudlow site II was close to the value calculated for the high-affinity binding site using
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frontal analysis. This result might explain why there was a change in the apparent
activity at these binding sites using the two-site frontal analysis model. Perhaps the
model was starting to differentiate between these two high-affinity sites. Now that the Ka
values were further from each other than with the gHSA1 column, this model might have
been primarily detecting the interactions at Sudlow site II for the high-affinity site while
the Ka value for Sudlow site I interaction was closer to the lower-affinity result. This
would also explain why the lower-affinity site Ka value using the frontal analysis model
was higher than expected for only non-specific binding interactions.

Acetohexamide Binding to gHSA3
The gHSA3 column contained the most glycation of the three tested columns,
with almost double the value of mol hexose/mol HSA compared to the gHSA1 column.
The determination of binding constants for this column again began with frontal analysis
studies. The data were fit to a single-site binding model using Equation 5-1 and a
double-reciprocal plot. This plot also had non-linear deviations at high concentrations, so
Equation 5-5 was used to estimate the high-affinity binding constants using
concentrations of 1-10 mM (r = 0.999, n = 5). The Ka value calculated using this model
was 1.9 (± 0.1) x 105 M-1. The corresponding mL value was 1.6 (± 0.1) mol.
The two-site model was employed next, as was done for the previous columns, to
further examine both the high- and lower-affinity binding sites. Using this model, Ka
values of 2.0 (± 0.3) x 105 M-1 and 4.1 (± 0.7) x 103 M-1 were calculated for the highaffinity and low-affinity sites, with corresponding mL values of 1.5 (± 0.1) x 10-8 mol and
3.0 (± 0.1) x 10-8 mol, respectively. As seen with the gHSA2 column, this model shows a
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Ka value for the high-affinity sites in strong agreement with the one-site model when
using Equation 5-5 and data at low concentrations. The binding capacities and the
protein content of the column were again used to examine the relative activity of the
binding sites. An activity of 0.80 (± 0.09) was calculated for the high-affinity binding
sites, which was statistically identical to that found for the gHSA2 column, while the
activity for the lower-affinity sites was higher and had a larger standard deviation, 1.6 (±
0.5). This result was explored more using zonal elution competition studies.
Competition studies were performed to examine the binding occurring at Sudlow
sites I and II on HSA. Plots of 1/k vs. [acetohexamide] for L-tryptophan and R-warfarin
both appeared to give linear results, with correlation coefficients of 0.999 and 0.971,
respectively.

The calculated retention factor at [I] = 0 for the competition of L-

tryptophan and acetohexamide was 4.7 (± 0.1), while the predicted value was 4.5 (± 0.1).
These values fell within two standard deviations of one another and there was only a
5.2% difference between these values.
R-Warfarin retention factors were also determined.

The calculated retention

factor at [I] = 0 for this interaction was 47 (± 1) and the predicted value was 44 (± 3)
when no acetohexamide was present. These values were within 7.2% of one another and
within two standard deviations. The warfarin data did not fit quite as neatly to a one-site
model as was seen when using the gHSA1 and gHSA2 columns (Figure 5-6). It was
observed that at low acetohexamide concentrations (1-10 µM), warfarin gave a linear fit
with a correlation coefficient of 0.999; however, at the higher concentrations (15 and 20
µM), the retention factor for the probe increased (i.e., a decrease in 1/k). When linear
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Figure 5-6.

Determination of the R-warfarin retention on the gHSA3 column in the
presence of acetohexamide, as analyzed using Equation 5-6. The solid
line represents the best-fit line for the entire data set, while the dashed line
represents the best-fit line for only the bottom four concentrations (1-10
µM acetohexamide). The best-fit line for the entire data set was y = 930
(± 100) x + 0.023 (± 0.001), r = 0.971, n = 6. The best-fit line for the
lower four concentrations was y = 1400 (± 100) x + 0.021 (± 0.001), r =
0.999, n = 4. The error bars represent ± 1 SD.
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regression was performed on only the lower four concentrations, a predicted retention
factor of 47 (± 1) was obtained at [I] = 0, which gave a 1.3% difference between this
value and the experimental value.
Association equilibrium constants were calculated using the regression data from
the competition studies. Acetohexamide was calculated to bind to gHSA3 with a Ka
value of 1.2 (± 0.1) x 105 M-1 at Sudlow site II. This value was close to the one
calculated for the high-affinity sites using the two-site frontal analysis model. Using the
full concentration range for R-warfarin, a Ka value of 4.1 (± 0.6) x 104 M-1 was calculated
for acetohexamide binding to Sudlow site I, with this value increasing to 6.5 (± 0.2) x 104
M-1 if only the lower acetohexamide concentrations were used. It appears as though the
frontal model is able to detect the high-affinity region at site II but perhaps is not able to
differentiate the lower-affinity site I interactions. It is also interesting to note that the Ka
value at this binding site decreased for gHSA2 and increased for gHSA3, while the
binding at Sudlow site II steadily increased as the level of glycation increased.

Tolbutamide Binding to gHSA1
Similar studies were performed using tolbutamide. Much like the acetohexamide
studies, these studies started with the column containing HSA with the lowest level of
glycation, gHSA1. The method of frontal analysis was used to gain information about
the overall binding of tolbutamide to HSA, with increasing levels of glycation being
present when using the three glycated HSA columns. Tolbutamide breakthrough curves
began at a shorter timeframe than those obtained for acetohexamide, so initial
experimental observations suggested that the association equilibrium constants should be
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smaller than the Ka values calculated for acetohexamide.

However, upon further

investigation, the breakthrough times were only slightly lower for tolbutamide due to the
slope of its breakthrough curves (see Figure 5-7). The initial data was fit to a one-site
model using Equation 5-1. Using this model it was clear that linear deviations at high
concentrations were present for this drug, indicating that binding to more than one
binding site was occurring. This result was also seen for previous studies using HSA
with no glycation. The apparent “double break” in the breakthrough curve seen in Figure
5-7 for tolbutamide also could elude to a two-site binding system. Equation 5-5 was
employed to estimate the binding at the high-affinity site using concentrations of 1-10
µM.

The resulting Ka value using this model was 9.1 (± 0.2) x 104 M-1, with a

corresponding mL value of 1.7 (± 0.3) x 10-8 mol (r = 0.999, n = 6).
The two-site model was used next to see if more binding sites could be
differentiated for this drug. This was accomplished using Equation 5-4 and non-linear
regression. The calculated values for tolbutamide binding to gHSA1 were as follows: Ka
= 1.2 (± 0.2) x 105 M-1 and mL = 1.1 (± 0.2) x 10-8 mol for the high-affinity set of binding
sites, and Ka = 9.5 (± 3.2) x 103 M-1 and mL = 1.7 (± 0.1) x 10-8 mol for the lower-affinity
binding sites. The first thing noted for these binding constants was the large Ka value for
the high-affinity binding site. This Ka value was larger than the one calculated using
Equation 5-5 but was also notably larger than the value calculated for a column with nonglycated HSA, which had a value of 8.7 (± 0.6) x 104 M-1 when using Equation 5-4.
The activity calculated for the high-affinity sites using the two-site model gives a
value of 0.82 (± 0.18). This activity is lower than expected to include more than one
binding region, but with the associated error it is difficult to determine if it is showing
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Figure 5-7.

Breakthrough curves for 100 µM tolbutamide and 100 µM acetohexamide
on the gHSA3 column. Due to differences in absorbance values, the
curves have been normalized to appear the same height.
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one binding region or two. The activity at the lower-affinity binding sites was 1.2 (± 0.2)
suggesting tolbutamide was binding at more than one binding region within this group of
sites.
Zonal elution competition studies were used to further examine the interactions at
these binding sites. In these studies, concentrations of 0-20 µM tolbutamide were used,
while the injections made using no competing agent in the mobile phase were collected
from the acetohexamide competition studies. Unfortunately, it was determined later that
the data collected using no competing agent in the mobile phase did not correspond well
to the other data collected for this drug.

Compared to the L-tryptophan data, this

concentration had a lower retention factor (higher 1/k) than the data collected for the
gHSA1 and gHSA2 columns, while R-warfarin data had a higher retention factor (lower
1/k) for these columns (Figure 5-8). This effect was present but not as drastic for the
gHSA3 column. Therefore, the data when no competing agent was present in the mobile
phase was removed for the tolbutamide studies.
A retention factor of 5.0 (± 0.2) was found for L-tryptophan on this column. The
best-fit line for this model gave a correlation coefficient of 0.998. The calculated value
(the zero concentration point that was disregarded from these studies to calculate the
best-fit line) was 3.9 (± 0.1). The difference between the calculated and the predicted
value was 23%. This difference was calculated to further explain why this concentration
was not used in the linear regression of this model.

R-Warfarin showed similar

differences of 20% with a predicted retention factor of 47 (± 1) using the best-fit line with
a correlation coefficient of 0.999 (n = 5), while the experimental k value was 59 (± 1).
The association constant of tolbutamide was also calculated using the method of
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Figure 5-8.

Determination of (a) R-warfarin and (b) L-tryptophan retention in the
presence of tolbutamide, as analyzed using Equation 5-6. The best-fit line
for R-warfarin was y = 1500 (± 100) x + 0.021 (± 0.001), r = 0.999, n = 5.
The best-fit line for L-tryptophan was y = [1.2 (± 0.1) x 104] x + 0.20 (±
0.01), r = 0.998, n = 5. The error bars represent ± 1 SD.
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zonal elution. The Ka value for tolbutamide binding at Sudlow site I was 5.9 (± 0.3) x
104 M-1 and the Ka value for the binding of tolbutamide at Sudlow site II was 6.9 (± 0.2)
x 104 M-1. These values were close to one another, showing a possibility of why the
frontal analysis studies were unable to differentiate these binding constants at the highaffinity sites. Without running zonal elution studies, frontal analysis alone would have
overestimated the high-affinity binding constant for tolbutamide due to an inability to
separate such closely related binding constants for these two regions. This is a good
example of why zonal elution and frontal analysis can be used to complement one
another in gaining information about drug-protein interactions. Similar results were
found for a normal HSA column, where the binding of tolbutamide at Sudlow site I gave
a Ka of 5.5 (± 0.2) x 104 M-1 and at Sudlow site II gave a Ka of 5.3 (± 0.2) x 104 M-1. The
binding constants at both of these sites increased slightly on the gHSA1 column, perhaps
attributing to the overall increase in the binding constant that was found when using
frontal analysis.

Tolbutamide Binding to gHSA2
The gHSA2 column was used to examine the binding of tolbutamide at higher
levels of glycation. Frontal analysis was performed and the data were fit to Equation 5-1
for a one-site model. The data deviated from linearity at high concentrations, so Equation
5-5 was used to calculate binding constants for the high-affinity sites using the lower
analyte concentrations of 1-10 µM. This gave a Ka value of 1.1 (± 0.1) x 105 M-1 and an
mL value of 2.1 (± 0.3) x 10-8 mol with a correlation coefficient of 0.999 (n = 5).
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The data were then fit to the two-site model. This model gave a lower Ka value of
8.4 (± 1.6) x 104 M-1 for the high-affinity binding site, which was similar to the Ka value
calculated using the single-site model. The lower-affinity binding sites also seemed to
have a larger standard error, giving a Ka value of 7.8 (± 5.1) x 103 M-1. The binding
capacities for these two sites are 2.2 (± 0.4) x 10-8 mol and 1.9 (± 0.2) x 10-8 mol,
respectively. The binding capacities along with the protein content of the column gave
activities of 1.0 (± 0.3) for the high-affinity binding sites and 0.87 (± 0.18) for the loweraffinity sites. These activities suggested more than one binding region was taking part in
the interactions at these binding sites.
Zonal elution studies were performed to determine the retention factors and
binding constants for tolbutamide at Sudlow sites I and II. In these studies, R-warfarin
was used to examine Sudlow site I, where a retention factor of 58 (± 3) was calculated for
the drug at [I] = 0. For consistency, the concentration at 0 µM tolbutamide was removed
from the linear regression (r = 0.994, n = 5). This experimental value gave a retention
factor of 64 (± 1), which was 10% different from the predicted value. L-Tryptophan was
used to examine Sudlow site II, where a retention factor of 6.8 (± 0.2) at [I] = 0 was
calculated for the compound, with a correlation coefficient of 0.999 for the best-fit line.
Again, the data when no tolbutamide was present in solution was removed from the
regression calculations but was found to be 5.8 (± 0.1) or a 14% difference from the
predicted value.
Association equilibrium constants for tolbutamide were calculated to be 6.6 (±
0.5) x 104 M-1 for Sudlow site I and 7.2 (± 0.3) x 104 M-1 for Sudlow site II. The
association equilibrium constant for Sudlow site I was statistically identical to the gHSA1
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column when taking into account the standard deviation of this value. The association
constant for Sudlow site II increased in this column compared to the gHSA1 column.
The Ka values calculated using this model were both lower than the high-affinity Ka value
calculated using either of the frontal analysis models, but considering the proximity of the
values to one another the frontal analysis model might not have been able to differentiate
these two values.

Tolbutamide Binding to gHSA3
The final study was performed using the third and most highly glycated HSA
column. Frontal analysis was performed for this system with the data fit to a one-site
model. As expected, the data deviated from linearity at high analyte concentrations, so
the low analyte concentrations were used to estimate binding constants for the highaffinity binding sites. Using Equation 5-5, a Ka of 1.0 (± 0.2) x 105 M-1 and an mL of 1.8
(± 0.3) x 10-8 mol was calculated for this set of sites. This association equilibrium
constant was comparable to the Ka calculated for the gHSA2 column.
A two-site binding model was used to try and differentiate the high- and loweraffinity binding sites for this column. This model resulted in association equilibrium
constants of 8.9 (± 0.6) x 104 M-1 and 1.7 (± 1.1) x 103 M-1 for the high- and loweraffinity binding sites, respectively. The corresponding mL values for these sites were 1.9
(± 0.1) x 10-8 mol and 3.6 (± 1.4) x 10-8 mol, with activities of 1.0 (± 0.1) and 1.9 (± 0.8),
respectively. The Ka and activity calculated for the high-affinity binding sites were
similar to those for the gHSA2 column, possibly indicating that any binding changes for
this drug had begun to level out. The lower-affinity binding constants gave values
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expected for non-specific binding interactions, including lower Ka values with high
associated errors and high activities.
Competition studies were performed to determine if changes were taking place at
Sudlow sites I and II at this level of glycation (Note: although this column did not seem
to give deviations when no tolbutamide was present in the mobile phase, as did the other
two columns, the point at [I] = 0 was still removed to make the data analysis consistent).
Linear regression performed on each data set resulted in responses with correlation
coefficients of 0.998 for L-tryptophan and 0.999 for R-warfarin (n = 5). From these
plots, R-warfarin had a predicted retention factor of 45 (± 1), or a value only 5% from the
experimental retention factor of 47 (± 1) at [I] = 0. Likewise, L-tryptophan had a
predicted retention factor of 5.3 (± 0.1) at [I] = 0, which was within 5% of the
experimental value of 5.1 (± 0.1). The Ka value calculated for tolbutamide at Sudlow site
I using this model was 6.5 (± 0.2) x 104 M-1. This value was comparable to the binding
constant determined for the gHSA2 column; the error associated with the gHSA2 column
overlapped with this value, making the results statistically identical.

The Ka value

calculated for tolbutamide at Sudlow site II was 6.4 (± 0.3) x 104 M-1. This value
decreased from the gHSA2 column value, which had increased from the gHSA1 value.

Conclusion
These studies showed that as glycation levels increase on HSA, acetohexamide
and tolbutamide continue to have access to and bind to Sudlow sites I and II on HSA.
Frontal analysis using acetohexamide indicated that there was no appreciable change in
going from normal HSA to mildly glycated HSA, but as the level of glycation was further

227
increased small increases in the association equilibrium constant were evident. Similar
studies using tolbutamide showed an increase in the equilibrium constant for the highaffinity group of sites in going from normal to glycated HSA, which decreased for
subsequent glycation levels.
Competition studies indicated that the association equilibrium constant of both
tolbutamide and acetohexamide at Sudlow site I increased from normal HSA to glycated
HSA but then decreased with increased glycation levels. At Sudlow site II, the Ka for
acetohexamide decreased from normal to glycated HSA then increased with increased
levels of glycation, while tolbutamide binding increased from normal HSA through
gHSA2 but then decreased for gHSA3. Even small changes in drug-protein binding can
affect the free fraction of the drug, which can have serious consequences on the blood
sugar levels of an individual with diabetes.

This is important when determining a

patient’s dosage level. Further studies can be done to examine the binding of these drugs
in combination with other drugs.
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CHAPTER 6
THEORETICAL CONSIDERATIONS IN DRUG-PROTEIN BINDING

Introduction
Binding to serum proteins greatly influences the pharmacokinetics and
pharmacodynamics of drugs.1

Binding to such proteins affects the absorption,

distribution, metabolism and excretion of these compounds.2 In many situations, the
binding of a drug to a serum transport protein can aid or impair the distribution of the
drug to target tissues, which can affect the efficacy of the drug. Any modifications in the
protein, such as structure or concentration, can also alter the binding of a drug to the
protein.3
There are many proteins in human plasma, however, only a small number of these
are considered transport proteins. The transport proteins that bind with the highest
affinity are often specific for a particular compound, such as vitamin D (vitamin Dbinding protein) or thyroxine (thyroxine-binding globulin).3 The proteins with lower
binding affinities are often less specific and bind a wider range of analytes. The two
most important of these latter transport proteins are α1-acid glycoprotein (AGP) and
human serum albumin (HSA).1, 3 The focus of this text will be on drug-protein binding
with HSA.
HSA binds a wide variety of endogenous and exogenous compounds and is the
most important nonspecific transport protein in the circulation. It is the most abundant
protein in plasma, with a concentration of ~40 mg/mL, and accounts for almost 60% of
total plasma proteins.2

Although HSA binds and transports many endogenous
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compounds (e.g. fatty acids, bilirubin, bile salts, and hormones) it is most studied for its
startling ability to bind a wide variety of drugs.2 HSA has two major binding sites for
drugs: Sudlow site I, or the warfarin-azapropazone site, and Sudlow site II, or the indolebenzodiazepine site, as well as a number of minor binding sites.4-6
Equilibrium dialysis, ultrafiltration, and ultracentrifugation are the most widely
used methods in drug-protein binding studies.1

In these techniques, a drug-protein

solution must reach equilibrium before the free fraction and bound fraction of the drug
are separated and analyzed to determine the free fraction in solution. Typically these
techniques require high sample and protein concentrations in order to allow detection of
the free fraction. Another method used in these types of studies is high-performance
affinity chromatography (HPAC). This method offers low sample requirements and does
not require a prior separation step. It also offers good precision, reproducibility, and ease
of automation.7
There are two main methods utilized with HPAC: zonal elution and frontal
analysis.

Zonal elution involves injecting a small plug of sample onto a column

containing an immobilized ligand while monitoring the elution time or volume of an
injected solute.7, 8 Frontal analysis is performed by continuously applying a sample to the
column and instead of a peak, like that obtained in zonal elution, a breakthrough curve
will result and a measurement of the breakthrough time is then made. There are a
number of practical considerations to consider when performing these studies; however,
this text will focus primarily on determining the appropriate analyte concentration that
should be used to ensure that all binding interactions are observed during drug-protein
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binding studies. Also, optimization of these concentrations may allow use of a small
analyte concentration range that will save time and money for such studies.

Theory
Frontal Analysis Theory
The frontal analysis data used in these theoretical studies were previously
analyzed using Equations 6-1 and 6-2 for a single-site binding model (Note: derivations
for Equations 6-1 and 6-2 can be found in Reference 9).7-9

1
m Lapp

=

1
1
+
( K a m L [A]) m L

(6-1)

m L K a [A]
(1 + K a [A])

(6-2)

m Lapp =

In these equations, mLapp is the apparent moles of analyte required to saturate the column
at a given analyte concentration [A], while mL is the binding capacity of the column. The
value Ka is the association equilibrium constant for the analyte with the ligand. When
1/mLapp vs. 1/[A] is plotted, Equation 6-1 predicts a linear result if single-site binding is
taking place between the analyte and the ligand. If linear deviations occur at high
concentrations (low 1/[A] values), more than one binding site on the ligand is involved in
analyte binding.
The above equations can be expanded to describe multiple binding sites.
Equations 6-3, 6-4, and 6-5 are examples of such expansions for a two-site binding
model.7, 8, 10
1
m Lapp

1 + K a1 [A] + β 2 K a1 [A] + β 2 K a21 [A] 2
=
m Ltot {(α 1 + β 2 − α 1 β 2 ) K a1 [A] + β 2 K a21 [A] 2 }

(6-3)
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lim

[A]→0

1
m Lapp

2

=

2

α1 + β 2 − α1β 2
1
+
m Ltot (α 1 + β 2 − α 1 β 2 ) K a1 [A] m Ltot (α 1 + β 2 − α 1 β 2 ) 2
m Lapp =

m L1 K a1 [A]
m K [A]
+ L2 a2
(1 + K a1 [A]) (1 + K a 2 [A])

(6-4)

(6-5)

In these equations, Ka1 is the association equilibrium constant for the binding site with the
highest affinity (L1), while Ka2 is the association equilibrium constant for the binding site
with the lowest affinity (L2). The term β2 is the ratio of the association equilibrium
constants, where β2 = Ka2/Ka1 and 0 < Ka2 < Ka1. The values mL1 and mL2 correspond to
the binding capacities at the high- and low-affinity binding sites, respectively, and the
term α1 represents the fraction of all binding regions that make up the high affinity
binding sites (i.e., α1 = mL1,tot/mLtot). Equation 6-4 is a linear approximation of Equation
6-3 as the concentration of the analyte goes to zero. Although a plot of data according to
Equation 6-3 will be non-linear throughout a broad range of concentrations for multi-site
binding, a plot using Equation 6-4 approaches linearity at low concentrations and can be
used to estimate the binding constant and binding capacity at the high-affinity binding
site in this situation.10 A plot of mLapp vs. [A] based on Equation 6-5 can be used to find
binding constants and binding capacities at both high- and low-affinity binding sites.

Concentration Effects
Some previous theoretical studies have already been conducted that can aid in
determining a concentration range suitable for frontal analysis studies in a case with
single-site binding.7 As it turns out, this concentration range is primarily dependent on
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the equilibrium constant of the analyte under investigation, as is shown in the following
equation.7
m Lapp
mL

=

K a [A]
1 + K a [A]

(6-6)

It can be seen from Equation 6-6 that the fraction of active ligand sites that are bound to
the analyte (mLapp/mL) is dependent only on the association equilibrium constant of the
analyte (Ka) and the concentration of the analyte ([A]).7 A plot made according to this
equation can be seen in Figure 6-1. When no analyte is present in the system, mLapp/mL is
equal to zero. As the concentration of the analyte approaches infinity, the fraction
mLapp/mL will increase and approach a limit of one. The Ka[A] range between zero and
infinity shows where mLapp/mL has a detectable change in value. For a given 1:1 binding
system where 10-90% of the binding sites are filled (i.e., a shift of ± 10% or an mLapp/mL
range of 0.1-0.9), a Ka[A] range between ~0.1 and 10 would be needed. For an analyte
like S-warfarin that has a high Ka value of 2.5 x 105 M-1 on immobilized HSA, this would
mean working with a concentration range of 0.5 to 35 µM to see this shift. On the other
hand, L-tryptophan, which has a lower binding affinity of 1.1 x 104 M-1 for HSA, would
need a concentration range that spans from 10 to 800 µM to produce similar shifts.
Theoretical determinations such as these found by using Equation 6-6 are
important to ensure that a drug-protein system has been thoroughly examined. For
instance, many compounds bind to HSA at more than one binding site, with initial
preferences toward a higher affinity site at lower analyte concentrations. Typically a
drug will bind to the highest affinity binding site at lower concentrations while binding to
secondary or tertiary sites will become more important as the concentration increases. It
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Figure 6-1.

Change in mLapp/mL vs. Ka[A] for a frontal analysis experiment where the
analyte-ligand system has single-site binding
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is essential to use a concentration range that is large enough to encompass these
secondary interactions to ensure that a full representation of the drug-protein interactions
is made. Such interactions were studied here using experimental data of compounds that
have been previously shown to have interactions at more than one binding region on
HSA.11

Concentration Determinations Using Confidence Intervals
In this work, confidence intervals are used to examine data from compounds that
have multi-site interactions with HSA. Equation 6-4 was used to determine the best-fit
line for the drug-protein binding data used in these studies. Confidence intervals were
then used to investigate the linear deviations observed for each data set using the
following equation at each data point.12

 1 (x − x)2 

Vy = Vres  +

n
S
xx



(6-7)

In Equation 6-7, Vy is the variance of the estimate of y for the best-fit line. Vres is the
variance of the residuals as defined below,12
2
Vres = Sres

( yi − y ) 2
∑
=
n−2

(6-8)

where Sres2 is the standard deviation of the residuals squared, yi is the calculated value of
y at point i, while y is the predicted value for i from the best-fit line. The value n is the
number of data points used in the calculation of the best-fit line. The value x was the
concentration, while x was the average concentration for the data set. The value Sxx was
the standard deviation, as calculated using Equation 6-9.12
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S xx = ∑ ( xi2 ) − (∑ xi ) 2 / n

(6-9)

Once the variance for y had been determined at a given data point, a confidence
level for y, CL(y), was calculated using the following equation.12
CL( y ) = a + b ∗ x ± t ( f , p ) ∗ Vy

(6-10)

In Equation 6-10, a is the intercept and b is the slope given by the best-fit line. The value
t is taken from the t-test for the given number of data points and confidence level. The
standard deviation of the mean (SD y = SD/ y ) was then used along with the t-value to
determine the 95% confidence interval (C.I.) at that data point.12
y ± t ∗Sy

(6-11)

This was repeated at all data points for the given drug-protein system and used to create a
confidence interval at a 95% confidence level for the best-fit line.

Experimental
All experimental materials and methods for the frontal analysis studies can be
found in Chapters 3 and 5 of this dissertation.

Results and Discussion
Acetohexamide has been investigated in previous binding studies with both
normal and glycated HSA (see Chapters 3 and 5).11 An initial fit of the normal HSA data
to a one-site binding model using Equation 6-1 showed linear deviations at high
concentrations, suggesting that acetohexamide was interacting with HSA at more than
one binding site. In this instance, data at relatively low concentrations (i.e., 1-10 µM
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acetohexamide) were used to estimate the association equilibrium constant for the highaffinity binding sites using Equation 6-4. This value was determined to be 2.0 (± 0.1) x
105 M-1. The data was also fit to two- and three-site binding models, with the best fit
determined to be to a two-site model. This drug was found to have an overall association
equilibrium constant of 1.3 (± 0.2) x 105 M-1 for its high-affinity binding sites using a
two-site model (Equation 6-5), as determined using a concentration range of 1-1000 µM
acetohexamide.
Using the equilibrium constant from the single-site binding model with Equation
6-6, a concentration range of 1-50 µM acetohexamide would have been sufficient to
perform these studies, while using the data from the two-site model and Equation 6-6 a
concentration range of 1-70 µM would be needed.

The difference in estimated

equilibrium constants using Equation 6-4 and Equation 6-5 resulted in a 40% increase in
the concentration range necessary to observe the full binding range for this drug. The
general question that this leads to is what concentration range is necessary to gain reliable
binding data from such a system?
Using the acetohexamide data and the single-site binding model, the best-fit line
for the lower concentrations (1-5 µM) was analyzed to determine when the data deviated
from this line at a 95% confidence level. Calculations were performed at each data point
using Equations 6-7 to 6-11. The number of data points used to evaluate the best-fit line
was determined using a series of residual plots.

Concentrations 1 to 5 µM

acetohexamide, n = 5, gave seemingly scattered residuals while adding two more data
points (going up to 10 µM acetohexamide) started to show a pattern in the residual plot
(Note: little variation was noted between the slope and intercept of these two plots;
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however, it seemed prudent to use only the lower five concentrations when performing
the fit for these studies due to the information gained from the residual plots). A t value
of 3.18 was used in these calculations for a 95% confidence level.
Equations 6-7 to 6-11 were used to determine the confidence interval at each
concentration from 1 to 1000 µM acetohexamide and plotted along with the best-fit line.
The numerical results are shown in Table 6-1, with the graphical results seen in Figure 62. From these results, it appeared as though the results started to move out of the 95%
confidence interval at 10 µM acetohexamide and were visibly outside of this interval at
20 µM acetohexamide. This theoretical model suggested that using a concentration range
of 1-50 µM is more than adequate to see the binding heterogeneity that is present in
multi-site binding models for acetohexamide when using plots made according to
Equation 6-4.
The frontal analysis data for acetohexamide data were also fit to a two-site model
using Equation 6-5. While theoretical calculations were not made using this type of
model, simple visual observations were used to examine the results found using the
linear-regression confidence interval calculations. The entire data set was originally fit to
a two-site model to obtain a Ka value at the high-affinity binding site of 1.3 x 105 M-1. A
smaller data set was used to fit only concentrations of 1-50 µM acetohexamide to this
model. This concentration range was used to examine both the one-site model (Equation
6-2) and the two-site model to determine if distinctions could be made using this
concentration range (Figure 6-3). Deviations of the data from the one-site model are
most evident at 20 and 50 µM acetohexamide shown in Figure 6-3(a), while the two-site
model, shown in Figure 6-3(b) appears to have an improved fit for these data points.
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Table 6-1.

Confidence interval data calculated for acetohexamide according to

Equations 6-7 through 6-11 at the 95% confidence level. The first three significant
figures are underlined.

1/[Acetohexamide]
(M-1)

Predicted

C.I. (+)

C.I. (-)

Experimental

SD
(Experimental)

1.00E+06

305688241.6

312071164.5

299305318.8

305222354.5

380483.9206

8.00E+05

255819160.2

260334073.5

251304246.9

254595312.8

99898.50694

5.71E+05

198825924.3

202490150.3

195161698.3

200187021.9

364343.8178

4.00E+05

156080997.4

160510830.6

151651164.1

159088335.5

152574.2973

2.00E+05

106211915.9

112474476.6

99949355.27

103533214.7

417335.3436

1.33E+05

89588888.78

96568234.46

82609543.10

84483318.50

58417.05282

1.00E+05

81277375.21

88626659.25

73928091.17

73554876.54

228816.6904

5.00E+04

68810104.85

76725701.99

60894507.72

58312815.86

209566.7377

3.33E+04

64654348.07

72761333.65

56547362.49

50826782.33

159533.4508

2.00E+04

61329742.64

69590676.86

53068808.42

43722616.43

403027.2491

1.00E+04

58836288.57

67213146.10

50459431.03

36514118.79

671536.8986

3.33E+03

57172271.68

65626702.30

48717841.07

32113840.57

1182529.949

2.00E+03

56841525.31

65311394.30

48371656.33

25256511.44

508298.3995

1.33E+03

56675215.27

65152849.60

48197580.94

23582722.87

1565851.176

1.00E+03

56592120.08

65073634.89

48110605.26

20485137.35

1447220.635
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Figure 6-2.

Frontal analysis data for acetohexamide with low concentrations fit to a
best-fit line according to Equation 6-4. Confidence intervals at a 95%
confidence level are shown on either side of the best-fit line.
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Figure 6-3.

Plot of mLapp vs. [acetohexamide] for concentrations 1-50 µM using (a)
Equation 6-2 and (b) Equation 6-5.
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Using these concentrations, it was apparent that the data still fit best to the two-site
binding model versus the one-site model. A Ka value of 2.2 (± 0.2) x 105 M-1 was
obtained for the high-affinity binding site using the two-site model. This value was
within one standard deviation of the Ka value calculated using only the low
concentrations of the original linear one-site model and Equation 6-4. Similar results
were shown for acetohexamide binding to glycated HSA (results not shown).
Theoretical calculations were performed using data gained from studies with
tolbutamide and a normal HSA column.

Using a concentration range of 1-10 µM

tolbutamide, a best-fit line was made to the data. This concentration range was chosen
after making a series of residual plots made for the data. Previous studies determined the
Ka value of tolbutamide at the high-affinity binding site to be 8.7 (± 0.6) x 104 M-1.
Equation 6-1 predicts that a concentration range of 1-100 µM is necessary to see the
entire interaction of tolbutamide with HSA for such a site. These studies originally used
a concentration range of 1-200 µM tolbutamide which was more than sufficient for such
work.
The previous studies performed with tolbutamide binding to normal HSA showed
that tolbutamide binds to HSA at two high-affinity binding sites with statistically
identical affinity. This made it especially difficult to separate the high-affinity binding
site into two distinct binding sites. Analyzing the best-fit line for tolbutamide at the 95%
confidence level gave the plot shown in Figure 6-4 and corresponding numerical values
shown in Table 6-2. At the 95% confidence level, 100 µM tolbutamide is outside of the
linear range of the data, as shown in Table 6-2. The plot shows that linear deviations are
becoming apparent by 50 µM tolbutamide but the data, listed in Table 6-2, shows that the
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Table 6-2.

Confidence interval data calculated for tolbutamide according to

Equations 6-7 through 6-11 at the 95% confidence level. The first three significant
figures are underlined.

1/[Tolbutamide]
(M-1)

Predicted

C.I. (+)

C.I. (-)

Experimental

SD
(Experimental)

8.00E+05

572622265.9

583826460.1

561418071.7

574377438.9

1587647.500

5.71E+05

424893789.2

432119810.1

417667768.4

420005087.1

220492.0343

4.00E+05

314097431.7

320241095.4

307953768.1

316414774.3

969010.3201

2.00E+05

184835014.7

192882170.4

176787859.0

188643514.7

109449.3259

1.00E+05

120203806.1

130001227.7

110406384.5

117211492.6

248278.5945

5.00E+04

87888201.85

98660273.21

77116130.49

82705486.88

2022745.247

2.00E+04

68498839.29

79877964.40

57119714.17

57952437.24

542308.4366

1.00E+04

62035718.43

73620327.47

50451109.39

48320244.42

411295.4363

5.00E+03

58804158.00

70492050.14

47116265.87

41485039.78

1015414.310
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Figure 6-4.

Frontal analysis data for tolbutamide with low concentrations fit to a bestfit line according to Equation 6-4.

Confidence intervals at a 95%

confidence level are shown on either side of the best-fit line.
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Figure 6-5. Plot of mLapp vs. [tolbutamide] using (a) Equation 6-2 and (b) Equation 6-5.
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data is not quite outside the 95% confidence interval.
This smaller data set was tested by fitting the concentration range of 1-50 µM
tolbutamide to non-linear models using Equation 6-5 (Figure 6-5). The data showed
some deviations from the one-site model at 20 and 50 µM tolbutamide, much like
acetohexamide. Similar to what was seen when using the full data set, this model had a
noticeably better fit to a two-site binding model, giving a Ka of 9.6 (± 3.2) x 104 M-1 for
the high-affinity binding site. This concentration range also produced a higher affinity
secondary binding site of 1.2 (± 2.4) x 104 M-1, but this site had a high associated
standard error.

Conclusion
Theoretical studies examined the concentration ranges that should be used for
frontal analysis studies.

While the minimum concentration range recommended for

acetohexamide, as determined from the experimental binding constant, was between 1
and 50 µM, the theoretical studies showed that linear deviations could actually be seen
before reaching 50 µM. It was also shown that a smaller concentration range gave results
statistically equivalent to previously determined binding constants using a two-site
binding model.

The same was true for tolbutamide.

This later work is especially

important for this study due to the lower experimental binding constant of tolbutamide
compared to acetohexamide and two similar high-affinity binding sites. However, it was
shown that the same binding constants could be calculated using a narrower
concentration range, which will conserve solutions, decrease drug cost, and cut down
experiment run times in the future.
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CHAPTER 7
SUMMARY AND FUTURE WORK

Summary of Work
Drug-protein interactions affect the transport and efficacy of the drug in the body.
The work in this dissertation used the method of high-performance affinity
chromatography to examine drug-protein binding.

Frontal analysis was used to

determine association equilibrium constants and binding capacity for various analytes
with human serum albumin (HSA) and glycated human serum albumin (gHSA). Zonal
elution competition studies were used to determine the specific binding location(s) on this
protein for each of the analytes.
The first chapter gave a general introduction on the topics presented in this
manuscript. It began with a background discussion on diabetes and lead into a brief
summary of one specific class of drugs used to treat this disease. This chapter also
highlighted the importance of HSA as a transporter protein within the human body and
discussed the significance of drug-protein binding studies in determining the efficacy of
drugs in the body. The method of high-performance affinity chromatography was also
introduced, along with methods such as frontal analysis and zonal elution.
The work in chapter two examined four coumarin compounds as alternatives to
warfarin as a probe for drug-protein binding studies using HSA. This study used frontal
analysis and zonal elution to determine the binding constants and binding location of the
compounds with HSA. All four compounds had interactions that fit a two-site binding
model, and warfarin showed direct competition at the high-affinity site for each
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compound. After taking into consideration non-specific binding, binding strength, and
the number of binding sites on HSA, 4-hydroxycoumarin was determined to be the best
alternative to warfarin as a site-selective probe for HSA.
Chapter 3 demonstrated the depth of information that can be gleaned when using
both frontal analysis and zonal elution as complimentary methods to look at drug-protein
binding. The binding of two sulfonylureas, acetohexamide and tolbutamide, to HSA was
examined using high-performance affinity chromatography.

Frontal analysis studies

showed that acetohexamide and tolbutamide had interactions at two different classes of
binding sites on HSA: a high-affinity group of sites and a lower-affinity class of sites.
The data obtained using competition studies and zonal elution indicated that the both
drugs bound to Sudlow sites I and II with relatively high affinity. It was determined that
the combined binding at Sudlow sites I and II made up the high-affinity class of sites
found using frontal analysis.
The overall goal of this research was to examine the binding of diabetes drugs to
HSA during diabetes.

Chapters 4 and 5 use glycated HSA columns to aid in the

understanding of these interactions.

In Chapter 4, the binding of warfarin and L-

tryptophan to glycated HSA was studied. These compounds are often used in drug-HSA
binding studies as probe compounds for Sudlow sites I and II, respectively.

The

association equilibrium constant for warfarin remained consistent as the levels of
glycation were increased. The binding constant for L-tryptophan showed an increase
with glycated HSA compared to literature values for normal HSA; however, the binding
constant remained the same with increasing levels of glycation. These compounds were
found to be suitable for use in drug-protein binding studies using glycated HSA.

257
The binding of acetohexamide and tolbutamide to gHSA was examined in
Chapter 5 to determine if changes in binding were exhibited as the level of glycation on
HSA was increased to levels typically seen in diabetic individuals. The association
equilibrium constants and binding capacities were determined using frontal analysis for
the overall drug-protein interactions, while competition studies were used to examine
interactions at Sudlow sites I and II. The data obtained using frontal analysis showed
little change in the overall binding constant when going from no glycation to mildly
glycated HSA at the high-affinity site for acetohexamide; this was followed by a small
increase in the association equilibrium constant as glycation levels were increased
further. The binding constant for tolbutamide at the high-affinity binding site appeared to
have an initial increase when glycation was introduced. However, this value decreased to
levels seen for normal HSA as glycation was increased. Competition studies showed an
increase in binding constants for both acetohexamide and tolbutamide at Sudlow site I in
going from normal to minimally glycated HSA, followed by a decrease as glycated levels
increased. The binding of these drugs differed at Sudlow site II, where the association
equilibrium constant for acetohexamide decreased upon initial HSA glycation while the
binding constant of tolbutamide increased.
Chapter 6 examined the range of analyte concentrations that should be used in
frontal analysis studies when examining drug-protein binding for systems with multi-site
interactions. Confidence intervals were used to examine data from two compounds that
are known to bind to HSA at more than one type of binding site. Theoretical studies with
various concentration ranges were compared to known experimental values. This data
was used to determine the concentration range that could be used with the tested analytes.
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Future Work
These studies primarily focused on the binding of one class of drugs to HSA as
glycation levels were increased. The work involved in this dissertation used HSA that
was glycated in vitro and immobilized via the Schiff base method onto silica. With this
in mind, future work could lead in many directions.
More studies could be undertaken to examine the immobilization of the glycated
HSA to the silica. Glycated HSA is a heterogeneous compound that can take on many
forms. Initial glycation of HSA is actually reversible. It is not until the Amadori product
is formed that a stable, covalent bond is made with a sugar molecule. Furthermore, this
product can undergo subsequent glycation rearrangements to form advanced glycation
endproducts. Therefore, when undertaking covalent immobilization to silica, stability
studies would be a valuable tool in determining the length of time in which glycation
levels of the proteins remain consistent upon immobilization. To further expand on this,
it would also be valuable to look at glycation levels of HSA directly before and directly
following immobilization to ensure that the same amount of glycated HSA was being
immobilized to the silica without preference to more mildly glycated HSA.

Other

methods of protein immobilization are currently being explored in our group, including
entrapment.
Diabetic patients are unfortunately afflicted with a myriad of illnesses brought on
by diabetes. This often means that a large regiment of prescription medications are used
to combat these multiple conditions. It is also common for diabetic patients to be on
more than one medication for the control of diabetes. Future studies could include work
with multiple drugs that are most commonly used for the treatment of diabetes and
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diabetes-induced illnesses/symptoms. One relatively new treatment uses a synthetic,
incretin mimetic, glucoregulatory peptide in combination with sulfonylureas to control
type II diabetes.1, 2 Future studies could include such drugs as competing agents in drugprotein binding studies.
Ongoing work in our group is looking at serum samples containing glycated HSA
that have been collected from diabetic patients. The HSA from these samples has been
separated from the serum and immobilized onto silica for use in similar studies as have
been outlined in this work. Comparing such samples to the in vitro samples used in these
studies will also be valuable in future work.
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